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Ade      Adenine    
ADP        Adenosine  diphosphate 
APS      Ammonium  persulfate    
ATP        Adenosine  triphosphate      
BSA        Bovine  serum  albumin 
Ca
2+      Calcium  ion 
[Ca
2+]      Calcium  ion  concentration 
cAK      cAMP-dependent  protein  kinase 
cAMP        Cyclic  adenosine  monophosphate     
c D N A         C o p y   D N A  
cfu        Colony  forming  unit 
cGK        cGMP-dependent  protein  kinase 
cGMP        Cyclic  guanosine  monophosphate   
C i       C u r i e s  
Cy3/5      Cyanin  3/5       
DAG        1,2-Diacylglycerol      
DEAE-Dextran   Diethylaminoethyl-Dextran   
DMEM      Dulbecco’s  modified  Eagle’s  medium 
DMSO      Dimethylsulfoxide 
DNA        Deoxyribonucleic  acid 
Doc2      Double  C2  domain   
DTE      Dithioerythreitol 
DTT      Dithiothreitol 
EDRF      Endothelium-derived  relaxing  factor      
EDTA        Ethylenediamine  tetra-acetic  acid 
EGTA      Ethyleneglycol  tetra-acetic  acid 
e.g.      Latin:  exempli  gratia;  for  example 
EGFP        Enhanced  green  fluorescent  protein 
ELISA      Enzyme-linked  immunosorbent  assay 
Fig.      Figure 
FBS        Fetal  bovine  serum 
g       G r a m  
g       Gravity (= 9.81 m/s
2) 
GAL4AD       Gal4  activation  domain       
GAL4BD       Gal4  binding  domain 
GAP        GTPase  activating  protein 
GDI      GDP  dissociation  inhibitor 
GDP        Guanosine  diphosphate 
GDPβS    Guanosine  5`-O-[β-thio] diphosphate 
GEF        Guanine  nucleotide  exchange  factor 
GFP      Green  fluorescent  protein 
GGT      Geranylgeranyl  transferase 
g m       Gunmetal 
GP      Glycoprotein 
GPCR      G  protein-coupled  receptor 
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GSH      Glutathione 
GST        Glutathione-S-transferase 
GT      Glanzmann`s  thrombasthenia 
GTP        Guanosine  triphosphate 
GTPγS      Guanosine  5`-O-[γ-thio] triphosphate 
h      Hour 
HA      Hemagglutinin 
HEPES    4-(2-Hydroxyethyl)-1-piperzineethanesulfonic  acid 
H i s       H i s t i d i n e  
HRP      Horseradish  peroxidase 
5HT      5-Hydroxytryptamine,  serotonin 
IB      Immunoblot 
i.e.      Latin:  id  est;  that  is 
IF      Immunofluorescence   
IgG      Immunoglobulin  G        
IP        Immunoprecipitation 
IP3      Inositol-1,4,5-trisphosphate 
IPTG      Isopropyl-β-D-1-thiogalactopyranoside 
kb      Kilobase  pairs 
kD      Kilodalton   
l       L i t e r  
LB      Luria-Bertani  medium     
Leu
      Leucine 
LDH      Lactate  dehydrogenase 
LSM      Laser  scanning  microscope 
M       M o l a r i t y  
mg      Milligram 
MHD      Munc  homology  domain 
min      Minute 
mmol      Millimol 
ml      Milliliter 
Mr,  MW     Molecular  weight 
mRNA      Messenger  RNA 
Ni-NTA    Nickel-nitrilotriacetic  acid  agarose     
NO      Nitric  oxide 
NSF      N-ethylmaleimide  sensitive  factor 
OCS      Open  canalicular  system 
OD600      Optical density at 600 nm 
P      Phosphate      
PAR        Protease-activated  receptor 
PBS        Phosphate  buffered  saline 
PCR        Polymerase  chain  reaction 
PDE        Phosphodiesterase 
PDZ-GEF                                         Postsynaptic density-95 discs-large and zona occludens  
 protein  1-GEF 
PGI2       Prostaglandin I2, prostacyclin 
PH  domain     Pleckstrin  homology  domain 
PIP      Phosphoinositide 
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PKA/B/C/G       Protein  kinase  A/B/C/G 
PKI      PKA  inhibitor 
PLC      Phospholipase 
PSA      Prostate-specific  antigen 
P-VASP     phosphorylated  VASP 
RG1      Rap1GAP1 
RG2      Rap1GAP2 
RNA      Ribonucleic  acid 
Rp-8-Br-cAMPS                      Rp-8-Bromoadenosine-3`,5`-cyclic 
monophosphorothioate 
rpm      Rotations  per  minute 
RT      Room  temperature 
sec      Second 
SD      Standard  deviation 
SDS      Sodium  dodecyl  sulphate 
SDS- PAGE         SDS-Polyacrylamide gel elektrophoresis 
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Slac      Slp  homologue  lacking  C2  domains 
Slp      Synaptotagmin-like  protein   
SNAP      Soluble  NSF  attachment  protein 
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SPA-1      Signal-induced  proliferation-associated  protein  1 
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TxA2      Thromboxane  A2 
U       U n i t    
VAMP      Vesicle-associated  membrane  protein 
VASP      Vasodilatator-stimulated  phosphoprotein 
VSV      Vesicular  stomatitis  virus  glycoprotein    
v/v        Volume  per  volume 
WB      Western  blotting 
w t       W i l d - t y p e  
w/v        Weight  per  volume 
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SUMMARY 
Platelets are anucleate cells that play a major role in hemostasis and thrombosis in the 
vasculature. During primary hemostasis platelets adhere to sites of vascular damage and the 
initial platelet coat is reinforced by additional platelets forming a stable aggregate. At the 
same time platelets secrete their intracellular granules containing substances that further 
activate platelets in an autocrine and paracrine fashion and affect local coagulation and 
endothelial smooth muscle cell function. The small guanine nucleotide binding protein Rap1 
regulates the activity of the platelet integrin αIIbβ3 and thus platelet aggregation. Rap1 activity 
is controlled by guanine nucleotide exchange factors and GTPase activating proteins. In 
platelets, Rap1GAP2 is the only GTPase activating protein of Rap1.  
In order to identify Rap1GAP2-associated proteins, a genetic two-hybrid screening in yeast 
was performed and synaptotagmin-like protein 1 (Slp1, also called JFC1) was found as a 
new putative binding partner of Rap1GAP2. Slp1 is a tandem C2 domain containing protein 
and is known to bind to Rab27, a small GTPase involved in platelet dense granule secretion. 
The direct interaction between Rap1GAP2 and Slp1 was confirmed in yeast and in 
transfected cells. More importantly, Slp1 is expressed in platelets and binding of endogenous 
Rap1GAP2 and Slp1 was verified in these cells. The Rap1GAP2 and Slp1 interaction sites 
were mapped by mutational analysis. Rap1GAP2 binds through the -TKXT- motif within its C-
terminus to the C2A domain of Slp1. Moreover, the Slp1 binding -TKXT- motif of Rap1GAP2 
was confirmed by complementary approaches using short synthetic Rap1GAP2 peptides. 
The C2A domain of Slp1 is a phospholipid binding domain and thus mediates binding of Slp1 
to the plasma membrane. Phospholipid overlay assays revealed that simultaneous binding of 
Slp1 via its C2A domain to Rap1GAP2 and to phospholipids can occur. In addition, the 
interaction between Rap1GAP2 and Slp1 is regulated by cAMP-dependent protein kinase 
(cAK or PKA), and kinase activation in platelets enhanced binding of endogenous 
Rap1GAP2 to Slp1. In-vitro phosphorylation assays revealed that Slp1 is a substrate of PKA, 
and serine 111 was identified as phosphorylation site. Since Slp1 is a Rab27 binding protein, 
a trimeric complex of Slp1, Rab27 and Rap1GAP2 is conceivable. The association of Slp1, 
Rab27 and Rap1GAP2 was investigated by immunofluorescence and co-immuno-
precipitation experiments in both, transfected cells and platelets. By Slp1 affinity 
chromatography and subsequent mass spectrometric analysis additional Slp1 binding 
proteins were identified in platelets, and binding of Slp1 to Rab8 was confirmed in pull-down 
assays. To investigate the functional significance of the interaction between Rap1GAP2 and 
Slp1, an assay system was established to determine serotonin secretion of streptolysin-O 
permeabilized platelets. Addition of recombinant Slp1 protein to permeabilized platelets 
strongly inhibited platelet dense granule secretion, whereas addition of recombinant 
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Rap1GAP2 protein or synthetic Rap1GAP2 peptide enhanced secretion. Deleting the Slp1 
binding -TKXT- motif abolished the stimulatory effect of Rap1GAP2 on secretion. Addition of 
Rap1 to permeabilized platelets had no effect on secretion. These findings indicate that the 
Rap1GAP2 effect on platelet secretion does not depend on the GTPase activating function of 
Rap1GAP2, but is rather dependent on the -TKXT- mediated interaction of Rap1GAP2 with 
Slp1. In addition, in-vitro GAP assays revealed that Slp1 binding to Rap1GAP2 does not 
affect the Rap1GAP activity of Rap1GAP2, and adhesion assays excluded a role for the 
Rap1GAP2/Slp1 interaction in cell adhesion.  
Altogether, the results of the present study demonstrate that besides its function in platelet 
aggregation by controlling the activity of the small guanine nucleotide binding protein Rap1, 
Rap1GAP2 is involved in platelet dense granule secretion by the new -TKXT-  mediated 
interaction with the Rab27 and membrane binding protein Slp1. In addition, the interaction 
between Rap1GAP2 and Slp1 is embedded into an elaborate network of protein-protein 
interactions in platelets which appear to be regulated by phosphorylation. Future studies will 
in particular aim to dissect the molecular details of Rap1GAP2 and Slp1 action in platelet 
secretion and investigate the potential biochemical and pharmacological value of the unique 
protein binding -TKXT- motif of Rap1GAP2. 
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1. INTRODUCTION 
 
1.1 Platelets  
Platelets, or thrombocytes, are specialized blood cells that play a central role in physiological 
and pathological processes of hemostasis and thrombosis (Davi and Patrono 2007). 
Platelets are the smallest (0.5 x 3.0 µm) and most numerous (normal range: 2-3 x 10
8/ml) 
corpuscular components of the circulating blood (Italiano 2008). They are produced from 
megakaryocytes in the bone marrow (Hartwig and Italiano 2003). Once released, platelets 
have a lifespan of about 7-10 days. Degradation of platelets occurs in the reticulo-endothelial 
system of liver and spleen (Gawaz 1999). Platelets do not have a nucleus and thereby lack 
genomic DNA (Italiano and Shivdasani 2003). However, they contain megakaryocyte-derived 
messenger RNA (mRNA) and the translational machinery needed for protein synthesis 
(reviewed by Davi and Patrono 2007). Moreover, pre-mRNA splicing, a typical nuclear 
function, has recently been detected in the cytoplasm of these anucleate cells (Denis et al. 
2005). Platelets are rich in mitochondria and store three different types of granules, alpha 
granules, dense granules and lysosomes (Rendu and Brohard-Bohn 2001). In the resting 
state, platelets are discoid shaped having granules homogenously distributed throughout the 
platelet body. Upon activation, however, platelets undergo a shape change during which 
pseudopodia are formed and granules are centralized. Platelets are characterized by a 
unique membrane network including the dense tubular and the surface-connected open 
canalicular system. The dense tubular system is the main storage pool for free calcium ions 
(Jardin et al. 2008). The open canalicular system (OCS) is an elaborate system of membrane 
tunnels and serves on the one hand as a direct passageway to the bloodstream, into which 
platelet granule contents can quickly be released, and on the other hand, as a reservoir for 
platelet plasma membrane and membrane receptors (Gawaz 1999, Italiano 2008). The main 
platelet plasma membrane receptors are adhesive glycoprotein receptors (e.g. GPIb for von 
Willebrand factor, GPVI for collagen), several G protein-coupled receptors (GPCRs) (e.g. 
PAR1 and PAR4 for thrombin, P2Y1 and P2Y12 for adenosine diphosphate), and β1 and β3 
integrin receptors (e.g. α2β1 for collagen, αIIbβ3 for fibrinogen) (Gachet 2008, Coughlin 2005, 
Varga-Szabo et al. 2008).  
Platelets in primary hemostasis 
In circulation, the major physiological function of platelets is to sentinel the integrity of the 
vascular system and to prevent bleeding/hemorrhage after vascular injury, a process called 
primary hemostasis (Fig.1.1) (Ruggeri 2002, Davi and Patrono 2007). Under conditions of 
rapid blood flow the initial platelet tethering at sites of vascular injury involves the interaction 
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of von Willebrand factor with the platelet glycoprotein complex GPIb-V-IX. Moreover, 
interaction of collagen with glycoprotein GPVI  and  integrin α2β1 further promotes platelet 
adhesion and activation (Varga-Szabo et al. 2008, Ruggeri and Medolicchio 2007). Platelet 
activation results in platelet shape change, granule secretion and aggregation. Platelet 
granule secretion leads to the release of granule contents which activate platelets in an 
autocrine and paracrine fashion, thereby perpetuating the initial platelet response. In 
addition, more platelets are recruited from the circulation to form a growing platelet 
aggregate. Platelet aggregation is mediated by binding of fibrinogen to the activated integrin 
αIIbβ3 (also called GPIIb-IIIa) leading to cohesion of adjacent platelets (Jackson 2007). The 
so formed primary hemostatic plug, however, is still fragile and only temporarily arrests 
bleeding. Therefore, stable clot formation is induced during secondary hemostasis through 
activation of the plasma coagulation system, resulting in thrombin-mediated conversion of 
fibrinogen to fibrin (Gawaz 1999, Jurk and Kehrel 2005).  
 
 
Figure 1.1: Platelets in primary hemostasis. 
Primary hemostasis can be classified into different phases ultimately leading to the formation of a primary 
hemostatic platelet plug. (1) Initial adhesion of resting platelets to sites of vascular damage is mediated through 
the interaction of immobilized extracellular von Willebrand factor with GPIbα which is part of the GPIb-V-IX 
complex. The interaction of collagen with GPVI especially induces the activation of adherent platelets. In turn, 
activated α2β1 integrin binds to collagen, thereby promoting firm platelet adhesion. (2) Platelet activation leads to 
platelet shape change, granule secretion and aggregation. Activated platelets secrete substances (e.g. adenosine 
diphosphate) which activate platelets in an autocrine and paracrine fashion operating through G protein-coupled 
receptors. (3) Platelet aggregation is mediated by binding of fibrinogen to activated αIIbβ3 integrin leading to 
cohesion of adjacent platelets. (4) More platelets are recruited and accumulate into a growing platelet thrombus. 
EC: endothelial cell; GP: glycoprotein; vWF: von Willebrand factor; GPCR: G protein-coupled receptor. Arrows 
indicate activation. Figure was modified according to Jackson 2007. 
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Although presented here as separated events, primary and secondary hemostasis are 
closely linked, e.g. activated platelets accelerate plasma coagulation, and products of the 
plasma coagulation system, such as thrombin, stimulate platelet aggregation. 
1.2 Platelet activation and inhibition 
Platelets are rapidly activated by various agonists. Irrespective of collagen as the main non-
diffusible platelet agonist, diffusible mediators of platelet activation are α-thrombin, 
adenosine diphosphate (ADP), and thromboxane A2  (TxA2). Platelet activation is 
counteracted by platelet inhibition. The main platelet inhibitors are nitric oxide (NO, also 
termed endothelium-derived relaxing factor (EDRF) and prostaglandin I2 (PGI2, also termed 
prostacyclin). 
1.1.1 Platelet  activators 
Diffusible platelet agonists activate platelets through G protein-coupled receptors. Platelet 
activation via GPCRs involves three major G protein-mediated signaling pathways that are 
initiated by the activation of the G proteins Gαq, Gαi and Gα12/13 (reviewed by Offermanns 
2006). Gαq-mediated signaling activates phospholipase Cβ (PLCβ). Activation of PLCβ 
results in the hydrolysis of phophatidylinositol-4,5-bisphosphate and the formation of the 
second messengers inositol-1,4,5-trisphosphate (IP3) and 1,2-diacylglycerol (DAG). IP3 
increases intracellular [Ca
2+], whereas DAG activates protein kinase C (PKC). By contrast, 
activated Gαi inhibits adenylyl cyclase and thus formation of the inhibitory cyclic adenosine 
monophosphate. Finally, Gα13, a member of the Gα12/13 family, activates guanine nucleotide 
exchange factors of the small GTPase Rho (Hart et al.1998, Fukuhara et al. 2001), leading to 
the formation of Rho-GTP and rearrangement of the platelet actin cytoskeleton and shape 
change. 
Thrombin           
The serine protease α-thrombin is one of the most potent platelet activators. Upon vascular 
injury exposure of tissue factor to plasma coagulation factors initiates thrombin formation 
(Daubie et al. 2007). Thrombin is produced on cellular surfaces including that of activated 
platelets (Heemskerk et al. 2002). Activation of platelets by thrombin is mediated by 
protease-activated  receptors (PARs) (Coughlin 2000). To date four PARs have been 
described: PAR1, PAR2, PAR3, and PAR4. PARs are activated by proteolytic cleavage of 
their extracellular N-terminal domain which leads to the generation of a tethered ligand. 
While PAR1, PAR3, and PAR4 are cleaved and activated by thrombin, PAR2 is activated by 
trypsin, tryptase and coagulation factors VIIa and Xa (Nystedt et al. 1994, Molino et al. 1997, 
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Camerer et al. 2000). Human platelets express PAR1 and PAR4 (Kahn et al. 1999). PAR1 is 
the predominant human platelet thrombin receptor, and couples to Gαq, Gα12/13  and Gαi 
(reviewed by Coughlin 2005).  
In addition to interacting with PARs, α-thrombin binds also to GPIbα, which is part of the 
GPIb-V-IX complex (Okumara et al. 1978, Andrews et al. 1999). Deletion of the extracellular 
domain of GPIbα or blockade of the α-thrombin binding site decreased thrombin-induced 
platelet activation (Brass 2003). However, the precise role of α-thrombin interaction with 
GPIb-V-IX remains yet to be defined. 
Adenosine diphosphate 
Adenosine diphosphate is stored in platelet dense granules and is released upon platelet 
activation. Released ADP activates platelets in an autocrine and paracrine manner. ADP 
interacts with G protein-coupled receptors of the P2 receptor family: P2Y1 and P2Y12. P2Y1 
couples to Gαq, whereas P2Y12 to Gαi. Studies using receptor agonists revealed that 
concomitant activation of both receptors is required for a full response of platelets to ADP 
(Jin et al. 1998, Jantzen et al. 1999). The P2Y12  receptor is irreversibly inhibited by 
thienopyridines (e.g. ticlopidine, clopidogrel and prasugrel) which are used as antiplatelet 
drugs (Savi and Herbert 2005, Niitsu et al. 2005). Enzymatic conversion of ADP to the 
inactive adenosine monophosphate and phosphate by endothelial ecto-ADPase CD39 limits 
platelet activation by ADP (Atkinson et al. 2006). 
Additionally, a third platelet P2 receptor, P2X1, is activated by adenosine triphosphate (ATP). 
P2X1 is a gated cation channel responsible for a fast calcium influx that contributes to platelet 
activation (Gachet 2008). 
Other platelet activators 
Like ADP, thromboxane A2 functions as a positive feedback mediator during platelet 
activation. TxA2 is produced from arachidonic acid by the enzymes cyclooxygenase-1, which 
is the target of low dose aspirin (Patrono et al. 2005, Patrono and Rocco 2008), and by 
thromboxane synthase. Because of its short half-life, the action of TxA2 is locally restricted. 
TxA2 operates through its platelet surface receptor TP coupled to Gαq  and Gα12/13 
(Murugappan et al. 2004). 
Several other substances including epinephrine and serotonin can activate platelets, too. 
However, in contrast to thrombin, ADP, and TxA2, they are only weak platelet activators. 
Serotonin (5-hydroxytryptamine, 5HT) is taken up by platelets, stored in dense granules and 
released upon platelet activation. It activates platelets in a positive feedback mechanism 
through interaction with platelet surface receptor 5HT2A which couples to Gαq. Moreover, 
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platelet-derived serotonin causes vasoconstriction (Coppinger and Maguire 2007), and has 
recently been shown to mediate platelet effects on tissue regeneration (Lesurtel et al. 2006). 
1.2.2 Platelet inhibitors 
Endothelium-derived nitric oxide and prostaglandin I2 are the two major inhibitors of platelet 
activation (Schwarz et al. 2001, Davi and Patrono 2007). Gaseous NO diffuses into platelets 
and directly activates the soluble guanylyl cyclase to produce cyclic guanosine 
monophosphate (cGMP). By contrast, PGI2 acts through a platelet surface receptor, the IP 
receptor (Norel 2007), which couples to Gαs. Activation of Gαs then stimulates adenylyl 
cyclase to produce cyclic adenosine monophosphate (cAMP). Consequently, a rise in 
intracellular levels of cGMP and cAMP activates cGMP- and cAMP-dependent protein 
kinases (cGK/PKG and cAK/PKA). In platelets, PKG and PKA are highly expressed with 
PKGIβ and PKAIβ and IIβ representing the major isoforms (Schwarz et al. 2001). PKG and 
PKA phosphorylate substrate proteins leading to the inhibition of platelet activation and 
aggregation (Schwarz et al. 2001, Münzel et al. 2003, Hofmann et al. 2006). One of the 
major substrates of PKG and PKA in platelets is the vasodilator-stimulated phosphoprotein 
(VASP). VASP is phosphorylated at serine 157, serine 239, and threonine 278 by both PKG 
and PKA (Butt et al. 1994, Reinhard et al. 2001). VASP phosphorylation appears to be 
involved in the inhibition of agonist-induced activation of integrin αIIbβ3 and thus platelet 
adhesion and aggregation (Horstrup et al. 1994, Aszodi et al. 1999, Häuser et al. 1999, 
Massberg et al. 2004). 
cGMP and cAMP are hydrolyzed and thereby inactivated by phosphodiesterases (PDEs). 
Platelets contain at least three different types of PDEs: PDE2, PDE3, and PDE5 (reviewed 
by Schwarz et al. 2001, Colman 2004). 
1.3 Platelet granule secretion 
1.3.1 Platelet granules 
Three types of intracellular granules have been described in platelets: alpha granules, dense 
granules, and lysosomes. Alpha granules are the largest (~ 200-500 nm in diameter) and 
most abundant platelet granules (~ 80 per platelet) (Reed 2004, Italiano 2008). They store 
proteins (e.g. von Willebrand factor, fibrinogen) that are important for platelet adhesion, 
aggregation, and clot formation. Moreover, alpha granules contain various cytokines (e.g. 
platelet factor 4) and growth factors (e.g. platelet derived growth factor) that contribute to 
platelet interactions with leukocytes and other cells (Coppinger and Maguire 2007, Sierko 
and Wojtukiewicz 2007). Platelet dense granules, of which there are ~ 8 per platelet, are 250 
nm in size and characterized by virtue of their electron-dense cores. Dense granules contain 
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small molecules such as ADP, serotonin, calcium, and pyrophosphate (Gawaz 1999, Reed 
2004). In particular, the release of dense granule contents allows the recruitment of 
additional circulating platelets to sites of vascular injury.  
Several proteins (e.g. GPIb, αIIbβ3, P-selectin) that are critical for platelet function are 
incorporated into the limiting membranes of both alpha and dense granules (King and Reed 
2002, Rendu and Brohard-Bohn 2001). Upon platelet granule secretion these proteins 
become exposed on the platelet surface. The presence of GPIb and αIIbβ3 facilitates platelet 
adhesion and aggregation. P-selectin upon engagement of its ligand P-selectin glycoprotein 
ligand 1 recruits monocytes, neutrophils and lymphocytes, thereby initiating the formation of 
platelet-leukocyte aggregates (Furie et al. 2001, von Hundelshausen and Weber 2006, Jurk 
and Kehrel 2008).  
Unlike alpha and dense granules, lysosomes are generally considered as degradative 
compartments (Luzio et al. 2007). However, platelets and some other hematopoietic cells 
including macrophages and cytotoxic T lymphocytes contain the so-called secretory 
lysosomes, and lysosome release is stimulated by transient increase in intracellular calcium 
(Stichcombe and Griffiths 1999, Andrews 2000, Luzio et al. 2007). Platelet lysosomes 
contain lysosomal enzymes (e.g. β-hexosaminidase, cathepsin D, heparitinase) that might 
play a role in clot remodeling (Reed 2004).  
1.3.2 Molecular mechanisms of platelet granule secretion 
Platelet granule secretion is crucial for normal platelet function during primary hemostasis 
and can be summarized as a process occurring in three steps: (1) platelet activation initiated 
by a platelet agonist, leading to the increase of intracellular calcium and activation of protein 
kinase C with subsequent phosphorylation of effector molecules; (2) granule 
tethering/docking with the target membrane followed by ATP-dependent granule priming; and 
(3) granule/membrane fusion with release of granule contents into the extracellular 
environment. Various proteins have been reported to be essential for distinct steps during 
this process. For example, Rab GTPases and their effectors are widely believed to regulate 
granule secretion at the tethering/docking step, and membrane proteins of the soluble N-
ethylmaleimide sensitive factor attachment protein receptor (SNARE) family in concert with 
SNARE accessory proteins have been shown to control membrane fusion (Fig.1.2) (Reed et 
al. 2000, Rendu  and Brohard-Bohn 2001, Flaumenhaft 2003, Reed 2004).  
Calcium and protein kinase C  
Platelet agonists (e.g. collagen, thrombin, ADP) activate platelets through interaction with 
specific receptors on the platelet plasma membrane. Subsequent phospholipase C - 
mediated formation of inositol-1,4,5-trisphosphate and 1,2-diacyglycerol leads to an increase 
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in intracellular calcium and activation of protein kinase C. Both, calcium and PKC are critical 
determinants of platelet granule secretion, operating in synergy (Walker and Watson 1993, 
Reed et al. 2000). However, a rise in intracellular calcium is at all times sufficient to induce 
platelet granule release, and secretion of permeabilized platelets can be stimulated by 
addition of exogenous calcium
  ions (Flaumenhaft 2004). The exact mechanism through 
which an increase in intracellular calcium induces granule secretion is poorly understood. In 
this regard, specific calcium sensor/effector molecules could play a role. Among them, 
proteins containing C2 and EF hand domains appear to be likely candidates. The tandem C2 
domain containing protein synaptotagmin-I is the most prominent example of a Ca
2+-sensor 
not only in neurons, but also in non-neuronal cells (reviewed by Burgoyne and Morgan 2003, 
Martens and McMahon 2008). Other C2 domain containing proteins, all of which are 
implicated in regulated exocytosis, are rabphilin, Doc2, RIM, Munc13, and Slp (Burgoyne and 
Morgan 2003, Fukuda 2005, Martens and McMahon 2008). EF hand domain containing 
proteins are e.g. calmodulin and calcyclin. Both proteins are expressed in platelets and have 
been invoked in secretion (reviewed by Flaumenhaft 2003). 
Based on studies using broad spectrum pharmacological inhibitors and activators of protein 
kinase C, there is evidence suggesting a general role for PKC in platelet activation and in 
particular, a stimulatory role for this kinase in platelet granule secretion. Inhibitors of PKC 
block platelet dense granule release (Chung et al. 2000, Rozenvayn and Flaumenhaft 2003, 
Reed 2004). Phorbol esters such as 12-O-tetradecanoyl phorbol-13-acetate (TPA) activate 
protein kinase C by mimicking DAG, and stimulation of PKC with TPA in platelets resulted in 
increased platelet granule release (Rink et al. 1983). Moreover, a purified rat brain PKCα has 
been shown to augment Ca
2+-dependent platelet alpha and dense granule secretion 
(Yoshioka et al. 2001). PKCs form a family of related serine/threonine kinases that are part of 
the AGC-type kinase (protein kinase A/protein kinase B/protein kinase C) superfamily. In 
platelets, isoforms α, βI, βII, δ, η, θ and ζ are present, and recently, PKCδ has been shown to 
be required for PAR-mediated platelet dense granule secretion (Murugappan et al. 2004). 
Activation of PKC results in phosphorylation of downstream effector molecules such as 
myristoylated alanine-rich C kinase substrate (MARCKS) and Munc-18c (reviewed by 
Flaumenhaft 2003). 
Rab proteins and their effectors 
Rab proteins are members of the Ras superfamily of small GTPases and involved in various 
aspects of intracellular membrane trafficking (Zerial and McBride 2001). To date more than 
60 Rab isoforms have been identified in mammals. Some of these are ubiquitously 
expressed, whereas others are cell-type specific. After synthesis Rab GTPases are soluble. 
However, post-translational modification by prenylation turns Rab proteins into peripheral 
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membrane proteins. Attachment of geranylgeranyl group(s) to cysteine residue(s) which is 
carried out by Rab geranylgeranyl transferase (RabGGT) allows Rab proteins to associate 
with membranes. Like other small GTPases, Rab GTPases are molecular switches 
alternating between an active guanine-nucleotide triphopshate (GTP)-bound form and an 
inactive guanine nucleotide diphosphate (GDP)-bound form. This GTP/GDP cycle is 
controlled by guanine nucleotide exchange factors (GEFs) and GTPase activating proteins 
(GAPs). So far, only few Rab GEFs and GAPs have been identified. In the active GTP-bound 
form Rab proteins are membrane-associated and interact with specific effector molecules. In 
contrast, GDP-bound Rab proteins are removed from the membrane and are kept cytosolic 
by means of the Rab GDP dissociation inhibitor (RabGDI) (reviewed by Behnia and Munro 
2005, Ali and Seabra 2005). 
 
 
 
Figure 1.2: Platelet dense granule secretion requires Rab27 and SNARE proteins. 
Dense granules in platelets are loaded with small molecules (e.g. ADP, serotonin) that are released on platelet 
activation. Platelet dense granule release requires the small GTPase Rab27 and the SNARE proteins VAMP-8, 
syntaxin-2 and SNAP-23. GTP-Rab27 is dense granule-associated and through engagement of effector proteins 
regulates granule motility (1) and granule tethering/docking to the plasma membrane (2). Rab27 effector proteins 
interact with motor proteins (e.g. myosin) and/or plasma membrane components (e.g. phospholipids). Once a 
dense granule is docked, membrane fusion is mediated by SNARE proteins. VAMP-8 is a vesicle-associated (v)-
SNARE, and syntaxin-2 and SNAP-23 are target/plasma membrane-associated (t)-SNAREs. SNARE proteins are 
characterized by SNARE motifs. VAMP-8 and syntaxin-2 each possess a single SNARE motif, whereas SNAP-23 
contains two SNARE motifs separated by a palmitoylated linker. Assembly of the SNARE motifs into a tight four 
α-helix bundle, the so-called SNARE core complex, drives fusion of the two lipid bilayers and hence delivery of 
dense granule contents into the extracellular environment. GTP: guanine nucleotide triphosphate; SNARE: 
soluble NSF attachment protein receptor; TM: transmembrane domain; PL: palmitoylated linker. 
 
First evidence that Rab proteins and in particular Rab27 are involved in platelet granule 
secretion came from studies of gunmetal (gm) mice. The naturally occurring gunmetal mice 
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have a mutation in the RGGTA gene encoding the α-subunit of the Rab geranylgeranyl 
transferase which results in a reduction of RabGGT activity to approximately 20 % of wild-
type (Detter et al. 2000). In consequence, Rab27 and other Rab proteins in platelets remain 
unprenylated and thus cytosolic (Detter et al. 2000). Mice with gm mutation exhibit 
abnormalities in platelet alpha and dense granules, thrombocytopenia, and prolonged 
bleeding (Seabra et al. 2002). Additional evidence that Rab proteins play a critical role in 
platelet secretion was obtained from studies with Rab GDP dissociation inhibitor. When 
introduced into permeabilized platelets, RabGDI extracted Rab GTPases from membranes 
and inhibited Ca
2+-induced alpha granule secretion (Shirakawa et al. 2000). The same study 
by Shirakawa et al. 2000 demonstrated that Rab4 blocked platelet alpha granule but failed to 
affect secretion from dense granules. These data suggest that the regulatory mechanisms 
governing alpha and dense granule secretion in platelets are distinct, and Rab4 is required 
for alpha but not dense granule release. Conversely, incubation of permeabilized platelets 
with Rab27 inhibited platelet dense granule secretion, and this inhibition could be rescued by 
addition of Munc13-4 (Shirakawa et al. 2004). Rab27 is expressed in two isoforms, Rab27a 
and Rab27b, that share 71 % identity at the amino acid level (Pereira-Leal and Seabra 
2001). Both, Rab27a and Rab27b are present in platelets and localize predominantly to 
membranes of platelet dense granules (Barral et al. 2002). Much recent interest has focused 
on Rab27a because it is the first Rab protein closely associated with human disease (Seabra 
et al. 2002). In humans, defects in the RAB27A gene cause Griscelli syndrome (GS), a rare 
autosomal disorder which is characterized by hypopigmentation and loss of cytotoxic killing 
activity. At cellular level, the disease reflects dysfunction in melanosome transport in 
melanocytes and lytic granule release in cytotoxic T lymphocytes. The corresponding mouse 
model for GS is designated ashen and exhibits a loss-of-function mutation in RAB27A. 
Interestingly, the issue of platelet dysfunction in ashen mice has been a matter of debate. 
Despite the fact that platelet functional defects are not observed in patients with GS, a 
platelet phenotype has been reported for ashen  mice (Wilson et al. 2000). Subsequent 
analysis, however, revealed that the platelet defect seen by Wilson and his co-workers is due 
to a mutation in a second gene, Slc35d3, which encodes an orphan putative sugar nucleotide 
transporter (Chintala et al. 2007). Consistent with studies of GS in humans, normal platelet 
function in the presence of RAB27A loss-of-function mutation has been described in ashen 
by Barral et al. 2002, suggesting that presence of Rab27b in platelets compensates for the 
loss of Rab27a. Deletion of RAB27B in mice, however, resulted in a bleeding phenotype, 
albeit the bleeding tendency was more severe in double RAB27A/B knockout animals 
(Tolmachova et al. 2007). Both, Rab27a and Rab27b have been demonstrated to participate 
in platelet dense granule release with a distinct and probably non-redundant role for Rab27b 
in dense granule formation (Tolmachova et al. 2007). Conversely, the morphology and 
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secretion of platelet alpha granules were not affected, consistent with only minor association 
of Rab27a and Rab27b with alpha granule membranes (Tolmachova et al. 2007, Barral et al. 
2002). Rab27 regulates platelet dense granule secretion, operating upstream of SNARE 
proteins and thus upstream of the membrane fusion event. Rab27 is thought to exert its 
function by promoting granule motility and/or granule tethering/docking to the plasma 
membrane (Fig.1.2) (Seabra and Coudrier 2004, Fukuda 2006). Therefore, Rab27 needs to 
interact with effector molecules, and Munc13-4 was identified as the first Rab27-binding 
protein in platelets (Shirakawa et al. 2004). To date three groups of Rab27 effectors have 
been described (Fig.1.3): Slp (synaptotagmin-like proteins), Slac2 (Slp homologue lacking 
C2 domains), and Munc13-4. Slp and Slac2 family members are defined by a conserved N-
terminal synaptotagmin-like protein homology domain (SHD) that binds to Rab GTPases and 
in particular Rab27 (Fukuda 2005). In addition, Slps contain two tandem C2 domains at their 
C-termini that are homologous to the C2A and C2B domains of synaptotagmins. In contrast,                          
 
 
 
 
 
 
Figure 1.3: Domain structures of putative Rab27 effector proteins. 
Three groups of Rab27 binding proteins are known: Slp (synaptotagmin-like proteins), Slac2 (Slp homologue 
lacking C2 domains) and Munc13-4. A: There are five Slp family members (Slp1, 2, 3, 4, and 5). All of them 
contain an N-terminal Slp homology domain (SHD), which mediates binding to Rab27, and two C-terminal tandem 
C2A and C2B domains. The Slp homology domain of Slp3, Slp4 and Slp5 is separated by a zinc finger motif 
(Zn
2+). Besides Rab27, Slp1 binds to Rab8 and Slp4 binds to Rab3 and Rab8. B: There are three Slac2 family 
members (Slac2-a, -b and -c). All of them contain the N-terminal Slp homology domain (SHD), which binds to 
Rab27, but lack tandem C2 domains. Instead, Slac2-a and Slac2-c possess myosin and actin binding domains. 
Slac2-a binds to myosin Va and Slac2-c binds to myosin Va and VIIa.. C: Munc13-4 contains two separate C2 
domains and two Munc13 homology domains (MHD). Munc13-4 is a Rab27 binding protein, however, the Rab27 
binding site in Munc13-4 is yet unknown. Figure was modified according to Fukuda 2005. 
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Slac2 proteins lack such domains. In mammals, there are five synaptotagmin-like proteins: 
Slp1/JFC1, Slp2/exophilin-4, Slp3, Slp4/granuphilin-a, and Slp5. Several studies implicate 
Slps in the regulation of membrane trafficking in different secretory cells (reviewed by 
Martens and McMahon 2008). 
SNAREs and SNARE accessory proteins 
Membrane fusion in platelets depends on SNAREs and is a process whereby two separate 
lipid bilayers (e.g. granule and OCS/plasma membrane) merge to become one. SNARE 
proteins are membrane-associated, and on the basis of their localization can be divided into 
vesicle (v)-SNAREs and target membrane (t)-SNAREs. Prior to granule/membrane fusion, a 
ternary core complex of SNARE proteins is formed in trans on opposing membranes, 
bringing the granule and plasma membranes into close apposition. Then, upon fusion a cis 
SNARE complex is formed in which all of the contributing SNARE proteins are localized to 
the same membrane. This cis complex is subsequently disassembled by the AAA-ATPase 
NSF (N-ethylmaleimide  sensitive  factor) and α-SNAP (soluble  NSF  attachment  protein) 
(Jahn and Scheller 2006). In platelets, t-SNAREs syntaxin-2, -4, -7, -11 (Lemons et al. 1997, 
Chen et al. 2000a, Chen et al. 2000b), and SNAP-23, -25, -29 are present (Flaumenhaft et 
al. 1999, Reed et al. 1999, Polgar et al. 2003). Platelets also contain the v-SNAREs VAMP-2, 
VAMP-3, VAMP-7, and VAMP-8 (Flaumenhaft et al. 1999, Polgar et al. 2002, Schraw et al. 
2003, Ren et al. 2007). Experiments using permeabilized platelets strongly suggest a role for 
SNARE proteins in platelet granule release (reviewed by Flaumenhaft 2003). However, 
despite the consensus on t-SNAREs, it was long time unclear which v-SNARE(s) are 
involved. Recent studies with transgenic mice demonstrated a redundancy of v-SNAREs in 
platelets, with VAMP-8 as the primary v-SNARE for platelet granule secretion (Ren et al. 
2007). Thus, platelet dense granule release requires syntaxin-2, SNAP-23 and VAMP-8 
(Fig.1.2), whereas platelet alpha granule and lysosome secretion are mediated by syntaxin-4 
and syntaxin-2, SNAP-23 and VAMP-8 (Lemons et al. 1999, Flaumenhaft et al. 1999, Chen 
et al. 2000a, Chen et al. 2000b, Ren et al. 2007).  
In addition, SNARE accessory proteins such NSF, α-SNAP and Munc-18c have been shown 
to serve as important modulators of SNARE function in platelets. By means of inhibitory 
peptides and antibodies a role for NSF in platelet dense, alpha and lysosomal granule 
release could be assigned (Chen et al. 2000a, Lemons et al. 2000, Polgar et al. 1999). Upon 
inhibition of NSF, SNARE proteins are sequestered in cis complexes and are unavailable to 
interact with SNARE proteins on opposing membranes. α-SNAP binds and activates NSF 
(Clary et al. 1990). In platelets, wild-type α-SNAP stimulated Ca
2+-induced granule secretion, 
whereas a dominant-negative mutant of α-SNAP and anti-α-SNAP antibodies inhibited 
granule release (Chen et al. 2000). Moreover, the Sec1/Munc18 homologue Munc-18c (also 
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known as platelet Sec1 protein) was identified in platelets (Reed et al. 1999). Munc-18c 
binds to syntaxin-4, and is phosphorylated by PKC upon platelet activation (Reed et al. 1999, 
Houng et al. 2003). Phosphorylation of Munc-18c decreases binding to syntaxin-4, 
suggesting that activation-induced dissociation of the Munc-18c/syntaxin-4 complex might 
contribute to platelet granule secretion. Accordingly, peptides mimicking Munc-18c binding 
sites augmented Ca
2+-induced dense granule release from permeabilized platelets, and 
similarly, antibodies that inhibit Munc-18c/syntaxin-4 complex formation promoted platelet 
granule secretion (Houng et al. 2003). 
Taken together, platelet granule secretion is essential to hemostasis and is a process 
mediated by an elaborate protein machinery regulating distinct steps of granule motility, 
granule tethering/docking and granule/membrane fusion. Yet, the organization of this protein 
network in platelets is not well understood. Undoubted is the role for SNARE proteins in 
membrane fusion, and it is clear that small GTPases such as Rab GTPases by engagement 
of effector molecules are involved as well. Apart from extensive work that has been done on 
SNAREs, only little is known about Rab proteins and their effectors. So far, Rab4 and Rab27 
have been shown to play a role in platelet granule secretion. However, Rab effector proteins 
have not yet been identified, except for Munc13-4. Moreover, the issue of how agonist-
induced platelet activation elicits platelet granule release is obscure. It is evident that 
elevation of intracellular calcium and activation of protein kinase C play a crucial role. 
However, the exact signaling mechanism remains to be established. 
1.4 Platelet aggregation 
The accumulation of platelets into a hemostatic plug is based on the formation of multiple 
platelet-platelet interactions (platelet aggregation). The major receptor mediating platelet 
aggregation is integrin αIIbβ3 (also known as GPIIb-IIIa), which is the most abundant receptor 
on the platelet surface (Fullard 2004, Varga-Szabo et al. 2008). In humans, lack or 
dysfunction of αIIbβ3 cause the bleeding disorder Glanzmann`s thrombasthenia (GT) (Nurden 
and Nurden 2008). Mice lacking the β3 integrin resemble the phenotype of GT with absent 
platelet aggregation and reduced uptake of fibrinogen into platelets (Hodivala-Dilke et al. 
1999, Fullard 2004). Integrin αIIbβ3 binds various ligands including von Willebrand factor, 
fibrinogen and fibronectin, all of which contain the classical integrin recognition sequence 
arginine-glycine-aspartic acid (Jackson 2007, Varga-Szabo et al. 2008). In resting platelets, 
αIIbβ3 is in a low affinity or inactive state, in which it is not able to bind to its ligands. Agonist-
induced platelet activation, however, induces intracellular signaling processes that activate 
αIIbβ3  by converting it into an active high affinity conformation (inside-out signaling and 
change in affinity). In addition, αIIbβ3 lateral mobility and clustering within the platelet plasma 
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membrane (change in avidity) supports ligand binding to αIIbβ3 and thus platelet aggregation 
(Shattil et al. 2004, Ginsberg et al. 2005).  
The exact signaling mechanisms linking agonist-induced platelet activation and activation of 
platelet integrins (e.g. αIIbβ3) have been extensively studied, but are yet not fully understood. 
Recently, Rap1 has been suggested to be an important intermediate (Bos et al. 2001, Shattil 
et al. 2004, Stork and Dillon 2005). Rap1 is a member of the Ras superfamily of small 
nucleotide binding proteins and has been implicated to be involved in various aspects of cell 
adhesion (Bos et al. 2001, Bos et al. 2003, Bos 2005). Rap1 has two isoforms, Rap1a and 
Rap1b, that share 95 % sequence identity at the amino acid level (Scrima et al. 2008). 
Rap1b is the predominant isoform in platelets (Klinz et al. 1992). Like other small guanine 
nucleotide binding proteins, Rap1 exists in an inactive GDP-bound form and is activated, 
when guanine nucleotide diphosphate is exchanged for guanine nucleotide triphosphate. 
Replacement of GDP for GTP is stimulated by guanine nucleotide exchange factors, 
whereas GTPase activating proteins promote the hydrolysis of bound GTP to GDP and thus 
Rap1 inactivation (Fig.1.4) (Bos et al. 2007).  
 
 
 
 
 
Figure 1.4: Regulation of Rap1 in platelets. 
The small guanine nucleotide binding protein Rap1 regulates the activity of the platelet integrin αIIbβ3, which is 
required for fibrinogen binding and thus platelet aggregation. Rap1 cycles between an inactive GDP- and an 
active GTP-bound form. This GDP/GTP cycle is regulated by guanine nucleotide exchange factors (GEFs) and 
GTPase-activating proteins (GAPs). In platelets, PDZ-GEF1, CalDAG-GEFI and III, and Rap1GAP2 are present. 
PDZ-GEF:  postsynaptic density-95 discs-large and zona occludens protein 1-GEF; CD-GEF: CalDAG-GEF 
(where cal stands for calcium and DAG for 1,2-diacylglycerol); GDP: guanine nucleotide diphosphate; GTP: 
guanine nucleotide triphosphate. 
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In murine megakaryocytes, overexpression of the constitutively active Rap1 mutant 
augmented agonist-induced binding of fibrinogen to integrin αIIbβ3 (Bertoni et al. 2002). 
Moreover, deficiency of Rap1 in mouse platelets resulted in abnormal platelet function and a 
severe hemostatic defect caused by reduced agonist-induced αIIbβ3 activation and thus 
platelet aggregation (Chrzanowska-Wodnicka et al. 2005).  
Rap1 becomes rapidly activated on platelet activation with various agonists (Franke et al. 
1997, Franke et al. 2000, Woulfe et al. 2002). Rap1 activation is mediated by Rap1-specific 
GEFs, of which PDZ-GEF1 and CalDAG-GEFI and III are expressed in platelets (Schultess 
et al. 2005). In particular, CalDAG-GEFI and III are likely candidates to integrate agonist-
induced formation of second messengers into the activation of Rap1. Both, CalDAG-GEFI 
and III, are activated by calcium and 1,2-diacylglycerol (Bos et al. 2007). Recently, platelets 
from mice lacking CalDAG-GEFI have been demonstrated to have decreased agonist-
induced activation of Rap1 and αIIbβ3, and thus impaired aggregation and thrombus formation 
(Crittenden et al. 2004). Conversely, platelet inhibition by NO and PGI2, leading to the 
activation of cGMP- and cAMP-dependent protein kinases, blocks agonist-induced formation 
of Rap1-GTP (Franke et al. 1997, Danielewski et al. 2005). Rap1 is phosphorylated by both, 
PKG and PKA, in platelets (Siess et al. 1990, Miura et al. 1992, Siess and Grünberg 1993, 
Danielewski 2005). However, the effect of this phosphorylation is currently unknown. The 
slow kinetics of Rap1 phosphorylation does not correlate with the fast inhibition of the 
protein, suggesting that Rap1 phosphorylation per se is not responsible for the fast 
inactivation of Rap1. Alternatively, phosphorylation and activation of a Rap1-specific GAP 
could play a role in this process. Two major groups of Rap1-specific GAPs have so far been 
described. The first group includes SPA-1 (signal-induced proliferation-associated protein 1) 
and E6TP1α (SPAR/SPAL), whereas the second group consists of Rap1GAP1 and the 
recently identified Rap1GAP2 (Bos et al. 2001, Stork and Dillon 2005, Schultess et al. 2005). 
In platelets, only Rap1GAP2 is present (Schultess et al. 2005). Rap1GAP2 contains a 
conserved catalytic GAP domain, a dimerization domain, an N-terminal 14-3-3 binding site 
and a large C-terminal region of so far unknown function (Fig.1.5) (Daumke et al. 2004, 
Schultess et al. 2005, Hoffmeister et al. 2008). Platelet activation results in phosphorylation 
of Rap1GAP2 on serine 9, binding of 14-3-3 and inhibition of GAP function (Hoffmeister et al. 
2008). Conversely, phosphorylation of Rap1GAP2 by PKG and PKA at serine 7 inhibits 14-3-
3 binding to Rap1GAP2 (Schultess et al. 2005, Hoffmeister et al. 2008). The release of 14-3-
3 protein from Rap1GAP2 might contribute to the inhibition of platelet aggregation initiated by 
NO and PGI2. 
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Figure 1.5: Rap1GAP2 is a multidomain protein.
Rap1GAP2 is a modular protein composed of a central catalytic GAP domain (GAP), a dimerization domain 
(dimer) and an N-terminal 14-3-3 binding site. The C-terminal part of Rap1GAP2 is predicted to have low 
structural organization and is so far of unknown function.  
 
 
1.5 Aims of the present study 
Rap1GAP2 was identified in our laboratory as the first and so far only known GTPase 
activating protein of Rap1 in human platelets (Schultess et al. 2005). Since no other Rap1 
specific GAPs are available, tight regulation of Rap1GAP2 is probably required. In addition to 
the central catalytic GAP domain, Rap1GAP2 contains large N- and C-terminal regions of 
unknown function. It was hypothesized that these regions could be involved in protein-protein 
interactions. Subsequently, a genetic screening in yeast was performed in order to identify 
Rap1GAP2-associated proteins. Apart from 14-3-3 (Hoffmeister et al. 2008), synaptotagmin-
like protein 1 (Slp1, also called JFC1) was found as a new putative interaction partner of 
Rap1GAP2.  
Based on the results of the yeast-two-hybrid screening, the specific aims of the present study 
were to  
(1) verify binding of Slp1 and Rap1GAP2,  
(2) map the interaction site(s) involved in binding of Slp1 and Rap1GAP2,  
(3) investigate complex formation by Slp1, Rap1GAP2, Rab27 and other  proteins,  
(4) determine the function of Slp1/Rap1GAP2 interaction. 
The investigations were carried out in both, mammalian cells and human platelets. In 
particular, in order to define the functional significance of the interaction between Slp1 and 
Rap1GAP2, both, cellular and platelet models were established and applied. 
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2. MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Plasmids and cDNAs 
pGBKT7      Clontech Takara Bio, Saint-Germain-en-Laye, France 
pACT2       Clontech Takara Bio, Saint-Germain-en-Laye, France 
pGEX-4T-3      GE Healthcare, Freiburg, Germany 
pET28     Novagen,  Darmstadt,  Germany 
pcDNA
TM4/TO    Invitrogen,  Karlsruhe,  Germany 
pcDNA3.1
TM/myc-His   Invitrogen, Karlsruhe, Germany 
pCMV-3Tag-3     Stratagene, La Jolla, USA 
pRluc-N3    BioSignal,  Montreal,  Canada 
  
Full-length Slp1 cDNA, clone IRATp970G0456D6, was obtained from RZPD (Deutsches 
Ressourcenzentrum für Genomforschung GmbH, Berlin, Germany). 
 
2.1.2 Constructs and primers 
All constructs and primers that were provided or generated and used in this work are listed in 
the appendix. Primers were purchased from MWG Biotech AG, Martinsried, Germany. 
2.1.3 Yeast and bacteria strains, cell lines 
Saccharomyces cerevisiae AH109    Clontech Takara Bio, Saint-Germain-en-Laye, 
France 
Escherichia coli strain TOP10    Invitrogen, Karlsruhe, Germany 
Escherichia coli strain XL-10 Gold
TM   Invitrogen, Karlsruhe, Germany 
Escherichia coli strain BL21 Star
TM (DE3)   Invitrogen, Karlsruhe, Germany 
COS-1  cells      DSMZ,  Braunschweig,  Germany 
African green monkey kidney cells 
HeLa cells          Dr. M. Innocenti, IBCII, Frankfurt, Germany 
Human epithelial cervixcarcinoma cells 
LNCaP  cells      DSMZ,  Braunschweig,  Germany 
Human prostate carcinoma cells   
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2.1.4 Antibodies 
Primary antibodies 
Antigen Species  (clone) IB  IP IF  Generated  by 
Protein-specific antibodies 
Rap1GAP2 rabbit 1:500  -  - A.  Smolenski 
Slp1 rabbit  1:2000  -  -  ImmunoGlobe   
Rap1  rabbit  1:500  -  -  Santa Cruz  
Rab27a mouse  (1G7)  1:2000  1:50  -  Abnova 
Rab8a mouse  (3G1)  1:2000  -  -  Abnova 
P-VASP  mouse (16C2)  1:5000  -  -  A. Smolenski 
LDH goat  1:5000  -  -  Chemicon   
Tag-specific antibodies 
FLAG mouse  (M2)  1:10000  1:100  -  Sigma 
c-Myc 
 
mouse (9E10) 
rabbit 
1:2000 
1:100 
1:50 
- 
1:250 
- 
Santa Cruz  
 
HA mouse  (16B12)  1:2000  -  -  Covance 
VSV mouse  (P5D4)  1:5000  1:200  1:250  Sigma 
T7 mouse  1:10000  -  -  Novagen 
GFP  mouse (7.1 & 13.1)  1:1000  1:100  -  Roche 
His6 mouse  1:5000  -  -  Novagen 
GST mouse  (GST-2)  1:10000  -  -  Sigma 
. 
 
Secondary antibodies 
 
Horseradish peroxidase-coupled donkey anti-goat IgG, goat anti-rabbit IgG and goat anti-
mouse IgG were purchased from Dianova, Hamburg, Germany and used as secondary 
antibodies for immunoblot analysis in dilutions 1:10000. Cy3- and Cy5-labelled secondary 
antibodies were obtained from Jackson Immunoresearch, West Grove, USA and used for 
immunofluorescence analysis in dilutions 1:250. 
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2.1.5 Enzymes and purified proteins 
Pfu DNA Polymerase       Stratagene, La Jolla, USA 
      Fermentas,  St.  Leon-Rot,  Germany 
Quick T4 DNA Ligase        New England Biolabs, Beverly, USA 
Restriction enzymes        New England Biolabs, Beverly, USA 
      Fermentas,  St.  Leon-Rot,  Germany 
 
Human  thrombin     Sigma,  Taufkirchen,  Germany 
Human  fibronectin     Calbiochem,  Darmstadt,  Germany 
 
Creatine phosphokinase      Sigma, Taufkirchen, Germany 
Streptolysin-O     Prof. Dr. S. Bhakdi, Mainz, Germany 
Catalytic subunit of PKA    Dr. E. Butt-Dörje, Würzburg, Germany 
2.1.6 Standards and kits 
GeneRuler DNA Ladder Mix     Fermentas, St. Leon-Rot, Germany 
Unstained Protein MW Marker    Fermentas, St. Leon-Rot, Germany 
 
QIAquick Gel Extraction Kit      Qiagen, Hilden, Germany 
NucleoSpin® Plasmid MiniPrep Kit    Macherey-Nagel, Düren, Germany 
NucleoBond® PC500 MaxiPrep Kit    Macherey-Nagel, Düren, Germany 
 
ECL
TM WB detection kit      Amersham Biosciences, Freiburg, Germany 
Immobilon
TM  WB detection kit    Millipore, Billerica, USA 
 
Renilla Luciferase Assay System    Promega, Mannheim, Germany   
Active® PSA ELISA Kit    Diagnostic Systems Laboratories, Sinsheim, 
Germany 
2.1.7 Chemicals and special reagents 
Metafectene
TM      Biontex,  Martinsried,  Germany 
DEAE-Dextran    Sigma,  Taufkirchen  ,  Germany 
Chloroquine      Sigma,  Taufkirchen,  Germany 
6α-fluorotestosterone     Biomol,  Hamburg,Germany 
ADP       Sigma,  Taufkirchen,  Germany 
Forskolin      Sigma,  Taufkirchen,  Germany 
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Prostaglandin I2 (PGI2)    Biozol,  Eching,  Germany 
Sp-5,6-DCI-cBiMPS     Biolog,  Bremen,  Germany 
Rp-8-Br-cAMPS     Biolog,  Bremen,  Germany 
ortho-Phthalaldehyde     Sigma,  Taufkirchen,  Germany 
Serotonin creatinine sulfate      Sigma, Taufkirchen, Germany 
Creatine  phosphate     Fluka,  Buchs,  Switzerland 
Protein A/G Plus Agarose      Santa Cruz Biotechnology, Santa Cruz, USA 
GSH Sepharose
TM 4B      GE Healthcare, Freiburg, Germany 
Ni-NTA        Qiagen,  Hilden,  Germany 
Bio Rad Protein Assay      Bio-Rad, München, Germany 
Albumine bovine fraction V      Sigma, Taufkirchen, Germany 
Albumin bovine fraction V, fatty acid-free  Serva Electrophoresis, Heidelberg, Germany 
 
Rap1GAP2 wild-type peptide with the sequence HNSMEVTKTTFSPPV (amino acids 518-
532 of Rap1GAP2a) and Rap1GAP2ΔEVTKTT peptide with the sequence GISHNSMFSPP 
VVAA (amino acids 515-535 of Rap1GAP2a lacking amino acids 522-527) were obtained 
from Schafer-N, Copenhagen, Denmark. All chemicals and reagents for yeast culture and 
transformation were obtained from Clontech Takara Bio, Saint-Germain-en-Laye, France and 
Sigma, Taufkirchen, Germany, except for x-α-Gal which was purchased from Glycosynth, 
Warrington, UK. All cell culture media and solutions were purchased from PAA Laboratories, 
Pasching, Austria. Other chemicals and reagents not listed above were obtained from Sigma, 
Taufkirchen, Germany, Applichem, Darmstadt, Germany, Merck, Darmstadt, Germany and 
Roth, Karlsruhe, Germany.                                                   
2.1.8 Buffers, solutions and gels 
1x TAE Buffer      
40  mM  Tris      
20 mM Acetic acid       
1 mM EDTA pH 8.0 
  
TBS       TBS-T                                              
10 mM Tris-HCl pH 7.6     TBS pH 7.6               
150 mM NaCl       + 0.1 % (v/v) Tween
® 20 
 
1x SDS Electrophoresis Loading Buffer 
0.01 M Tris-HCl pH 8.0 
1 mM EDTA 
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1 % (w/v) SDS (electrophoresis grade) 
5 % (v/v) β-Mercaptoethanol 
10 % (v/v) Glycerine 
0.05 % (w/v) Bromophenol blue 
 
1x SDS Electrophoresis Running Buffer 
25 mM Tris  
112 mM Glycine 
0.1 % (w/v) SDS 
 
Transfer Buffer 
25 mM Tris-NaOH pH 8.3 
150 mM Glycine 
10 % (v/v) Methanol 
 
Ponceau S Staining Solution   
1 % (w/v) Ponceau S          
15 % (w/v) Trichloroacetic acid       
 
Hot Coomassie Staining Solution 
Phast Gel
TM Blue R (Coomassie R 350 stain) 
GE Healthcare, Freiburg, Germany 
 
LB Medium (Luria-Bertani Medium) 
1 % (w/v) Tryptone 
0.5 % (w/v) Yeast extract 
1 % (w/v) NaCl 
 
Synthetic drop-out (SD) agar medium 
-Trp/-Leu/-His/-Ade: 
4.67 % (w/v) minimal SD agar base 
0.06 % (w/v) -Trp/-Leu/-His/-Ade DO supplement 
For SD/-Trp/-Leu/-His/-Ade supplemented with x-α-Gal, 40 mg/l of x-α-Gal were added. 
 
X-α-Gal stock solution 
5-bromo-4-chloro-3-indolyl-α-D-galactopyranoside (x-α-Gal) was dissolved in N,N-
Dimethylformamide to a final concentration of 20 mg/ml and stored in the dark at -20°C. 
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Polyacrylamide gels  
 
 
Resolving gel  Stacking gel 
[ml]  9 %  10 %  12 %  4% 
H2O 27.725  26.025  22.725  11.38 
Acrylamide 30 %  15  16.7  20  2.7 
3 M Tris-HCl pH 8.9  6.25  6.25  6.25  - 
0.5 M Tris-HCl pH 6.7 -  -  -  5 
SDS 10 %  0.5  0.5  0.5  0.5 
TEMED 0.025  0.025  0.025  0.02 
APS 10 %  0.5  0.5  0.5  0.4 
. 
2.1.9 Consumables 
Protran
® nitrocellulose transfer membrane    Whatman, Dassel, Germany 
Pore size 0.45 µm 
Fuji Medical X-ray film Super RX      Fujifilm, Tokyo, Japan 
PD-10 desalting columns        GE Healthcare, Freiburg, Germany 
Amicon® Ultra centrifugal filter devices    Millipore, Billerica, USA 
3K / 10K / 50K / 100K         
All cell culture dishes and flasks were purchased from Greiner, Frickenhausen, Germany. All 
other plastic consumables were from Greiner, Frickenhausen, Germany and Sarstedt, 
Nuembrecht, Germany. 
2.1.10 Equipment  
PCR: 
GeneAmp® PCR system 9700      Applied Biosystems, Foster City, USA 
Eppendorf  Mastercycler     Eppendorf,  Hamburg,  Germany 
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Agarose gel analysis: 
Gel Doc 2000 with Quantity One software    Bio Rad, München, Germany 
Immunflourescence analysis: 
Zeiss LSM 510 confocal laser scanning microscope    
with Plan-Apochromat 63x/1.4 oil DIC objective lens 
and LSM 510 Meta software       Carl Zeiss, Göttingen, Germany 
  
Centrifuges: 
Eppendorf centrifuge 5415D       Eppendorf, Hamburg, Germany 
Eppendorf centrifuge 5417R       Eppendorf, Hamburg, Germany 
Eppendorf centrifuge 5810R       Eppendorf, Hamburg, Germany 
Avanti
TM J-30I centrifuge        Beckman Coulter, Krefeld, Germany 
 
Photometric analysis: 
Eppendorf  BioPhotometer     Eppendorf,  Hamburg,  Germany 
Wallac Victor
3 1420 Multilabel Counter    Perkin Elmer, Fremont, USA 
 
2.2 Molecular biological methods 
2.2.1 Agarose gel electrophoresis 
DNA fragments were separated by electrophoresis on 1 % agarose gels according to their 
size. Gels were prepared using standard agarose and 1x TAE running buffer. For DNA 
visualization, 1 µg/ml ethidium bromide was added. Before loading, samples were mixed with 
6x DNA loading buffer (Fermentas, St- Leon-Rot, Germany). Gels were run at 100 V 20 min 
in 1x TAE buffer and finally examined under UV (Gel Doc 2000, Quantity One). 
2.2.2 Cloning of PCR products 
DNA fragments were amplified by polymerase chain reaction (PCR) using thermostable 
proofreading DNA polymerase Pfu (Stratagene; Fermentas). Primers for cloning were 
designed with overhangs in their 5` regions containing the appropriate sites for restriction 
enzymes. All primers that were used can be found in the appendix. Unless otherwise 
specified, a standard hot start PCR protocol was applied in which the polymerase was added 
after the initial denaturation step. 
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Reaction mixture: 
 
Component     Final      Volume 
          concentration   for 50 µl of reaction mixture 
  
dH2O      -    variable 
10x  Pfu  buffer     1x    5  µl 
10 mM dNTPs        0.2 mM each    1 µl 
Forward primer 10 µM    0.1 µM     1 µl 
Reverse primer 10 µM    0.1 µM     1 µl 
Template  DNA   100  ng    variable 
Pfu DNA polymerase 2.5 U/µl  2.5 U      1 µl 
 
Cycling conditions: 
Step    Temperature  Time        
 
Initial denaturation  95°C    3 min 
Hot start   80°C   1  min     Pfu DNA polymerase was added. 
Denaturation   95°C   20  sec 
Annealing   variable
A  20 sec    25 - 30 cycles       
Extension   72°C   variable
B                 
Final Extension  72°C    20 min 
Cool  down   12°C   unlimited 
 
A usually primer Tm - 5°C, as standard was used 55°C; 
B n [min] = size of insert  [kb] x 1.5 
plus increments of 1 sec per cycle. 
 
The amplified DNA was separated by agarose gel electrophoresis and analysed under UV. 
For further processing, DNA of appropriate size was cut out and extracted using QIAquick 
Gel Extraction Kit according to manufacturer`s instructions. For directional cloning into the 
plasmid vector, the purified  fragment (insert) and the vector were digested with the 
appropriate restriction enzymes. Then, purified and digested insert and vector were ligated at 
a molar ratio of insert:vector of 3:1 using Quick T4 DNA Ligase according to manufacturer`s 
instructions. Ligation products were transformed into ultra-competent Escherichia coli Top10 
cells and grown overnight on LB-agar plates containing the appropriate antibiotic at 37°C. On 
the next day, transformed colonies were picked and grown in LB with antibiotic overnight at 
37°C under vigorous shaking. The plasmid DNA was purified using NucleoSpin® Plasmid 
MiniPrep Kit according to manufacturer`s instructions. The presence of the amplified cloned 
fragment was confirmed by (i) digesting with restriction enzymes and analysis of the 
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restricted DNA by agarose gel electrophoresis and (ii) by DNA sequencing (MWG Biotech, 
Martinsried, Germany). 
2.2.3 In-vitro mutagenesis 
To create a mutation (truncation, deletion or point mutation) of any given DNA sequence, 
site-directed in-vitro mutagenesis was performed. For this purpose, target wild-type DNA was 
amplified by PCR using mutagenic primer pairs (see appendix, list of primers for 
mutagenesis) and Pfu DNA polymerase. The PCR product was digested with DpnI 
(Fermentas, St. Leon-Rot, Germany) for 1 h at 37°C. DpnI specifically cleaves methylated 
and thereby bacterially generated DNA used as template. DpnI-resistant DNA was 
transformed into Escherichia coli XL-10 Gold
TM by KCM method. In brief, to prepare 
competent Escherichia coli XL-10 Gold
TM,
 cells were grown in LB medium without antibiotic to 
an OD600
 of 0.3 to 0.6 at 37°C under vigorous shaking. After short centrifugation, the bacterial 
pellet was resuspended in ice-cold TSB (LB medium with 10 % (v/v) polyethylene glycol, 5 % 
(v/v) DMSO, 20 mM Mg2SO4). Then, 80 µl of dH2O, 20 µl of 5x KCM buffer (0.5 M KCl, 0.15 
M CaCl2, 0.25 M MgCl2), 5 µl of DpnI-digested PCR product and 100 µl of competent 
Escherichia coli XL-10 Gold
TM were mixed and incubated on ice for 20 min, followed by 
further incubation for 10 min at RT. Then, 800 µl of LB medium were added and cells were 
shaken for 1 h at 37°C. Prior to plating on selective LB-agar with antibiotic, cells were 
centrifuged at 8000 rpm for 1 min. The supernatant was removed and cells were 
resuspended in 100 µl of LB medium. Cells were plated and grown overnight at 37°C. The 
desired mutation was verified by DNA sequencing (MWG Biotech, Martinsried, Germany).                           
2.3 Cell biological methods 
2.3.1 Cell culture and transfection 
30 
COS-1 and HeLa cells were cultured in Dulbecco`s modified Eagle`s medium (DMEM) with 
4500 mg/l glucose and L-glutamine. LNCaP cells were cultured in RPMI 1640 medium with 
L-glutamine. All media were supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin (PAA Laboratories, Pasching, Austria). Cells were kept at 37°C and 
ambient air containing 5 % CO2. For cell splitting, trypsin-EDTA (1x) solution (PAA 
Laboratories, Pasching, Austria) was used. In brief, one 10 cm dish of confluent cells was 
washed once with 10 ml of PBS to remove residual medium and cell debris. Then, 2 ml of 
trypsin-EDTA were added and cells were incubated for up to 10 min at 37°C 5 % CO2. In 
order to inactivate trypsin, the detached cells were mixed with a surplus of DMEM and then 
collected. An appropriate split ratio was calculated (generally 1:10 to 1:20) and cells were 
replated. The newly seeded cells were left undisturbed for at least 12 to 24 h.  
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Transient transfections of COS-1 cells were performed with DEAE-dextran. For this purpose, 
6 x 10
5 cells counted with CASY cell counter (Innovatis, Bielefeld, Germany) were seeded 
per 10 cm dish. On the following day, cells were washed with PBS, and 8 to 10 µg of 
expression plasmids were applied in 5.7 ml of serum-free DMEM mixed with 300 µl of DEAE-
dextran (1 mg/ml stock) and 12 µl of chloroquine (100 mM stock). After incubation for 3 h, the 
transfection mixture was removed and cells were cultured in DMEM with 10 % FBS for 24 to 
48 h prior to use. HeLa and LNCaP cells were transiently transfected using Metafectene
TM 
according to manufacturer`s instructions. 
2.3.2 Platelet preparation 
Washed platelets were obtained by sequential centrifugation. In brief, 20.8 ml freshly drawn 
venous blood from healthy volunteers who gave their informed consent according to the 
declaration of Helsinki was collected into 4.2 ml of prewarmed ACD buffer (85 mM sodium 
citrat, 65 mM citric acid, 100 mM glucose) and centrifuged at 200 g for 15 min without brake. 
Platelet rich plasma was removed and platelets were pelleted at 600 g  for 15 min. The 
platelet pellet was then resuspended in prewarmed resuspension buffer (145 mM NaCl, 5 
mM KCl, 1 mM MgCl2, 10 mM HEPES, 10 mM glucose, pH 7.4) to a final concentration of 
approximately 1-3 x 10
8 platelets/ml counted with CASY cell counter (Innovatis, Bielefeld, 
Germany). The platelet suspension was incubated at 37°C for 30 min prior to use. 
2.3.3. Cell lysis 
Adherent COS-1 or HeLa cells were washed three times with ice-cold PBS and detached by 
scraping with a rubber policeman. Washed platelets or washed COS-1 or HeLa cells were 
lysed 10 min on ice with lysis buffer (50 mM Tris-HCl pH 7.5, 1% (v/v) Triton X-100, 150 mM 
NaCl, 5 mM MgCl2), containing  phosphatase inhibitors (1 mM Na3VO4, 50 mM NaF, 5 mM 
Na4P2O7) and protease inhibitors (2 µg/µl aprotinin, 1 µg/µl leupeptin, 0.1 mM 
phenylmethylsylfonyl fluoride). In order to remove insoluble material, cell lysates were 
centrifuged at 14000 g 4°C for 20 min and cleared supernatants were collected for co-
immunoprecipitation and pull-down experiments. 
2.3.4 Immunofluorescence microscopy 
31 
HeLa cells were grown on glass coverslips (Falcon® culture slides, Becton Dickinson, USA) 
and transfected with expression vectors for EGFP-tagged Rab27a, VSV-tagged Rap1GAP2 
and myc-tagged Slp1. 24 h post-transfection, cells were fixed with 3.7 % paraformaldehyde 
in PBS for 15 min on ice, washed with PBS and permeabilized with 0.2 % (v/v) Triton X-100 
in PBS for 10 min at RT. To detect VSV-tagged Rap1GAP2 and myc-tagged Slp1, primary 
tag-specific antibodies, diluted with 1 % (w/v) BSA in PBS, were added and incubated for 1 h 
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at 37°C, followed by incubation with Cy5-conjugated anti-mouse IgG and Cy3-conjugated 
anti-rabbit IgG as secondary antibodies. After further washing with PBS and water, samples 
were mounted in GEL/Mount
TM (Biomeda, Foster City, CA). Staining was observed using 
Zeiss LSM 510 confocal laser scanning microscope (Carl Zeiss, Göttingen, Germany). 
2.4 Protein biochemical methods 
2.4.1 Yeast transformation 
Saccharomyces cerevisiae strain AH109 was retransformed with Rap1GAP2-Gal4BD and 
two positive clones of Slp1-Gal4AD (clone 27 and clone 87) obtained from the yeast-two-
hybrid screening with full-length Rap1GAP2a as bait and a human adult brain cDNA library 
as prey (Hoffmeister et al. 2008). Transformation was carried out by lithium acetate/single 
stranded DNA/polyethylene glycol method according to Agatep and Gietz 1998. To select for 
co-transformants, transformed yeasts were grown on synthetic dropout (SD) agar medium 
lacking tryptophane and leucine (SD/-Trp/-Leu) at 30°C for two days. Grown colonies were 
transferred on agar plates containing SD medium without tryptophane, leucine, histidine and 
adenine (SD/-Trp/-Leu/-His/-Ade) and SD/-Trp/-Leu/-His/-Ade supplemented with 5-bromo-4-
chloro-3-indoxyl-α-D-galactopyranoside (x-α-Gal). After two days, yeasts were analyzed for 
survival and α-galactosidase activity or blue coloration, respectively. 
2.4.2 Expression and purification of GST fusion proteins 
To produce recombinant glutathione-S-transferase (GST) fusion protein of Slp1, full-size 
cDNA of Slp1 was subcloned into EcoRI and XhoI sites of the prokaryotic expression vector 
pGEX-4T-3. For GST-14-3-3β protein production, full-size cDNA of 14-3-3β was subcloned in 
pGEX-4T-3 as described in Hoffmeister et al. 2008. Escherichia coli strain BL21 (DE3) was 
transformed with 50 ng of the appropriate plasmid by heat shock and a starter culture of 25 
ml LB medium with 100 µg/ml ampicillin (LB/ampicillin) was grown overnight at 37°C. On the 
next day, the confluent culture was diluted 20 times with LB/ampicillin (500 ml total) and 
grown to an OD600 of 0.9 at 37°C under vigorous shaking. Protein expression was induced 
with 0.1 mM isopropyl-β-D-1-thiogalactopyranoside (IPTG) and bacteria were grown 
overnight at 16°C. On the following day, cells were harvested by centrifugation at 5500 rpm 
4°C for 10 min in a Beckman JA-10 rotor (Avanti
TM J-30I centrifuge, Beckman Coulter). The 
bacterial pellet was resuspended in  5 ml of ice-cold lysis buffer (50 mM HEPES pH 7.5, 150 
mM NaCl, 1 mM EDTA, 5 % (v/v) glycerol, 0.1 % (v/v) Nonidet P40), containing the complete 
protease inhibitor cocktail (Roche, Mannheim, Germany). Bacterial walls were disrupted by 
sonication for 10 sec three times each. To obtain clear bacterial lysate, the bacterial cell 
32 
 Materials and methods 
_________________________________________________________________________________ 
 
suspension was centrifuged at 16000 rpm 4°C for 30 min in a Beckman JA-30.50 rotor 
(Avanti
TM J-30 centrifuge, Beckman Coulter). Meanwhile, glutathione (GSH) sepharose 
beads were prepared by washing of 250 µl of GSH sepharose twice with ice-cold PBS and 
once with lysis buffer. Beads were centrifuged in a swinging bucket rotor at 500 g 4°C for 5 
min (Eppendorf Centrifuge 5810R). The prewashed beads were incubated with clear 
bacterial lysate for 1 h at 4°C under gentle rotation, centrifuged and washed extensively 
three times with ice-cold lysis buffer, three times with PBS containing 0.1 % (v/v) Triton X-
100, and three times with PBS. Washed beads were resuspended in 250 µl of PBS 
supplemented with 5 % (v/v) glycerol, aliquoted, frozen and stored at -20°C. Alternatively, in 
order to obtain free GST-Slp1 protein, beads were incubated with 2.5 ml of elution buffer (50 
mM Tris-HCl pH 8.0, 10 mM glutathione) overnight at 4°C, followed by buffer exchange and 
protein concentration using Amicon® Ultra 50K centrifugal filter devices. 
2.4.3 Expression and purification of His6-tagged proteins 
For recombinant hexa-histidine (His6)-tagged protein production in Escherichia coli, full-size 
cDNA of Slp1 and the coding sequence of amino acids 1-167 of Rap1b were subcloned into 
the prokaryotic expression vector pET28. The plasmids were transformed into Escherichia 
coli BL21 and a starter culture of 10 ml LB medium with 30 µg/ml kanamycin (LB/kanamycin) 
was grown overnight at 37°C. On the next day, the confluent culture was diluted 50 times 
with LB/kanamycin (500 ml total) and grown to an OD600 of 0.6 at 37 °C under vigorous 
shaking. Protein expression was induced with 0.4 mM IPTG and bacteria were grown for 3 h 
at 37°C. Cells were harvested, as mentioned in 2.4.2, and lysed in 5 ml of ice-cold lysis 
buffer (50 mM NaH2PO4-NaOH pH 8.0, 300 mM NaCl) containing protease inhibitors, 
followed by sonication. Clear bacterial lysate was obtained by centrifugation as described in 
2.4.2. To purify His6-tagged proteins from the lysate, nickel-nitrilotriacetic acid-agarose (Ni-
NTA) was used. His6-tagged Slp1 was purified in batch mode, whereas His6-tagged Rap1b 
was purified via HisTrap HP column (GE Healthcare) using an ÄKTA-system (J. Babica, 
IBCII, Frankfurt, Germany). For batch purification of His6-Slp1, 1 ml Ni-NTA suspension was 
prewashed with ice-cold lysis buffer and subsequently incubated with clear bacterial lysate 
for 1 h at 4°C on a rotator. Once bound with protein, the resin was centrifuged at 4000 rpm 
4°C for 2 min in a swinging bucket rotor (Eppendorf Centrifuge 5810R). The spent lysate was 
poured off. Washing was performed by resuspension of Ni-NTA in wash buffer (50 mM 
NaH2PO4-NaOH pH 8.0, 300 mM NaCl, 20 mM imidazole) and subsequent centrifugation. 
The bound His6-Slp1 protein was eluted sequentially four times with 250 µl of elution buffer 
(50 mM NaH2PO4-NaOH pH 8.0, 300 mM NaCl, 250 mM imidazole). The eluted protein was 
then collected and combined. Imidazole-containing elution buffer was exchanged by PBS by 
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using PD-10 desalting columns according to manufacturer`s instructions, followed by 
concentration of protein with Amicon® Ultra centrifugal filter devices.  
Recombinant His6-tagged Rap1GAP2 wild-type and Rap1GAP2Δ522-527 mutant were 
affinity purified from COS-1 cells. Briefly, one hundred 10 cm dishes of COS-1 cells were 
transiently transfected with the appropriate plasmids. 48 h post-transfection, cells were lysed 
with lysis buffer (50 mM NaH2PO4-NaOH pH 8.0, 300 mM NaCl, 1% (v/v) Triton X-100) 
containing protease inhibitors, and His6-tagged proteins were affinity purified using Ni-NTA 
agarose, as described before for His6-Slp1 batch purification. The purity of all proteins was 
examined by SDS-PAGE followed by Coomassie Brilliant Blue staining. The concentration 
was determined by Bradford method (Bio-Rad) and from intensities of the bands in 
Coomassie Brilliant Blue-stained gels using BSA as standard. 
2.4.4 SDS-PAGE and immunoblotting 
SDS polyacrylamide gel electrophoresis was used to electrophoretically separate proteins 
according to their molecular weight and was carried out in vertical gels using Mighty Small II 
unit (GE Healthcare) and buffers listed under 2.1.8. Separated proteins were either stained 
with Coomassie Brilliant Blue or electrophoretically transferred from the gel to a nitrocellulose 
membrane using the semi-dry transfer unit Fastblot B44 (Whatman Biometra, Göttingen, 
Germany). Prior to immunoblotting, protein transfer was confirmed by staining the 
nitrocellulose membrane with Ponceau S staining solution. After short destaining with TBS-T, 
the membrane was blocked in 5 % (w/v) BSA/TBS-T for 1 h at RT, followed by further 
incubation with the primary antibody, diluted in 5 % (w/v) BSA/TBS-T, for 1 h at RT or 4°C 
overnight. After subsequent three rinses with TBS-T, the membrane was incubated with 
HRP-coupled secondary antibody for 1 h at RT and again washed three times with TBS-T. 
To detect the HRP signal, two different ECL solutions were used: the ECL
TM WB detection 
reagent from Amersham Biosciences showed good results for strong signals, whereas 
Immobilon
TM WB detection reagent from Millipore
 proved to be better for weak HRP signals 
2.4.5 Immunoprecipitation and pull-down assays 
Proteins were immunoprecipitated from 500 µl of lysate by addition of 5 µl of ANTI-FLAG M2 
affinity gel (Sigma, Taufkirchen, Germany) or other protein- or tag-specific antibody at 4°C for 
4 h or overnight. In case of immunoprecipitation with protein- or tag-specific antibodies, 7 µl 
of protein A/G plus agarose (Santa Cruz Biotechnology) were added to precipitate the 
immunocomplex. In pull-down experiments, 1 µl or 5 µl of GSH sepharose,
 saturated with 
GST, GST-Slp1 or GST-14-3-3β, respectively, were added to platelet or cellular lysate and 
incubated at 4°C for 4 h or overnight. After incubation, beads were washed three times with 
lysis buffer before adding 15 µl of 3x SDS electrophoresis loading buffer and boiling for 5 
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min. Bound proteins were separated by SDS-PAGE, transferred to a nitrocellulose 
membrane and visualized by immunoblotting using specific antibodies. 
2.4.6 Antibody production 
To detect Slp1, a polyclonal antibody against Slp1 was produced using full-length 
recombinant glutathione-S-transferase-tagged Slp1 purified from Escherichia coli BL21 as 
antigen. Immunization of rabbits and subsequent purification were performed by 
ImmunoGlobe Antikörpertechnik (Himmelstadt, Germany). 
2.4.7 Phospholipid binding assay (PIPStrip) 
PIP Strips
TM (Echelon Biosciences, Salt Lake City, USA) spotted with 100 pmol of various 
lipids were blocked with 3 % (w/v) fatty-acid free BSA/TBS-T and incubated with 0.5 µg/ml 
purified recombinant proteins in TBS-T for 3 h at RT. The membranes were washed three 
times with TBS-T, incubated with either anti-GST antibody or anti-His6 antibody in 3 % (w/v) 
fatty-acid free BSA/TBS-T for 1 h at RT, washed three times with TBS-T and incubated with 
HRP-coupled goat anti-mouse IgG diluted 1:20000 in 3 % (w/v) fatty-acid free BSA/TBS-T for 
1 h at RT. After washing with TBS-T, bound proteins were detected using ECL
TM WB 
detection reagent (Amersham Biosciences). 
2.4.8 Peptide binding assay (PepSpot) 
Synthetic peptides with either wild-type Rap1GAP2 sequence HNSMEVTKTTFSPP (amino 
acids 518-531 of Rap1GAP2a) or with one amino acid mutated to alanine or single 
threonines phosphorylated were synthesized on cellulose membrane (ImmunoGlobe 
Antikörpertechnik) and incubated with 1 µg/ml of purified recombinant GST-Slp1 in 5 % (w/v) 
BSA/TBS-T for 3 h at RT. Bound GST-Slp1 was visualized by immunoblotting using anti-GST 
antibody. 
2.4.9 In-vitro phosphorylation 
COS-1 cells were transiently transfected with myc-tagged wild-type Slp1 and mutants of Slp1 
having serine-to-alanine mutations of serine 117 and serine 311. 48 h post-transfection, cells 
were lysed in lysis buffer, as described in 2.3.3, and proteins were immunoprecipitated with 
anti-myc antibody (9E10) and protein A/G plus sepharose. Precipitated proteins were 
washed and transferred into 20 µl of kinase buffer (30 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 2 
mM MgCl2) supplemented with 0.1 % (v/v) β-mercaptoethanol and without or with the 
catalytic subunit of PKA at a final concentration of 20 ng/µl. In parallel, 50 µl of cold ATP (200 
nM stock) and 1 µl of γ-[
32P] ATP (10 µCi/µl, obtained from Hartmann Analytic, 
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Braunschweig, Germany) were carefully mixed, and 5 µl of this mixture were used to start the 
phosphorylation reaction. Proteins were phosphorylated for 10 min at 30°C. The reaction was 
stopped by addition of 12.5 µl of 3x SDS electrophoresis loading buffer and boiling for 5 min. 
Samples were subjected to SDS-PAGE and transferred to a nitrocellulose membrane. 
32P 
incorporation was detected by autoradiography. Slp1 expression was analyzed by 
immunoblotting using anti-myc antibody. 
2.4.10 Affinity chromatography 
Affinity chromatography was performed using 1 ml HiTrap
TM NHS-activated HP columns (GE 
Healthcare, Freiburg, Germany) and a peristaltic pump P-1 (Pharmacia). As ligand up to 8 
mg/ml of purified recombinant His6-tagged Slp1 protein in coupling buffer (0.2 M NaHCO3, 
0.5 M NaCl, pH 8.3) were covalently coupled to the NHS-activated sepharose according to 
manufacturer`s instructions. As negative control, HiTrap
TM NHS-activated HP column without 
ligand was prepared and treated identically. As source for interacting proteins, lysate of 
washed human platelets prepared from 100 ml freshly drawn venous blood was used. Prior 
to administration onto the column, platelet lysate was adjusted to the composition of the 
binding buffer (50 mM Tris pH 7.5, 150 mM NaCl) by buffer exchange using PD10 desalting 
columns. Lysate was filtered through a 0.45 µm filter and applied onto the column with a flow 
rate of 0.2 ml/min according to manufacturer`s instructions. After washing with 20 ml of 
binding buffer, bound proteins were eluted with 3 ml of elution buffer (0.1 M glycine pH 3.0) 
and collected in 6 fractions to 500 µl. Each fraction was concentrated with Amicon® Ultra-4 
10K centrifugal filter devices, mixed with 3x SDS electrophoresis loading buffer, boiled and 
separated by SDS-PAGE followed by Coomassie Brilliant Blue staining. Protein bands of 
different molecular weight ranging from 16 to 100 kD were finally excised and analyzed by 
tryptic digest and mass spectrometry (Dr. Guiliano Elia, Conway Institute for Biomolecular 
and Biomedical Research, Dublin, Ireland).  
2.5 Other methods 
2.5.1 In-vitro GAP assay 
36 
For GTP loading, 25 µM His6-Rap1b was incubated with 125 nM [
32P]GTP (800 Ci/mmol, 10 
µM/µl, obtained from Hartmann Analytic, Braunschweig, Germany) in the presence of 25 µM 
GTP, 10 mM EDTA, 1 mM DTE, and 30 mM Tris-HCl pH 7.5 for 1 h at RT. The exchange 
reaction was stopped by adding 20 mM of MgCl2. The non-incorporated nucleotides were 
removed by gel filtration using NAP-5 columns (GE Healthcare). FLAG-tagged Slp1 and 
Rap1GAP2 proteins were purified from transfected HeLa cells using ANTI-FLAG M2 affinity 
gel (Sigma). Precipitated proteins were incubated with purified [
32P] GTP-loaded His6-Rap1b 
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in a buffer containing 30 mM Tris-HCl pH 7.5, 5 mM MgCl2 and 1 mM DTE in 50 µl aliquots at 
25°C. After different time points, 5 µl aliquots were removed and mixed with 395 µl of ice-
cold 5 % (w/v) charcoal suspension in 20 mM phosphoric acid. After centrifugation at 12000 
rpm 4°C for 10 min, 200 µl of supernatants were removed, mixed with 2 ml of scintillation 
fluid and counted (TRI-CARB 2900 TR liquid scintillation analyzer plus QuantaSmart
TM 
software, Perkin Elmer, Fremont, USA). 
2.5.2 Cell adhesion assay 
96 well plates were coated overnight at 4°C with 20 µg/ml fibronectin in PBS, washed with 
PBS, and blocked for 1 h at RT with 0.5 % (w/v) BSA in PBS. After washing, 50 µl of DMEM 
containing 10% (v/v) FBS were added per well. HeLa cells were transiently transfected with 
pRluc-N3 (BioSignal Packard), either alone or in combination with Rap1GAP2-FLAG or 
Rap1GAP2-FLAG and Slp1-myc. Cells were washed, detached with 0.05 % (w/v) EDTA in 
PBS, spun down, resuspended in DMEM containing 10 % (v/v) FBS, counted using 
Neubauer counting chamber and finally diluted to a concentration of 2 x 10
5 cells/ml.  50 µl of 
cell suspension were added per well of the previously prepared 96 well plate. After a short 
spinning down for 1 min at 10 g, cells were allowed to adhere for 50 min at 37°C. Non-
adherent cells were removed by washing with prewarmed 0.5 % (w/v) BSA in PBS. Adherent 
cells were lysed and subjected to luciferase assay using Renilla luciferase assay system 
according to manufacturer`s instructions (Promega, Mannheim, Germany). Expression levels 
of transfected constructs were examined by immunoblotting. Numbers of bound cells were 
calculated and corrected for transfection efficiency by measuring luciferase activity of total 
input cells.  
2.5.3 Prostate-specific antigen secretion assay 
LNCaP cells were cultured as described in 2.3.1. Prior to transfection, cells were seeded in 
six well plates at 3 x 10
5 cells/ml and left undisturbed for 12-24 h. Cells were transiently 
transfected with 2 µg of the indicated expression plasmids with Metafectene
TM according to 
manufacturer`s instructions. 12 h post-transfection, medium was replaced with fresh RPMI 
1640 containing 100 nM 6α-fluorotestosterone or DMSO as control. Cells were incubated for 
additional 36 h at 37°C in 5 % CO2. Then, cell medium was collected and stored at -20°C 
before analysis. The concentration of secreted prostate-specific antigen (PSA) in the medium 
was measured using PSA ELISA kit as described by the manufacturer (Diagnostic Systems 
Laboratories, Sinsheim, Germany). Cells were washed with PBS, trypsinized, counted and 
diluted to a concentration of 2 x 10
5 cells/ml. For protein expression analysis, cells were 
lysed in hot 3x SDS electrophoresis loading buffer and boiled for 5 min. Proteins were 
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separated by SDS-PAGE, transferred onto a nitrocellulose membrane and subjected to 
immunoblotting using tag-specific antibodies. 
2.5.4 Serotonin secretion of intact platelets 
Serotonin (5-hydroxytryptamine, 5HT) forms a fluorophore with ortho-phthalaldehyde, which 
was detected by measuring the fluorescence emission at 475 nm using Wallac Victor 1420 
Multilabel Counter according to Holmsen and Dangelmaier 1989. To inhibit serotonin 
reuptake during secretion, 4 µM of fluoxetine hydrochloride, a selective serotonin reuptake 
inhibitor, were added to 300 µl of platelet suspension (approximately 1-3 x 10
8 platelets/ml, 
counted with CASY cell counter, Innovatis, Bielefeld, Germany). To induce serotonin 
secretion, washed platelets were either treated with thrombin at different concentrations for 5 
min at 37°C, or pretreated with 10 µM of forskolin for 20 min or 1 µM of sodium nitroprusside 
(SNP) for 5 min at 37°C, followed by thrombin treatment as indicated. The secretion reaction 
was stopped by addition of 30 µl of ice-cold 50 mM EDTA pH 7.4. Samples were mixed, 
centrifuged (except for the totals) and put on ice. For protein precipitation, 270 µl of 
supernatants and totals were transferred to Eppendorf tubes containing 60 µl of ice-cold 6 M 
trichloroacetic acid (TCA), vortexed and centrifuged. 250 µl aliquots of these TCA extracts 
were added to 1 ml of ortho-phthalaldehyde reagent (0.5 % (w/v) ortho-phthalaldehyde in 
ethanol mixed with 10 volumes of 8 N HCl), boiled for 10 min and cooled on ice. Samples 
and totals were transferred into 15 ml Falcon tubes and washed twice with chloroform by 
vigorous vortexing 10 sec each. Fluorescence emission of the upper phase was measured 
as described above. For assay validation, serotonin creatinine sulphate, dissolved to 1 mM in 
1 N HCl, was used as standard. Working solutions ranging from 0 to 5 µM were prepared in 
dH2O and processed as described above, starting with TCA protein precipitation. Blank 
values were subtracted from all readings.  
2.5.5 Serotonin secretion of permeabilized platelets 
Freshly obtained washed platelets (1 x 10
8 platelets/ml, counted with CASY cell counter, 
Innovatis, Bielefeld, Germany) were resuspended in 70 µl of prewarmed buffer A (50 mM 
HEPES-KOH pH 7.4, 78 mM KCl, 4 mM MgCl2, 2 mM EGTA, 0.2 mM CaCl2, 5 mM DTT), 
containing 4 mg/ml BSA, 5 mM ATP, 8 mM creatine phosphate, 50 μg/ml creatine 
phosphokinase. Platelets were permeabilized using 0.6 µg/ml streptolysin-O in buffer A 
containing 4 mg/ml BSA at 30°C for 5 min. Then, permeabilized platelets were placed on ice 
and incubated with proteins or peptides to be tested for additional 40 min, followed by further 
incubation at 30°C for 5 min. Finally, platelets were stimulated with either 10 µl of prewarmed 
buffer A, where the free calcium ion concentration was calculated to approximately 20 nM, or 
10 µl of prewarmed stimulation buffer (50 mM HEPES-KOH pH 7.4, 78 mM KCl, 4 mM 
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MgCl2, 2mM EGTA, 20 mM CaCl2), which results in 20 µM of free calcium, at 30°C for 1 min. 
In case of guanosine 5`-O-[γ-thio] triphosphate (GTPγS)-induced secretion of dense 
granules, platelets were stimulated with 100 µM of GTPγS at 30°C for 5 min. The reaction 
was stopped by addition of 200 µl of 2-fold concentrated ice-cold stop buffer (100 mM 
HEPES-KOH pH 7.4, 156 mM KCl, 8 mM MgCl2, 18 mM EGTA, 0.4 mM CaCl2) and 
incubation on ice for 5 min. Then, platelets were removed (except for totals) by centrifugation 
at 4°C 5000 g for 5 min, and released serotonin in the supernatant was measured as 
described in 2.5.4. In all cases, the secretion levels of serotonin were expressed as 
percentage of total serotonin stored in platelet dense granules. Permeabilization was 
monitored by immunoblotting of platelet total lysates and supernatants using anti-LDH 
antibody. 
2.5.6 Statistical analysis 
Shown data represent means ± SD of at least three independent experiments performed in 
triplicate. The statistical significance of the means was analyzed by Student`s t test using 
SigmaPlot 8.0. P-values are expressed as follows * p < 0.05, ** p < 0.01, *** p < 0.001 and 
considered as statistically significant. All experiments (e.g. co-immunoprecipitation and pull-
down assays) were conducted at least three times. Materials and methods 
_________________________________________________________________________________ 
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3. RESULTS 
3.1 Verification of Slp1 as new interaction partner of Rap1GAP2 
3.1.1 Slp1 is a new binding partner of Rap1GAP2  
To identify Rap1GAP2-associated proteins, a genetic two-hybrid screening in yeast was 
performed (O. Danielewski and A. Smolenski, IBCII, Frankfurt, Germany). Full-length wild-
type Rap1GAP2a, the predominant splice isoform of Rap1GAP2 in platelets, was subcloned 
into the pGBKT7 vector, generating a fusion protein between Rap1GAP2 and the DNA 
binding domain (BD) of the yeast transcription factor Gal4, and was used as bait (1. hybrid). 
Likewise, a human adult brain cDNA library was constructed into the pACT2 prey vector to 
generate fusions of the various proteins encoded by the library cDNAs and the Gal4 
transcriptional activation domain (AD) (2. hybrid). The bait vector and 3.5 x 10
6 cfu of the 
library were introduced into the yeast reporter strain AH109 and a high-stringency screening 
was carried out as described by the manufacturer. Yeasts were grown on synthetic dropout 
(SD) media and selected by proliferation (nutritional selection for TRP, LEU, HIS3 and 
ADE2). Among the 112 positive library clones that were found to interact in the screening, 
two clones were identified as synaptotagmin-like protein 1 (Slp1, also called JFC1) (clones 
27 and 87, accession numbers NP_116261 or BC035725).  
To confirm the two-hybrid interaction between Rap1GAP2 and Slp1, Rap1GAP2-Gal4BD and 
Gal4BD as negative control were co-transformed together with the prey plasmids of clone 27 
and clone 87 into AH109, and yeasts were assayed for growth and α-galactosidase activity 
(Fig.3.1). After initial selection for co-transformants on SD/-Trp/-Leu agar plates, yeasts were 
transferred on SD/-Trp/-Leu/-His/-Ade agar to select for co-transformants that host a positive 
two-hybrid interaction of Rap1GAP2 and Slp1. If Rap1GAP2 and Slp1 interact, the Gal4BD 
was brought into proximity to Gal4AD. Subsequently, the Gal4 transcription factor was 
reconstituted and activated the transcription of the reporter genes HIS3, ADE2 and MEL1. 
HIS3 and ADE2 encode the amino acids histidine and adenine, thereby enabling yeasts to 
produce and survive in absence of these amino acids. These yeasts were selected by growth 
on SD/-Trp/-Leu/-His/-Ade agar plates (Fig.3.1, left panel). In contrast, the gene product of 
MEL1 is α-galactosidase. α-Galactosidase cleaves x-α-Gal, yielding α-D-galactose and 5-
bromo-4-chloro-3-hydroxyindole which in turn is oxidized into the blue pigment 5,5'-dibromo-
4,4'-dichloro-indigo. To select for α-galactosidase activity, transformed yeasts were grown on 
SD/-Trp/-Leu/-His/-Ade agar plates supplemented with x-α-Gal. If Rap1GAP2 and Slp1 
interact, yeast colonies turned blue (Fig.3.1, right panel). In contrast, yeasts transformed with 
the empty bait vector pGBKT7 (Gal4BD) and prey vector pACT2 of Slp1 clone 27 did not 
survive on SD/-Trp/-Leu/-His/-Ade agar plates, indicating that absence of Rap1GAP2 as 
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binding partner of Slp1 results in physically separated Gal4BD and Gal4AD. In conclusion, 
yeast-two-hybrid screening revealed Slp1 as a new putative interaction partner of Rap1GAP2 
and the interaction between Rap1GAP2 and Slp1 was confirmed by yeast retransformation 
and x-α-Gal staining.  
 
 
 
 
 
 
 
Figure 3.1: Rap1GAP2 and Slp1 associate in yeast. 
AH109 yeasts were co-transformed with Rap1GAP2-
Gal4BD (RG2-Gal4BD) and Slp1-Gal4AD clone 27 and 
clone 87, respectively. As negative control, Slp1-Gal4AD 
clone 27 was co-transformed with empty vector pGBKT7 
expressing Gal4BD. Transformed yeasts were analyzed 
for growth on SD/-Trp/-Leu/-His/-Ade agar plates (left 
panel) and x-α-galactosidase activity on SD/-Trp/-Leu/-
His/-Ade supplemented with x-α-Gal (right panel). 
3.1.2 Rap1GAP2 and Slp1 interact in transfected mammalian cells 
To confirm the Rap1GAP2/Slp1 interaction outside the yeast-two-hybrid system, pull-down 
assays were performed. For this purpose, HeLa cells were transiently transfected with FLAG-
tagged Rap1GAP2. 24 h post-transfection, cells were lysed, and lysates were subjected to 
pull-down assays using equal amounts of purified recombinant full-length Slp1 fused to GST 
and GST as control. The precipitates were analyzed for the presence of bound FLAG-tagged 
Rap1GAP2 by immunoblot using anti-FLAG antibody. As shown in Fig.3.2A, GST-Slp1 was 
clearly able to pull down transfected Rap1GAP2 from cell lysates, whereas GST alone did 
not. To verify that Rap1GAP2 and Slp1 interact also in intact mammalian cells, co-
immunoprecipitation experiments were performed. HeLa cells were transfected with FLAG-
tagged Rap1GAP2 and myc-tagged Slp1 either alone or in combination. On the next day, 
cells were lysed, and Rap1GAP2 was immunoprecipitated with anti-FLAG antibody. The 
precipitates were analyzed for the presence of bound myc-tagged Slp1 by immunoblotting 
using anti-myc antibody. As shown in Fig.3.2B, Slp1 was only present in precipitates from 
cells overexpressing both, Slp1 and Rap1GAP2. This result was further confirmed in a 
reverse co-immunoprecipitation experiment using anti-myc antibody (Fig.3.2C). All 
experiments were also carried out using transfected COS-1 cells, yielding the same results 
(data not shown).  
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Figure 3.2: Rap1GAP2 interacts with Slp1 in transfected HeLa cells. 
A: Pull-down of transfected Rap1GAP2 with GST-Slp1. HeLa cells were transiently transfected with FLAG-
tagged Rap1GAP2 (RG2-FLAG). Equal amounts of GST as control and GST-Slp1 coupled to GSH sepharose 
beads were used for precipitation (lower panel). Bound Rap1GAP2 protein was visualized by immunoblot using 
anti-FLAG antibody (upper panel). The middle panel shows expression levels of Rap1GAP2 (total RG2-FLAG, 
2% input). The broad band of Rap1GAP2 is probably due to extensive post-translational modifications.  
B and C: Co-immunoprecipitation of transfected Rap1GAP2 and Slp1. HeLa cells were transiently transfected 
with FLAG-tagged Rap1GAP2, myc-tagged Slp1 or FLAG-tagged Rap1GAP2 together with myc-tagged Slp1. 
After cell lysis, Rap1GAP2 was immunoprecipitated with anti-FLAG antibody (B) and Slp1 with anti-myc 
antibody (C), respectively. The precipitates were analyzed for the presence of bound Slp1 (B, upper panel) or 
bound Rap1GAP2 (C, upper panel) by immunoblot using tag-specific antibodies. The two lower panels show 
expression levels of Slp1 (total Slp1-myc, 2% input) and Rap1GAP2 (total RG2-FLAG, 2% input). 
 
 
Taken together, the interaction between Rap1GAP2 and Slp1 was confirmed by pull-down 
assays and co-immunoprecipitation experiments in transfected mammalian cells.  
 
To investigate whether Slp1 also binds to other RapGAPs, Rap1GAP1 was tested. 
Rap1GAP1 is the closest relative of Rap1GAP2 with about 50 % overall identity at amino 
acid level (Schultess et al. 2005). HeLa cells were transiently transfected with HA-tagged 
Rap1GAP1, which was kindly provided by Prof. Dr. J. Bos, Utrecht, Netherlands. 24 h post-
transfection, cells were lysed, and lysates were subjected to GST-Slp1 pull-down assays. As 
shown in Fig.3.3, no binding of GST-Slp1 to Rap1GAP1 was observed. The same result was 
also obtained in co-immunoprecipitation experiments using transfected HeLa cells (data not 
shown). In conclusion, Slp1 does not bind to Rap1GAP1, indicating that the interaction 
between Slp1 and Rap1GAP2 is specific. 
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Figure 3.3: Rap1GAP1 does not bind to Slp1. 
HeLa cells were transiently transfected with HA-tagged Rap1GAP1 (RG1-HA). Cells were lysed, and lysates 
were subjected to pull-down assays using equal amounts of GST as negative control and GST-Slp1. The 
precipitates were analyzed for the presence of bound Rap1GAP1 by immunoblot using anti-HA antibody (upper 
panel). The lower panel shows expression levels of Rap1GAP1 (total RG1-HA, 2% input). 
 
3.1.3 Slp1 is expressed and binds to Rap1GAP2 in human platelets 
Rap1GAP2 is the only GTPase activating protein of Rap1 expressed in human platelets 
(Schultess et al. 2005). To asses the interaction between Rap1GAP2 and Slp1 in a more 
physiological context, pull-down assays using human platelet lysate were performed. 
Washed human platelets were lysed as described under Materials and Methods (2.3.3), and 
platelet lysates were subjected to pull-down assays using equal amounts of GST and GST-
Slp1. The precipitates were analyzed for the presence of endogenous Rap1GAP2 by 
immunoblot using anti-Rap1GAP2 antibody. As shown in Fig.3.4A, only GST-Slp1, but not 
GST, bound to endogenous Rap1GAP2 protein. So far, it was unknown if Slp1 is expressed 
in platelets. Endogenous expression of Slp1 in platelets, however, is a prerequisite for the 
association of both proteins, Rap1GAP2 and Slp1, at endogenous level and determines the 
physiological relevance of the Rap1GAP2/Slp1 interaction for platelet function. To check if 
Slp1 is present in platelets, a polyclonal antibody against full-length human Slp1 was 
generated (IBCII, ImmunoGlobe Antikörpertechnik). The antibody specifically recognized the 
66 kD Slp1 protein in HeLa cells transfected with myc-tagged Slp1, but not in mock-
transfected cells (Fig.3.4B). Importantly, the antibody recognized a band of similar molecular 
weight in human platelet lysate, suggesting that Slp1 is endogenously expressed in human 
platelets (Fig.3.4C). Unfortunately, neither this newly generated anti-Slp1 antibody nor our 
anti-Rap1GAP2 antibody were able to immunoprecipitate their antigens efficiently from 
human platelet lysates. Therefore, in order to obtain conclusive evidence that endogenous 
Rap1GAP2 and Slp1 interact, an alternative precipitation approach was developed and 
applied as described in Hoffmeister et al. 2008. 
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Figure 3.4: Endogenous Rap1GAP2 and Slp1 interact in human platelets.
A: Pull-down of endogenous Rap1GAP2 with GST-Slp1. Equal amounts of GST as control and GST-Slp1 
coupled to GSH sepharose beads were incubated with human platelet lysate. Bound endogenous Rap1GAP2 
protein was visualized with anti-Rap1GAP2 antibody (RG2, upper panel). Expression level of Rap1GAP2 is 
shown as 2% input of total Rap1GAP2.  
B: Anti-Slp1 antibody recognizes the 66 kD Slp1 protein in transfected HeLa cells. HeLa cells were transiently 
transfected with empty vector pcDNA3.1/mycHis (mock) or myc-tagged Slp1 (Slp1-myc). Cells were lysed, and 
lysates were analyzed by immunoblot using anti-Slp1 antibody.  
C: Slp1 is expressed in human platelets. Washed human platelets were lysed, and lysates were analyzed by 
immunoblot using preimmune serum and anti-Slp1 antibody, respectively.  
D: Pull-down of transfected Rap1GAP2 and Slp1 with GST-14-3-3β. COS-1 cells were transiently transfected 
with myc-tagged Slp1 and without or with FLAG-tagged Rap1GAP2 (RG2-FLAG). Cells were lysed, and GST 
fusion protein of 14-3-3β was used to precipitate Rap1GAP2 and indirectly Slp1 bound to Rap1GAP2. 
Precipitated Slp1 was detected by immunoblot using anti-myc antibody (top panel). Precipitation of Rap1GAP2 
was controlled by immunoblot with anti-FLAG antibody (second panel from top). In parallel, total cell lysates were 
analyzed for the expression of Slp1 (total Slp1-myc, 2% input) and Rap1GAP2 (total RG2-FLAG, 2% input).  
E: Pull-down of transfected Rap1GAP2 and 14-3-3β with GST-Slp1. COS-1 cells were transiently transfected 
with myc-tagged 14-3-3β and without or with FLAG-tagged Rap1GAP2 (RG2-FLAG). Cells were lysed, and GST 
fusion protein of Slp1 was used to precipitate Rap1GAP2 and indirectly 14-3-3β bound to Rap1GAP2. 
Precipitated 14-3-3β was detected by immunoblot using anti-14-3-3 antibody (top panel), and precipitated 
Rap1GAP2 using anti-FLAG antibody (second panel from top). The two lower panels show expression levels of 
14-3-3β  (total 14-3-3-myc, 2% input) and Rap1GAP2 (total RG2-FLAG, 2% input).  
F: Pull-down of endogenous Rap1GAP2 and Slp1 from human platelets. Washed human platelets were treated 
with 0.1 U/ml thrombin for 1 min at 37°C. Platelets were lysed, and lysates were subjected to pull-down assays 
using equal amounts of GST as control and GST-14-3-3β. The precipitates were analyzed for the presence of 
endogenous Rap1GAP2 (RG2) and Slp1 using specific anti-Rap1GAP2 and anti-Slp1 antibodies (first and 
second panel from top). Expression levels of Rap1GAP2 and Slp1 are shown as 2% input of total protein 
amounts. The lower panel shows the amounts of GST and GST-14-3-3β used for precipitation. Unspecific band 
is marked with asterisk (*).  
G: Pull-down of endogenous Rap1GAP2 and 14-3-3 from human platelets. Washed human platelets were 
treated with 0.1 U/ml thrombin for 1 min at 37°C as indicated. Platelets were lysed, and lysates were subjected to 
pull-down assays using equal amounts of GST as control and GST-Slp1. The precipitates were analyzed for the 
presence of endogenous 14-3-3 and Rap1GAP2 (RG2) by immunoblot with anti-14-3-3 and anti-Rap1GAP2 
antibodies (first and second panel from top). The two lower panels show expression levels of 14-3-3 (total 14-3-
3, 2% input) and Rap1GAP2 (total RG2, 2% input). 
 
To this end, a second Rap1GAP2 binding partner, 14-3-3, was expressed and purified as 
GST fusion protein from Escherichia coli BL21 and used to precipitate sufficient amounts of 
endogenous Rap1GAP2. Binding of 14-3-3 proteins to Rap1GAP2 was discovered and 
characterized in our group. We could show that 14-3-3 proteins bind to Rap1GAP2 at 
phosphorylated serine 9 within the N-terminus of Rap1GAP2. Moreover, platelet activation by 
ADP and thrombin enhances serine 9 phosphorylation and thereby increases 14-3-3 binding 
to endogenous Rap1GAP2 (Hoffmeister et al. 2008). To exclude the possibility that 14-3-3 
and Slp1, designated Rip2 in Hoffmeister et al. 2008, interact directly with each other, control 
experiments in COS-1 cells were performed. To mimic the endogenous situation in platelets, 
COS-1 cells were transiently transfected with myc-tagged Slp1 and FLAG-tagged 
Rap1GAP2. As control, cells were transfected with myc-tagged Slp1 only. After two days, 
cells were lysed, and GST-14-3-3  was used to pull down Rap1GAP2 and indirectly Slp1 that 
was associated with Rap1GAP2 in cells overexpressing both proteins. The precipitates were 
analyzed for the presence of FLAG-tagged Rap1GAP2 and myc-tagged Slp1 by immunoblot 
using tag-specific antibodies. As shown in Fig.3.4D, GST-14-3-3 precipitated Slp1 only in 
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presence of Rap1GAP2, demonstrating that 14-3-3 could not bind to Slp1 by itself. This 
result could further be confirmed in a reverse experiment using COS-1 cells transfected with  
myc-tagged 14-3-3 and with or without FLAG-tagged Rap1GAP2. Purified recombinant GST-
Slp1 was used to pull down Rap1GAP2 and indirectly 14-3-3 associated with Rap1GAP2. As 
expected, precipitated 14-3-3 was only detected in precipitates from cells overexpressing 
both, Rap1GAP2 and 14-3-3 (Fig.3.4E). To show that Rap1GAP2 and Slp1 interact at 
endogenous level in human platelets, purified recombinant GST-14-3-3 was used to pull 
down endogenous Rap1GAP2 from platelet lysate. To induce serine 9 phosphorylation and 
thereby enhance binding of GST-14-3-3 to Rap1GAP2, platelets were treated with thrombin. 
As shown in Fig.3.4F, GST-14-3-3 was clearly able to pull down endogenous Rap1GAP2 
and Slp1 bound to Rap1GAP2 from human platelets. In a reverse experiment, GST-Slp1 was 
used to pull down endogenous Rap1GAP2 from platelet lysate. As shown in Fig.3.4G, GST-
Slp1 was able to co-precipitate endogenous 14-3-3 via Rap1GAP2, whereas GST alone did 
not bind Rap1GAP2 or 14-3-3. Thrombin treatment of platelets resulted in increased binding 
of 14-3-3 to Rap1GAP2 at endogenous level (Fig.3.4G, top panel). Taken together, these 
experiments confirm that the interaction between Rap1GAP2 and Slp1 is direct and show 
that both proteins interact at endogenous level in human platelets. 
Slp1 is a member of the synaptotagmin-like protein (Slp) family, and to date, five distinct 
isoforms (Slp1-5) have been reported in mammals (Fukuda 2005). Database search 
(http://plateletweb.bioapps.biozentrum.uni-wuerzburg.de) revealed that among those, Slp4 is 
expressed in platelets, too. To test if Rap1GAP2 binds to Slp4 or other Slp isoforms (Slp2, 
Slp3 and Slp5), co-immunoprecipitation experiments were performed. No interaction 
between Rap1GAP2 and Slp2, Slp3, Slp4, and Slp5 was detected (data not shown).  
3.2 Characterization of the Rap1GAP2/Slp1 interaction  
3.2.1 The C2A domain of Slp1 is sufficient for binding to Rap1GAP2 
Slp1 is composed of an N-terminal Rab27 binding domain (SHD) and two tandem C2 
domains, C2A and C2B, at the C-terminus (Fukuda and Mikoshiba 2001, McAdara Berkowitz 
et al. 2001). From the yeast-two-hybrid screening the binding site for Rap1GAP2 within Slp1 
was assumed to be located within the two C2 domains of Slp1. Both Slp1 clones that were 
found to interact with Rap1GAP2 in yeast matched the C-terminal part of Slp1 containing the 
two tandem C2 domains (amino acids 293-549 of Slp1). Therefore, to determine the binding 
site for Rap1GAP2 within Slp1, mutants composed of C2A, C2B or C2AB domain of Slp1 
fused to GST were expressed and purified from Escherichia coli BL21 and used in pull-down 
assays (Fig.3.5A). In brief, HeLa cells were transfected with FLAG-tagged Rap1GAP2. After 
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cell lysis, equal amounts of GST as negative control, GST-C2A, GST-C2B, and GST-C2AB 
were used to precipitate transfected Rap1GAP2. The precipitates were analyzed for the 
presence of FLAG-tagged Rap1GAP2 by immunoblot using anti-FLAG antibody. As shown in 
Fig.3.5B, GST did not bind to Rap1GAP2. No binding was detected between GST-C2B and 
Rap1GAP2. In contrast, GST-C2A and GST-C2AB were able to pull down transfected 
Rap1GAP2 from HeLa cell lysates, indicating that the C2A domain is required and sufficient 
for binding of Slp1 to Rap1GAP2.  
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Figure 3.5: The C2A domain of Slp1 is sufficient for binding of Slp1 to Rap1GAP2.
A: Schematic representation of Slp1 mutants. GST fusion proteins of C2A (amino acids 292-393 of Slp1), C2B 
(amino acids 433-580 of Slp1) and C2AB (amino acids 292-580 of Slp1) were used in pull-down assays. Myc-
tagged C2A (amino acids 292-432 of Slp1) was used in co-immunoprecipitation experiments.  
B: Pull-down of transfected Rap1GAP2 with GST-Slp1 mutants. Lysates of HeLa cells overexpressing FLAG-
tagged Rap1GAP2 (RG2-FLAG) were subjected to pull-down experiments using equal amounts of GST as control 
and GST fusion proteins of C2A, C2B and C2AB. The precipitates were analyzed for the presence of bound 
Rap1GAP2 by immunoblot with anti-FLAG antibody (upper panel). The middle panel shows expression levels of 
Rap1GAP2 (total RG2-FLAG, 2% input), and the lower panel GST and GST fusion proteins of Slp1 used for 
precipitation.  
C: Co-immunoprecipitation of transfected Rap1GAP2 and Slp1-C2A. HeLa cells were transiently transfected with 
FLAG-tagged Rap1GAP2, myc-tagged C2A domain of Slp1 or FLAG-tagged Rap1GAP2 together with myc-
tagged C2A. After cell lysis, Rap1GAP2 was immunoprecipitated with anti-FLAG antibody. Precipitated C2A was 
detected by immunoblot using anti-myc antibody (upper panel). The two lower panels show expression levels of 
C2A (total C2A-myc, 2% input) and Rap1GAP2 (total RG2-FLAG, 2% input). 
 
 Results 
_________________________________________________________________________________ 
 
This result was further confirmed in intact mammalian cells. In co-immunoprecipitation 
experiments using HeLa cells overexpressing FLAG-tagged Rap1GAP2 and myc-tagged 
C2A domain of Slp1, C2A was co-immunoprecipitated together with Rap1GAP2 using anti-
FLAG antibody (Fig.3.5C).  
Binding activities of some C2 domains are modulated by calcium ions (Lemmon 2008). 
However, the Rap1GAP2/Slp1 interaction was not affected by calcium depletion in pull-down 
assays (data not shown). 
 
3.2.2 Binding of Rap1GAP2 does not affect lipid binding of Slp1 
It has previously been reported that Slp1 binds via its C2A domain to phosphoinositides in-
vitro, showing preference for PtdIns(3,4,5)P3 over PtdIns(3)P, PtdIns(3,4)P2, and 
PtdIns(4,5)P2 (McAdara Berkowitz et al. 2001, Catz et al. 2002). In transfected mammalian 
cells the C2A domain of Slp1 has been shown to localize exclusively to the plasma 
membrane, suggesting that the C2A domain of Slp1 is responsible for the specific membrane 
association of the full-length Slp1 protein (Catz et al. 2002). This finding was confirmed in live 
imaging experiments of HeLa cells transfected with DsRed-tagged Slp1 C2A domain 
(Fig.3.6A). Moreover, in the present work the C2A domain of Slp1 has been demonstrated to 
serve as protein-protein interaction domain and to mediate binding of Slp1 to Rap1GAP2. 
These two observations raise the question whether Rap1GAP2 binding to the C2A domain of 
Slp1 could affect the lipid binding ability of Slp1 via C2A and thus targeting of Slp1 to the 
plasma membrane and its plasma membrane association. To answer this question, 
phospholipid binding assays were performed. To first test and compare the lipid binding 
ability of full-length Slp1 and the C2A domain of Slp1, purified recombinant GST-C2A and 
GST-Slp1 were used to probe nitrocellulose membranes spotted with various biologically 
active phospholipids (PIPs) as indicated (Fig.3.6B). GST-tagged PH domain of PLCδ1 was 
used as positive control (Echelon Biosciences), and GST was used as negative control. As 
shown in Fig.3.6C, both controls yielded expected results. PLCδ1 PH domain bound to 
PtdIns(4,5)P2, whereas GST did not bind to any phospholipid. Importantly, GST-C2A and 
GST-Slp1 were able to bind to phospholipids, exhibiting a similar phosholipid binding pattern. 
The slight variations in binding intensities could be due to unintended variations in protein 
concentrations applied onto the membranes. Interestingly, both, GST-C2A and GST-Slp1 
bound preferentially to phosphatidic acid (PA) followed by phosphatidylinositol-
monophosphates PtdIns(3)P, PtdIns(4)P, PtdIns(5)P and phosphatidylinositolbisphosphates 
PtdIns(4,5)P2 and PtdIns(3,4)P2. Binding to PtdIns(3,5)P2 and PtdIns(3,4,5)P3 was apparent, 
but rather weak. To investigate next if binding of Rap1GAP2 to the C2A domain of Slp1 could 
affect phospholipid binding ability of Slp1, membranes were incubated with GST-Slp1 either 
alone or together with purified recombinant His6-tagged Rap1GAP2. To evaluate whether 
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Figure 3.6: Slp1 binds via C2A to phospholipids.
A: C2A domain of Slp1 localizes to the plasma membrane. LNCaP cells were transiently transfected with C-
terminally DsRed-tagged C2A domain of Slp1. 24 h post-transfection, cells were analyzed by confocal 
microscopy. Scale bar: 10 µm.                   
B: Schematic representation of phospholipids spotted on a nitrocellulose membrane (PIPStrip). 100 pmol of 
biologically active phospholipids were spotted onto a nitrocellulose membrane as indicated and used in protein 
phospholipid overlay assays.    
C: C2A domain of Slp1 and full-length Slp1 bind to phospholipids. PIPStrips
 were incubated with 0.5 µg/ml of 
purified recombinant GST, GST-tagged PLCδ1 PH domain, GST-tagged C2A domain and GST-tagged full-length 
Slp1. Bound proteins were detected by immunoblot with anti-GST antibody.    
D: Binding of Rap1GAP2 does not affect phospholipid binding of Slp1. PIPStrips
 were overlayed with 0.5 µg/ml 
of purified recombinant GST, His6-tagged Rap1GAP2, GST-tagged Slp1 and GST-tagged Slp1 together with 
His6-tagged Rap1GAP2. Bound proteins were detected by immunoblot with anti-His6 and anti-GST antibodies. 
LPA: Lysophosphatidic acid; LPC: Lysophosphocho-line; PtdIns: Phosphatidylinositol; PtdInsP: Phosphatidyl- 
inositolmonophosphate; PtdInsP2: Phosphatidylinositolbisphosphate; PtdInsP3: Phosphatidylinositoltris-
phosphate; PE: Phosphatidylethanolamine; PC: Phosphatidylcholine; S1P: Sphingosine-1-phosphate; PA: 
Phosphatidic acid; PS: Phosphatidylserine. 
Rap1GAP2 is able to bind to phospholipids by itself, one additional membrane was incubated 
with His6-Rap1GAP2 protein only. GST was used as negative control. As shown in Fig.3.6D, 
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no binding of Rap1GAP2 or GST to phospholipids was observed. Importantly, addition of 
Rap1GAP2 did not change the phospholipid binding ability of Slp1. Taken together, binding 
of Rap1GAP2 to the C2A domain of Slp1 does not affect the lipid binding ability of full-length 
Slp1, suggesting that simultaneous binding of Slp1 to Rap1GAP2 and phospholipids can 
occur. 
3.2.3 Rap1GAP2 interacts through the -TKXT- motif with Slp1 
Rap1GAP2 is a modular protein composed of a central catalytic GAP domain, a dimerization 
domain, the N-terminal 14-3-3 binding site and a large serine-rich C-terminus of low 
structural organization and so far unknown function. To map the binding site(s) for Slp1 in 
Rap1GAP2, truncation mutants of Rap1GAP2 were generated and used in GST-Slp1 pull-
down assays (Fig.3.7A). As shown in Fig.3.7B, Slp1 bound to wild-type Rap1GAP2 and 
Rap1GAP2ΔNterm mutant lacking the N-terminal part with equal potency. In contrast, no 
binding was detected between Slp1 and a C-terminally truncated Rap1GAP2 mutant 
(Rap1GAP2ΔCterm), suggesting that the binding site for Slp1 is harbored within the C-
terminus of Rap1GAP2.                                                                                                                    
 
 
Figure 3.7: Slp1 interacts with the C-terminus of Rap1GAP2. 
A: Schematic representation of FLAG-tagged Rap1GAP2 truncation mutants. C-terminally FLAG-tagged 
truncation mutants of Rap1GAP2 (RG2) were used in pull-down assays. Rap1GAP2ΔCterm lacks amino acids 
467-715, whereas Rap1GAP2ΔNterm lacks amino acids 1-121.  
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B: Pull-down of transfected FLAG-tagged Rap1GAP2 truncation mutants with GST-Slp1. HeLa cells were 
transiently transfected with either FLAG-tagged Rap1GAP2 (RG2-FLAG) wild-type or different FLAG-tagged 
Rap1GAP2 truncation mutants as indicated in A. Cells were lysed, and pull-down assays using GST and GST- 
Slp1 were performed. Precipitates were analyzed for the presence of Rap1GAP2 by immunoblot using anti-FLAG
antibody. The upper panel shows precipitation results, and the lower panel expression levels of Rap1GAP2 
proteins (total RG-FLAG, 2% input). 
 
To narrow down the Slp1 binding site, additional truncation mutants of Rap1GAP2 were 
generated and used in GST-Slp1 pull-down assays (Fig.3.8A). Since no binding between 
Slp1 and the N-terminus of Rap1GAP2 (amino acids 1-121) was observed (data not shown), 
these mutants were constructed as VSV-tagged at the N-terminus lacking amino acids 1-121 
and varying in the length of their C-termini. As shown in Fig.3.8B, Slp1 bound to 
Rap1GAP2ΔNterm C1, C2, C3, C4, and C5 mutants, whereas no binding was detected 
between Slp1 and Rap1GAP2ΔNterm C6, C7 and C8 mutants. These results indicate that 
the binding site for Slp1 is located within the C-terminal region of amino acids 526-534 of 
Rap1GAP2. 
 
 
 
Figure 3.8: Slp1 interacts with a short sequence within the C-terminus of Rap1GAP2. 
A: Schematic representation of VSV-tagged Rap1GAP2ΔNterm truncation mutants. N-terminally VSV-tagged 
Rap1GAP2 (RG2) mutants lacking amino acids 1-121 and varying in the length of their C-termini were used in 
pull-down assays.  
B: Pull-down of transfected VSV-tagged Rap1GAP2ΔNterm truncation mutants with GST-Slp1. HeLa cells were 
transiently transfected with different VSV-tagged Rap1GAP2ΔNterm (VSV-RG2ΔNterm) mutants truncated at the 
C-terminus as indicated in A. Cells were lysed, and lysates were subjected to GST-Slp1 pull-down assays. Bound 
Rap1GAP2 was detected by immunoblot with anti-VSV antibody. The upper panel shows precipitation results, 
and the lower panel expression levels of Rap1GAP2 proteins (total VSV-RG2ΔNterm, 2% input). 
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In order to specify the residues that are responsible for binding of Rap1GAP2 to Slp1, 
deletion mutants of Rap1GAP2 were generated, based on the information gained from the 
truncational analysis above. Rap1GAP2Δ522-527 mutant lack amino acids 522-527, 
whereas in the control mutant Rap1GAP2Δ536-542 amino acids 536-542 were deleted 
(Fig.3.9A). Both mutants were overexpressed in HeLa cells, and cell lysates were subjected 
to GST-Slp1 pull-down assays. As shown in Fig.3.9B, Rap1GAP2Δ536-542 mutant bound 
Slp1 comparable to wild-type Rap1GAP2, whereas Rap1GAP2Δ522-527 mutant did not bind 
Slp1, suggesting that the sequence EVTKTT (amino acids 522-527 of Rap1GAP2) mediates 
binding of Rap1GAP2 to Slp1. To determine the role of each amino acid residue within this 
motif, consecutive alanine point mutants of the EVTKTT sequence were generated and 
tested in GST-Slp1 pull-down assays. As shown in Fig.3.9C, mutation of E522 to alanine did 
not affect binding of Slp1 to Rap1GAP2. Mutation of V523 or T526 to alanine only slightly 
reduced binding, whereas mutation of T524, K525 or T527 almost completely abolished 
binding of Slp1 to Rap1GAP2, indicating that amino acids T524, K525 and T527, the so-
called  -TKXT- motif, are important for binding of Slp1 to Rap1GAP2. In addition, the 
importance of the T527 residue was supported by the observation that the VSV-tagged 
Rap1GAP2ΔNterm C6 mutant was not able to bind to Slp1, although it contains the residues 
EVTK (amino acids 522-525 of Rap1GAP2) and lacks only T526 and T527 (Fig.3.8A). 
Nevertheless, deletion of T527 was sufficient to abrogate binding of Rap1GAP2 to Slp1 
(Fig.3.8B and Fig.3.9C). To confirm and substantiate these data using a complementary 
approach, peptide binding assays were performed. For this purpose, short peptides 
containing the key sequence EVTKTT in wild-type form or with one amino acid mutated to 
alanine were synthesized on a cellulose membrane (ImmunoGlobe Antikörpertechnik) and 
incubated with purified recombinant GST-Slp1. As shown in Fig.3.9D, if T524, K525 and 
T527 were mutated, no binding of GST-Slp1 was detected. Interestingly, mutation of E522 to 
alanine led to a stronger binding of GST-Slp1. Taken together, these experiments indicate 
that the residues T524, K525 and T527 in the C-terminal part of Rap1GAP2 constitute the 
binding site for Slp1 within Rap1GAP2.  
It is conceivable that phosphorylation of the two threonine residues, T524 and T527, within 
the -TKXT- motif of Rap1GAP2 could occur. To answer this question, peptides having either 
T524, T527 or both phosphorylated were tested in GST-Slp1 overlay assays. No binding of 
GST-Slp1 to the phosphorylated versions of the -TKXT- motif of Rap1GAP2 was observed 
(Fig.3.9D,  lanes 9, 10 and 11), indicating that phosphorylation at the -TKXT- motif of 
Rap1GAP2 is not required and can even abolish Slp1 binding to Rap1GAP2.    
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Figure 3.9: Binding of Rap1GAP2 to Slp1 is mediated through the -TKXT- motif of Rap1GAP2. 
A: Schematic representation of Rap1GAP2 deletion mutants. C-terminally FLAG-tagged deletion mutants of 
Rap1GAP2 were used in pull-down assays. Rap1GAP2Δ522-527 lacks the sequence EVTKTT (amino acids 
522-527 of Rap1GAP2), whereas in Rap1GAP2Δ536-542 amino acids 536-542 were deleted.  
B: Pull-down of transfected Rap1GAP2 deletion mutants with GST-Slp1. Lysates of HeLa cells overexpressing 
either FLAG-tagged Rap1GAP2 wild-type (RG2-FLAG wt) or deletion mutants Rap1GAP2Δ536-542 as control 
and Rap1GAP2Δ522-527 were subjected to GST-Slp1 pull-down assays followed by immunoblot analysis using 
anti-FLAG antibody. The upper panel shows precipitation results, and the lower panel expression levels of 
Rap1GAP2 proteins (total RG2-FLAG, 2% input). 
  
53 
 Results 
_________________________________________________________________________________ 
 
C: Pull-down of transfected Rap1GAP2 alanine point mutants with GST-Slp1. HeLa cells were transiently 
transfected with FLAG-tagged Rap1GAP2 wild-type (RG2-FLAG wt) or different Rap1GAP2 point mutants 
having each of the amino-acids within the EVTKTT sequence (amino acids 522-527) changed to alanine as 
indicated. Cells were lysed, and lysates were subjected to GST-Slp1 pull-down assays followed by immunoblot 
analysis with anti-FLAG antibody. The upper panel shows precipitation results, and the lower panel expression 
levels of Rap1GAP2 proteins (total RG2-FLAG, 2% input).  
D: Peptide binding assay (PepSpot). Synthetic Rap1GAP2 (RG2) peptides covalently bound to a cellulose 
membrane containing either wild-type Rap1GAP2 EVTKTT sequence or with consecutive amino acids changed 
to alanine (A) or phosphorylated threonine residues (pT) as indicated were subjected to GST-Slp1 overlay assay 
followed by immunoblot analysis with anti-GST antibody. 
 
 
Finally, to test if short peptides containing the key sequence EVTKTT of Rap1GAP2 or 
peptides carrying a deletion of this motif could affect binding of Slp1 to endogenous 
Rap1GAP2, GST-Slp1 pull-down assays were performed using human platelet lysate 
supplemented with either Rap1GAP2 wild-type or Rap1GAP2ΔEVTKTT peptide. As shown in 
Fig.3.10B, addition of the wild-type peptide to platelet lysate blocked the interaction of Slp1 
and Rap1GAP2, whereas addition of the mutant peptide did not affect binding of Slp1 to 
Rap1GAP2. 
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Figure 3.10: Rap1GAP2 wild-type peptide prevents binding of endogenous Rap1GAP2 protein to Slp1.  
A: Schematic representation of Rap1GAP2 peptides. Synthetic Rap1GAP2 peptides were used in pull-down 
assays. Rap1GAP2 wild-type peptide contains the sequence HNSMEVTKTTFSPPV (amino acids 518-532 of 
Rap1GAP2). In contrast, Rap1GAP2ΔEVTKTT contains the sequence GISHNSMFSPPVVAA (amino acids 515-
535 of Rap1GAP2 lacking amino acids 522-527).  
B: Pull-down of endogenous Rap1GAP2 with GST-Slp1 from human platelets in absence or presence of 
Rap1GAP2 peptides. Native human platelet lysate or lysate supplemented with 100 µM of either Rap1GAP2 
wild-type (RG2wt) peptide or Rap1GAP2ΔEVTKTT (RG2ΔEVTKTT) peptide were subjected to GST-Slp1 pull-
down assays. The precipitates were analyzed for the presence of endogenous Rap1GAP2 protein by 
immunoblot using anti-Rap1GAP2 antibody. The upper panel shows precipitation results, and the lower panel 
expression levels of endogenous Rap1GAP2 (total RG2, 2% input). The used anti-Rap1GAP2 antibody was 
produced using an N-terminal peptide of Rap1GAP2 (amino acids 1-32) as antigen (Schultess et al. 2005). 
Therefore, it recognizes Rap1GAP2 protein only and does not detect Rap1GAP2 peptides. 
 
In summary, the mapping experiments revealed residues T524, K525 and T527, the so-
called -TKXT- motif, within the C-terminus of Rap1GAP2 as the binding site for Slp1 and 
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showed that phosphorylation at the -TKXT- motif is not required for binding of Slp1 to 
Rap1GAP2. 
3.2.4 Rap1GAP2/Slp1 interaction is enhanced upon activation of PKA in platelets 
In previous studies of our group we could show that Rap1GAP2 is phosphorylated by cGMP- 
and cAMP-dependent protein kinases (cGK and cAK, also called PKG and PKA) in-vitro and 
in intact platelets, and identified serine 7 as one phosphorylation site (Schultess et al. 2005, 
Hoffmeister et al. 2008). We demonstrated that PKG- and PKA-induced phosphorylation of 
serine 7 inhibits binding of 14-3-3 to Rap1GAP2 in platelets, and conversely, platelet 
activation by ADP and thrombin increases 14-3-3 binding to Rap1GAP2 (Hoffmeister et al. 
2008). Therefore, we were interested in investigating if binding of Slp1 to Rap1GAP2 is also 
affected upon platelet activation or platelet inhibition. To this end, GST-Slp1 pull-down 
assays were performed using lysates of platelets preincubated with various platelet 
activators or inhibitors. To determine if platelet activation could impair Slp1 binding to 
Rap1GAP2, washed human platelets were treated with thrombin and ADP as indicated 
(Fig.3.11A). Platelets were lysed, and lysates were incubated with GST and GST-Slp1. The 
precipitates were analyzed for the presence of endogenous Rap1GAP2 using anti-
Rap1GAP2 antibody. As shown in Fig.3.11A, treatment of platelets with thrombin and ADP 
did not affect Slp1 binding to endogenous Rap1GAP2. To investigate if activation of cAMP-
dependent protein kinase in platelets would influence binding of Slp1 to Rap1GAP2, a set of 
experiments was performed. In order to induce activation of PKA, washed human platelets 
were treated with prostaglandin I2, forskolin, and Sp-5,6-DCI-cBiMPS as indicated 
(Fig.3.11B-D). PGI2 initiates platelet inhibition through interaction with specific G protein-
coupled receptors on the platelet surface (1.2.1). Forskolin stimulates cAMP production 
through direct activation of adenylyl cyclase (Seamon et al. 1981, Insel et al. 1982), and Sp-
5,6-DCI-cBiMPS is a membrane permeable cAMP analogue and direct activator of PKA 
(Sandberg et al. 1991). After treatment platelets were lysed, and lysates were subjected to 
GST-Slp1 pull-down assays. The precipitates were analyzed for the presence of endogenous 
Rap1GAP2 by immunoblot. As shown in Fig.3.11B to D, at each step of activation a 
concentration-dependent increase in binding of Slp1 to Rap1GAP2 was observed. 
Phosphorylation of VASP, a well established PKG and PKA substrate in platelets, was in 
direct correlation with the PKA activity and detected by immunoblot using phosphospecific 
anti-P-VASP antibody (Smolenski et al. 1998, Li et al. 2003). To further evaluate the 
specificity of PKA activation on Slp1/Rap1GAP2 binding, platelets were treated with Rp-8-Br-
cAMPS, a specific PKA inhibitor, either alone or with forskolin on top (Fig.3.11E). GST-Slp1 
pull-down assays were performed as described above. As shown in Fig.3.11E, no increase in 
binding of Slp1 to Rap1GAP2 was observed if platelets pretreated with Rp-8-Br-cAMPS were 
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treated with forskolin. Inhibition of PKA by Rp-8-Br-cAMPS was reflected in decreased 
phosphorylation of VASP. In order to confirm this PKA effect on Slp1/Rap1GAP2 binding in a 
different system, HeLa cells were used. Cells were transfected with FLAG-tagged 
Rap1GAP2 either alone or in combination with the PKA inhibitor PKI. On the following day, 
cells were washed and incubated in serum-free medium without or with forskolin. Cells were 
lysed, and lysates were subjected to GST-Slp1 pull-down assays. As shown in Fig.3.11F, 
inhibition of PKA by PKI resulted in decreased binding of Slp1 to transfected Rap1GAP2. 
Probably due to a high basal phosphorylation state of Rap1GAP2 or other PKA substrates 
involved in Rap1GAP2/Slp1 complex formation in HeLa cells, no increase in Slp1 binding to 
Rap1GAP2 upon forskolin treatment was observed.  
 
 
 
Figure 3.11: Activation of PKA in platelets increases binding of Slp1 to endogenous Rap1GAP2. 
A: ADP and thrombin do not alter binding of Slp1 to Rap1GAP2. Washed human platelets were treated without or 
with 10 µM ADP or with 0.1 U/ml thrombin for 1 min at 37°C. Platelets were lysed, and lysates were subjected to 
GST-Slp1 pull-down assays. GST was used as negative control. The precipitates were examined for the 
presence of bound endogenous Rap1GAP2 protein by immunoblot using anti-Rap1GAP2 antibody. The upper  
panel shows precipitation results, and the lower panel expression levels of endogenous Rap1GAP2 (total RG2, 
2% input).  
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B, C and D: Activation of PKA in platelets results in increased binding of Slp1 to endogenous Rap1GAP2. 
Washed human platelets were treated without or with PGI2  (B), forskolin (C) or Sp-5,6-DCI-cBiMPS (D) as 
indicated. Platelets were lysed, and lysates were subjected to GST-Slp1 pull-down assays followed by 
immunoblot analysis using anti-Rap1GAP2 antibody. The upper panel shows precipitation results, and the lower 
panel expression levels of endogenous Rap1GAP2 (total RG2, 2% input). Phosphorylation of VASP was detected 
with anti-P-VASP antibody (total P-VASP, 2% input, lower panel).  
E: Inhibition of PKA in platelets abrogates forskolin-stimulated increase in binding of Slp1 to endogenous 
Rap1GAP2. Washed human platelets were treated without or with 0.5 mM Rp-8-Br-cAMPS for 30 min at 37°C. 
Then, platelets were incubated without or with 1 µM forskolin for 20 min at 37°C. Platelets were lysed, and lysates 
were subjected to GST-Slp1 pull-down assays followed by immunoblot analysis with anti-Rap1GAP2 antibody. 
The upper panel shows precipitation results, and the lower panel expression levels of endogenous Rap1GAP2 
(total RG2, 2% input). Phosphorylated VASP was detected by immunoblot using anti-P-VASP antibody (total P-
VASP, 2% input, lower panel).  
F: Inhibition of PKA in transfected HeLa cells results in decreased binding of Slp1 to Rap1GAP2. HeLa cells were 
transiently transfected with FLAG-tagged Rap1GAP2 without or with PKI. 24 h post-transfection cells were treated 
without or with 10 µM forskolin for 20 min at 37°C. Then, cells were lysed, and lysates were subjected to GST-
Slp1 pull-down assays. The precipitates were analyzed for the presence of bound Rap1GAP2 with anti-FLAG 
antibody (upper panel). The lower panel shows expression levels of Rap1GAP2 (total RG2-FLAG, 2% input). 
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her, activation of PKA in platelets enhanced binding of Slp1 to endogenous 
3.3.1  Rap1GAP2, Slp1 and Rab27a form a trimeric complex and co-localize in 
Slp1 has been shown to bind to Rab27, a small GTPase involved in vesicle regulated 
Taken toget
Rap1GAP2. The PKA effect is specific, because inhibition of PKA by a specific PKA inhibitor 
in platelets abolished the increase of Slp1 binding to Rap1GAP2 upon forskolin treatment. In 
HeLa cells, co-expression of Rap1GAP2 and PKI resulted in decreased Slp1 binding to 
transfected Rap1GAP2. 
3.3 Complex formation of Rap1GAP2, Slp1 and Rab27 
transfected HeLa cells 
exocytosis of many cell types (Fukuda 2005). Rab27 is expressed in 2 isoforms, Rab27a and 
Rab27b, that share 71 % identity at amino acid level (Pereira-Leal and Seabra 2001). To first 
confirm binding of Slp1 to both, Rab27a and Rab27b, co-immunoprecipitation experiments 
were performed. HeLa cells were transfected with EGFP-tagged Rab27a or Rab27b, which 
were kindly provided by Prof. Dr. M. C. Seabra, London, UK, and myc-tagged Slp1 either 
alone or in combination. 24 h post-transfection, cells were lysed, and Rab27 was 
immunoprecipitated using anti-GFP antibody. The precipitates were analyzed for the 
presence of bound Slp1 by immunoblot. As shown in Fig.3.12A and B, Slp1 bound to both, 
Rab27a and Rab27b. Interestingly, binding of Slp1 to Rab27b was much weaker than to 
Rab27a. To determine if Slp1, Rab27 and Rap1GAP2 form a trimeric complex, HeLa cells 
were transfected with epitope-tagged versions of Slp1, Rab27a and Rap1GAP2. Two days 
later, cells were lysed, and lysates were subjected to co-immunoprecipitation experiments 
using anti-FLAG antibody. Rab27a could only be detected in precipitates from cell lysates 
containing all three proteins, indicating that Rab27a, Slp1 and Rap1GAP2 indeed form a 
trimeric complex in intact mammalian cells (Fig.3.12C). This result was further confirmed in a 
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reverse experiment using anti-VSV antibody (Fig.3.12D). Unfortunately, due to very weak 
binding of Rab27b to Slp1 and insufficient expression levels of VSV-tagged Rab27b, a 
trimeric complex composed of Rab27b, Slp1 and Rap1GAP2 could not be proven. However, 
given the fact that Rab27b binds to Slp1 and Slp1 binds to Rap1GAP2, complex formation of 
Rab27b, Slp1 and Rap1GAP2 is quite conceivable.  
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igure 3.12: Rap1GAP2, Slp1 and Rab27 form a trimeric complex in transfected HeLa cells. 
yc-tagged Slp1 
 
 
F
A and B: Slp1 binds to both, Rab27a and Rab27b. HeLa cells were transiently transfected with m
and EGFP-tagged Rab27a (A) or Rab27b (B) either alone or in combination. Cells were lysed, and Rab27 was 
immunoprecipitated using anti-GFP antibody. The precipitates were examined for the presence of bound Slp1 
with anti-myc antibody (upper panel). The two lower panels show expression levels of Slp1 (total Slp1-myc, 2% 
input) and Rab27 (total Rab27-EGFP, 2% input).  
C and D: Co-immunoprecipitation of transfected Rap1GAP2 in complex with Slp1 and Rab27a. HeLa cells were 
transiently transfected with VSV-tagged Rab27a alone, together with FLAG-tagged Rap1GAP2, or with FLAG-
tagged Rap1GAP2 and myc-tagged Slp1. Cells were lysed, and Rap1GAP2 was immunoprecipitated with anti-
FLAG antibody (C) and Rab27a with anti-VSV antibody (D), respectively. The precipitates were analyzed for the 
presence of Rab27a using anti-VSV antibody (C) and Rap1GAP2 using anti-FLAG antibody (D). The upper panel 
shows the precipitation results. Immunoglobulin heavy and light chains are marked with asterisk (*) (C, upper 
panel). The lower panels demonstrate total amounts of transfected Rab27a-VSV (total Rab27a-VSV, 2% input), 
Slp1-myc (total Slp1-myc, 2% input) and Rap1GAP2-FLAG (total RG2-FLAG, 2% input). 
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To investigate the subcellular localization of Rab27, Slp1 and Rap1GAP2, HeLa cells were 
co-transfected with EGFP-tagged Rab27a, myc-tagged Slp1 and VSV-tagged Rap1GAP2. 
Cells were fixed, permeabilized and immunostained with tag-specific primary and dye-
labelled secondary antibodies. Subsequent immunofluorescence analysis revealed a partial 
co-localization of all three proteins in the cytosol as well as at the plasma membrane 
(Fig.3.13). 
 
 
 
 
Figure 3.13: Co-localization of transfected Rap1GAP2, Slp1 and Rab27a. 
Co-localization of EGFP-tagged Rab27a, VSV-tagged Rap1GAP2 and myc-tagged Slp1 overexpressed in HeLa 
cells was analyzed by immunofluorescence as described in Materials and Methods (2.3.4). Arrows indicate co-
localization of all three proteins. Scale bar: 10 µm. 
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3.3.2 Rap1GAP2, Slp1 and Rab27 form a trimeric complex in human platelets 
Both isoforms of Rab27 are present in platelets (Barral et al. 2002). To demonstrate that Slp1 
interacts with endogenous Rab27 expressed in human platelets, GST-Slp1 pull-down assays 
were performed. The monoclonal anti-Rab27a antibody, which was used to detect bound 
Rab27a, recognized both Rab27 isoforms (data not shown). Thus, the band for Rab27 most 
likely represents a mixture of Rab27a and Rab27b (Fig.3.14A). In reverse experiments using 
purified recombinant GST-Rab27a and GST-Rab27b, binding of endogenous Slp1 from 
human platelet lysate was observed to both isoforms of Rab27 (Fig.3.14B). Moreover, Slp1 
bound to both, GTP- and GDP-loaded Rab27a and Rab27b equally well. To verify complex 
formation of Slp1, Rab27 and Rap1GAP2 at endogenous level in human platelets, co-
immunoprecipitation experiments using platelet lysates were performed. As shown in 
Fig.3.14C, endogenous Rab27 was successfully co-immunoprecipitated with endogenous 
Slp1 and Rap1GAP2 from platelets.  
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Figure 3.14: Rap1GAP2, Slp1 and Rab27 form a trimeric complex in platelets. 
A: Pull-down of endogenous Rab27 with GST-Slp1. Human platelet lysate was subjected to GST-Slp1 pull-down 
assay followed by immunoblot analysis using anti-Rab27a antibody which recognizes both isoforms, Rab27a and 
Rab27b. The upper panel shows precipitation results, and the lower panel expression levels of endogenous 
Rab27 protein (total Rab27, 2% input).  
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B: Pull-down of endogenous Slp1 with GST-Rab27. Purified recombinant GST fusion proteins of Rab27a and 
Rab27b loaded either with GDPβS or GTPγS were used to precipitate endogenous Slp1 from human platelet 
lysate. Equal amounts of purified GST protein were used as negative control. The precipitates were analyzed for 
the presence of bound Slp1 by immunoblot with anti-Slp1 antibody (upper panel). The lower panel shows the 
amounts of GST and GST-Rab27 used for precipitation.  
C: Co-immunoprecipitation of endogenous Rap1GAP2 in complex with Slp1 and Rab27. Washed human platelets 
were treated with 10 µM of forskolin for 20 min at 37°C as indicated. Platelets were lysed, and lysates containing 
endogenous Rab27, Rap1GAP2 and Slp1 were subjected to co-immunoprecipitation using anti-Rab27a antibody.
The precipitates were examined for the presence of Rap1GAP2 and Slp1 by immunoblot using anti-Rap1GAP2 
and anti-Slp1 antibodies (first and second panels from top). Precipitated Rab27 was controlled by immunoblot 
using anti-Rab27a antibody (third panel from top). As indicated in A, the Rab27 band most likely consists of both 
isoforms, Rab27a and Rab27b. The three lower panels show expression levels of endogenous Rap1GAP2 (total 
RG2, 2% input), Slp1 (total Slp1, 2% input) and Rab27 (total Rab27, 2% input).  
 
Notably, treatment of platelets with forskolin resulted in stronger binding of Rab27 to Slp1, 
suggesting that activation of PKA and probably subsequent PKA phosphorylation of either 
Slp1 and/or Rab27 could impact complex formation by Slp1, Rab27 and Rap1GAP2 
(Fig.3.14D, lane 3).  
3.3.3 Slp1 is phosphorylated by PKA in-vitro 
To evaluate if Slp1 could be a substrate of PKA, in-vitro kinase assays were performed. To 
this end, HeLa cells were transiently transfected with myc-tagged Slp1. Expressed protein 
was precipitated with anti-myc antibody and subjected to in-vitro phosphorylation using γ-
[
32P] ATP and purified catalytic subunit of PKA, which was kindly provided by Dr. E. Butt-
Dörje, Würzburg, Germany. As shown in Fig.3.15A, strong phosphorylation of Slp1 by PKA 
was observed. By means of the computational tool ScanSite (http://scansite.mit.edu), two 
serine residues of Slp1 corresponding to the consensus sequence -(R/K)2-X-S/T- for 
phosphorylation by protein kinase A were predicted: serine 111 (-RKKS-) and serine 301 
 (-RRRS-). In order to identify the exact phosphorylation site(s), candidate serine residues 
were mutated to alanine. Mutation of serine 111 completely abolished in-vitro 
phosphorylation of Slp1 by PKA, whereas mutation of serine 301 only marginally reduced 
phosphorylation (Fig.3.15B).  Using the computational tool SMART (Simple  Modular 
Architecture  Research  Tool, http://smart.embl-heidelberg.de) for protein domain 
identification, the Rab27 binding SHD of Slp1 was assigned to amino acids 30 to 150, 
meaning that serine 111 residue is located within this domain. To investigate whether PKA 
phosphorylation of Slp1 at serine 111 could alter Slp1 binding to Rab27, co-
immunoprecipitation experiments were performed. For this purpose, Hela cells were 
transiently transfected with myc-tagged wild-type Slp1 and serine-111-to-alanine mutant 
either alone or in combination with VSV-tagged Rab27a. 48 h post-transfection, cells were 
lysed, and Rab27a was immunoprecipitated with anti-VSV antibody. The precipitates were 
examined for the presence of Slp1 by immunoblot using anti-myc antibody. Serine-to-alanine 
mutation of residue 111 of Slp1 strongly reduced binding of Slp1 to Rab27a (Fig.3.15C). 
 
 Results 
_________________________________________________________________________________ 
 
Taken together, Slp1 is in-vitro phosphorylated by PKA, and serine 111 was identified as 
phosphorylation site. Mutation of serine 111 to alanine resulted in decreased binding of Slp1 
to Rab27 in transfected mammalian cells. 
 
 
 
 
 
 
 
Figure 3.15: Slp1 is phosphorylated by PKA. 
A: Slp1 is in-vitro phosphorylated by PKA. HeLa cells were transiently transfected with myc-tagged Slp1. 
Expressed Slp1 protein was immunoprecipitated with anti-myc antibody, and in-vitro kinase assays were 
performed using γ-[
32P]-ATP and purified catalytic subunit of PKA (designated A). As negative control no kinase 
was added (designated -). To detect 
32P incorporation, proteins were separated by SDS-PAGE, blotted on a 
nitrocellulose membrane, and exposed to film (
32P, upper panel). The expression levels of Slp1 were determined 
by immunoblot using anti-myc antibody followed by ECL detection (IB, lower panel).  
B: Mutation of serine 111 to alanine abolishes in-vitro phosphorylation of Slp1 by PKA. Hela cells were 
transiently transfected with myc-tagged wild-type (wt) Slp1 and mutants of Slp1 having serine-to-alanine 
mutations of serine 111 (S111A) or serine 301 (S301A). Expressed proteins were immunoprecipitated with anti-
myc antibody, and in-vitro kinase assays were performed as described in A. The upper panel shows 
32P 
incorporation, and the lower panel the expression levels of Slp1 proteins detected by immunblot using anti-myc 
antibody (IB).  
C: Mutation of serine 111 to alanine reduces binding of Slp1 to Rab27a in transfected cells. HeLa cells were 
transiently transfected with myc-tagged wild-type Slp1 and Slp1S111A mutant having serine 111 changed to 
alanine either alone or together with VSV-tagged Rab27a. Cells were lysed, and Rab27a was 
immunoprecipitated with anti-VSV antibody. The precipitates were analyzed for the presence of bound Slp1 by 
immunoblot using anti-myc antibody (upper panel). The two lower panels show expression levels of Slp1 (total 
Slp1-myc, 2% input) and Rab27a (total Rab27a-VSV, 2% input). 
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3.3.4 Identification of Slp1 interacting proteins in platelets 
 
The next aim of the present study was to identify additional Slp1 interacting proteins in 
platelets. To this end, Slp1 affinity chromatography was performed using human platelet 
lysate as source for Slp1 binding proteins. Subsequent mass spectrometric analysis revealed 
fourteen new putative Slp1 interactors in platelets (Tab.3.1). A total of six proteins were 
identified as members of the Rab protein family that are believed to control intracellular 
membrane trafficking (Zerial and McBride 2001). The presence of Rab27 and Rab8 indicated 
that the method was successful. However, Rap1GAP2 was not identified. Binding of 
endogenous Rab8 to Slp1 was confirmed in GST-Slp1 pull-down assays using human 
platelet lysate (Fig.3.16). In contrast, binding of Rap1b to Slp1 could not be verified (data not 
shown). A total of four proteins were related to actin cytoskeleton, and among them myosin-9 
(non-muscle myosin heavy chain IIA, NMHC-IIA) was identified yielding the most peptide 
matches. Other putative Slp1 interacting proteins were the dual specificity protein 
phosphatase 3 (DUSP3), ATP synthase O subunit (ATPO) and programmed cell death 
protein 10 (PDCD10). Platelet expression of all identified proteins was confirmed by protein 
database search using “PlateletWeb-Knowledgebase”  (http://plateletweb.bioapps.bio-
zentrum.uni-wuerzburg.de, Dittrich et al. 2008) and by protein database “Human 
Proteinpedia” (http://www. humanproteinpedia.org). 
Taken together, affinity chromatography and mass spectrometric analysis revealed further 
Slp1 interacting proteins in platelets. Binding of Slp1 to endogenous Rab8 from human 
platelets was verified by GST-Slp1 pull-down assays. 
  
 
 
 
 
Figure 3.16: Slp1 interacts with endogenous Rab8 from platelets. 
Washed human platelets were lysed, and lysates were subjected to GST-Slp1 pull-down assays. GST was used 
as negative control. The precipitates were analyzed for the presence of Rab8 by immunoblot using anti-Rab8 
antibody. The upper panel shows precipitation results, and the lower panel the expression levels of endogenous 
Rab8 (total Rab8, 2% input). 
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Table 3.1: Slp1 interacting proteins in platelets.
Slp1 affinity chromatography and mass spectrometric analysis revealed 14 new putative Slp1 interacting proteins 
in human platelets. His6-Slp1 was bacterially expressed, coupled to NHS-activated sepharose and incubated with 
human platelet lysate as described in Materials and Methods (2.4.10). After elution, bound proteins were 
separated by SDS-PAGE and stained with Coomassie Brilliant Blue. Protein bands were excised and analyzed 
by mass spectrometry. 
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3.4 Functional analysis of the Rap1GAP2/Slp1 interaction 
 
To determine the function of the interaction between Rap1GAP2 and Slp1, two strategies 
were defined and pursued: firstly, the functional relevance of the interaction in terms of 
Rap1GAP2 function in Rap1-mediated cell adhesion, and secondly, the functional 
significance of the interaction in terms of Slp1 function in Rab27-mediated secretion. 
3.4.1 In-vitro GAP assay 
As GTPase activating protein of Rap1, Rap1GAP2 contains a central catalytic GAP domain 
that is required to confer GTPase activity towards Rap1 (Schultess et al. 2005). Rap1 is a 
small GTPase that regulates integrin function and thus cell adhesion (Bos 2005). In order to 
investigate if Slp1 binding to Rap1GAP2 could affect the GTPase activity of Rap1GAP2, in-
vitro GAP assays were performed. HeLa cells were transiently transfected with the 
appropriate plasmids of Rap1GAP2 and Slp1. Expressed proteins were affinity purified using 
anti-FLAG antibody. In parallel, Rap1b was purified from Escherichia coli BL21 and loaded 
with [
32P]-GTP as described in Materials and Methods (2.5.1). Precipitated Slp1 and 
Rap1GAP2 proteins either alone or in complex were added to GTP-loaded Rap1b and 
incubated at 25°C for 30, 60 and 120 sec. Released [
32P] was counted by liquid scintillation, 
and plotted as percentage of input [
32P]-GTP bound to Rap1b. As shown in Fig.3.17 and 
expected, Slp1 itself did not exhibit any GTPase activity. In contrast, in samples containing 
Rap1GAP2 a time-dependent increase in GAP activity was observed. However, no 
differences between free and Slp1 bound Rap1GAP2 was detected, indicating that Slp1 
binding to Rap1GAP2 did not affect the catalytic GTPase activity of Rap1GAP2 in-vitro. 
3.4.2 Cell adhesion assay 
Rap1GAP proteins are known to inhibit Rap1-mediated adhesion of intact cells (Bos et al. 
2001). As described in 3.4.1, Slp1 binding had no effect on the catalytic GTPase-activating 
function of Rap1GAP2 in-vitro. However, binding of Slp1 to Rap1GAP2 could affect the 
subcellular distribution of Rap1GAP2 leading to local changes of Rap1-GTP levels within the 
cell. Therefore, functional consequences of Slp1 binding to Rap1GAP2 on cell adhesion 
were studied. 
HeLa cells expressing endogenous Rap1 were transiently transfected with pRluc-N3 vector 
together with FLAG-tagged Rap1GAP2 and myc-tagged Slp1 either alone or in combination. 
Control cells were transfected with pRluc-N3 expressing luciferase only. One day after 
transfection, cells were seeded onto fibronectin-coated plates. Adherent cells were quantified  
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Figure 3.17: Slp1 binding does not affect the GAP activity of Rap1GAP2 in-vitro.
HeLa cells were transiently transfected with FLAG-tagged Slp1, FLAG-tagged Rap1GAP2 and FLAG-tagged 
Rap1GAP2 together with myc-tagged Slp1. Expressed proteins were affinity purified using anti-FLAG agarose 
beads. The amounts of precipitated Slp1 and Rap1GAP2 were analyzed by immunoblot using anti-FLAG 
antibody (A, upper panel). Presence of myc-tagged Slp1 bound to Rap1GAP2 was determined by immunoblot 
with anti-myc antibody (A, lower panel). In parallel, His6-tagged Rap1b was purified from E.coli and loaded with 
[
32P]-GTP as described in Materials and Methods (2.5.1). Precipitated Slp1 and Rap1GAP2 proteins were added 
to the GTP-loaded Rap1b, and reactions were incubated at 25°C. Aliquots were removed at indicated time 
points, amounts of released [
32P] were determined by liquid scintillation counting, and plotted as percentage of 
input Rap1b-bound [
32P]-GTP counts. Shown data (B)  represent the means + SD of three independent 
experiments performed in triplicate. 
 
as described in Materials and Methods (2.5.2), and plotted as percentage relative to the total 
amount of seeded cells. Expression levels of Rap1GAP2 and Slp1 were analyzed by 
immunoblotting using tag-specific antibodies (Fig.3.18A). As shown in Fig.3.18B, Rap1GAP2 
reduced cell adhesion to more than 50 % of mock-transfected cells, whereas Slp1 did not 
alter cell adhesion. Adhesion of HeLa cells overexpressing both, Rap1GAP2 and Slp1, was 
similar to cells overexpressing Rap1GAP2 only. In conclusion, Slp1 binding to Rap1GAP2 
did not affect the inhibitory function of Rap1GAP2 on Rap1-mediated cell adhesion.  
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Figure 3.18: Slp1 binding does not affect Rap1GAP2-mediated inhibition of cell adhesion. 
HeLa cells were transiently transfected with pRluc-N3 vector expressing luciferase together with FLAG-tagged 
Rap1GAP2 and myc-tagged Slp1 either alone or in combination. Control cells were transfected with pRluc-N3 
vector only (mock). 24 h post-transfection cells were seeded onto fibronectin-coated plates. Adherent cells were 
quantified and plotted as percentage of the total amount of seeded cells. Shown data (B) represent the means + 
SD of ten independent experiments performed in quintuplicate. The difference in adhesion between mock-
transfected cells and cells transfected with Rap1GAP2 is expressed as p < 0.001 and considered as statistically 
significant. In all experiments equal levels of Rap1GAP2 and Slp1 expression were confirmed by immunoblot 
using anti-FLAG and anti-myc antibodies (A). 
 
3.4.3 Prostate-specific antigen secretion assay 
Slp1 was previously shown to be expressed in human prostate carcinoma LNCaP cells and 
to be involved in secretion of prostate-specific antigen and prostate-specific acid 
phosphatase in these cells (Johnson et al. 2005). Moreover, LNCaP cells express Rab27a, 
and Rab27a was demonstrated to regulate the secretion of both, PSA and PSAP (Johnson et 
al. 2005). 
To elucidate the functional consequences of Slp1 binding to Rap1GAP2 in secretion, 
secretion of PSA was studied. LNCaP cells expressing endogenous Slp1 and Rab27a were 
transiently transfected with FLAG-tagged Rap1GAP2 (RG2) or the empty vector as negative 
control (mock). 12 h post-transfection, cells were incubated in absence (DMSO control) or 
presence of the androgen 6α-fluorotestosterone. LNCaP cells are androgen-responsive, and 
upon androgen treatment growth and secretion of these cells accelerated. Cells were 
stimulated for 36 h. Then, cell medium was collected and concentration of secreted PSA was 
determined using a specific PSA ELISA kit as described under Materials and Methods 
(2.5.3). The secretion of androgen-stimulated mock transfected cells was designated as 100 
% secretion. Expression levels of Rap1GAP2 were examined by immunoblot using anti-
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FLAG antibody. As expected, upon treatment of LNCaP cells with 6α-fluorotestosterone, 
expression of Rap1GAP2 was markedly increased compared to untreated cells (Fig.3.19A). 
In addition, cells overexpressing Rap1GAP2 showed significantly higher baseline (DMSO 
control) and 6α-fluorotestosterone-stimulated secretion of PSA, compared to mock 
transfected cells (Fig.3.19B), suggesting a stimulatory role for Rap1GAP2 in secretion. 
  
  
 
Figure 3.19: Rap1GAP2 stimulates the secretion of PSA in transfected LNCaP cells. 
LNCaP cells were transiently transfected with empty vector pcDNA4/TO (mock) or FLAG-tagged Rap1GAP2 
(RG2-FLAG). 12 h post-transfection cells were stimulated with 100 nM 6α-fluorotestosterone. Control cells were 
treated with DMSO. After 36 h cell medium was collected, and concentration of PSA was evaluated using a 
specific PSA ELISA kit. Shown data (B) are means + SD of eight independent experiments performed in 
triplicate. The secretion of 6α-fluorotestosterone-stimulated mock cells was arbitrarily designated as 100 % 
secretion. The difference in PSA secretion between mock and Rap1GAP2 transfected cells is expressed as p < 
0.05 and considered as statistically significant. In all experiments Rap1GAP2 expression was analyzed by 
immunoblot using anti-FLAG antibody (A). 
 
3.4.4. Serotonin secretion assay of platelet dense granules  
To confirm the Rap1GAP2 effect on secretion and to further investigate the impact of 
Rap1GAP2/Slp1 complex formation in this process, serotonin secretion from platelet dense 
granules was studied. In platelets, Rab27 has previously been shown to regulate dense 
granule secretion by interacting with Munc13-4 (Shirakawa et al. 2004). In the present work, 
the Rab27 binding protein Slp1 has been demonstrated to be expressed in platelets, too 
(Fig.3.4C). Moreover, Slp1 binds to Rap1GAP2, and a trimeric complex composed of 
Rap1GAP2, Slp1 and Rab27 is formed in platelets (Fig.3.14D). Therefore, to elucidate the 
roles of Slp1 and Rap1GAP2 in platelet dense granule secretion, a serotonin secretion assay 
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using streptolysin-O permeabilized human platelets was established (Flaumenhaft 2004, 
Shirakawa et al. 2005). Released serotonin which forms a fluorophore with ortho-
phthalaldehyde was determined using Wallac Victor 1420 Multilabel Counter by a chemical 
fluorimetric method (2.5.4, Holmsen and Dangelmaier 1989).  
 
 
 
 
 
 
 
Figure 3.20: Validation of serotonin secretion assay (1). 
A: Determination of serotonin creatinine sulfate as standard. Different concentrations ranging from 0 to 5 µM of 
serotonin creatinine sulfate were measured as described in Materials and Methods (2.5.4).  
B: Agonist-induced serotonin secretion of intact platelets. Washed human platelets were treated as indicated. 
Serotonin (5HT) secretion was determined as described in Materials and Methods (2.5.4), and plotted as 
percentage of total serotonin stored in platelet dense granules. Shown data represent the means + SD of at least 
three independent experiments. 
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To first test the accuracy of serotonin determination, serotonin creatinine sulfate was 
measured as standard. Different concentrations were used ranging from 0 to 5 µM. As shown 
in Fig.3.20A, a straight standard curve was produced. From the experiments hereafter, the 
total amount of serotonin in the platelet preparations varied from 2 to 6 µM depending on the 
donor with a mean platelet concentration of 1 x 10
8 platelets/ml.  
It is known that platelet activators (e.g. thrombin) induce secretion of platelet granules, 
whereas platelet inhibitors (e.g. forskolin, SNP) inhibit platelet granule secretion (Aktas et al. 
2003). Therefore and for further assay validation, serotonin secretion of intact platelets 
treated with platelet activators and inhibitors was evaluated. As shown in Fig.3.20B and 
expected, treatment of platelets with different concentrations of thrombin induced a 
concentration-dependent serotonin secretion of platelet dense granules. Up to 75 % + 6 of 
total stored serotonin were released upon treatment of platelets with 0.5 U/ml of thrombin, 
while baseline serotonin release was 17 % + 2. Conversely, treatment of platelets with 
forskolin or SNP resulted in an almost entire inhibition of thrombin-induced serotonin 
secretion. The amounts of released serotonin were comparable to that of untreated platelets 
(Fig.3.20B). 
Given the fact that platelets are anucleate cells, they are not amenable to transfection. 
Therefore, we decided to permeabilize platelets in order to introduce proteins or peptides of 
interest. Platelets were permeabilized using the pore forming bacterial toxin streptolysin-O, 
which was a generous gift of Prof. Dr. S. Bhakdi, Mainz, Germany. Streptolysin-O binds as 
monomer to cellular membranes containing cholesterol, i.e. platelet plasma membrane, 
followed by oligomerization into ring-shaped structures, which then surround pores of about 
30 nm in diameter (Palmer et al. 1998). Importantly, intracellular membranes are not 
disrupted, preventing thereby the release of granular contents. Assessment of 
permeabilization was carried out by evaluating the leakage of the cytosolic marker lactate 
dehydrogenase (LDH), which was monitored by immunoblot. As shown in Fig.3.21A, LDH 
was detectable in the supernatants of permeabilized platelets only. In contrast, no LDH was 
present in supernatants of non-permeabilized platelets (Fig.3.21A, right panel).  
Granule secretion of permeabilized platelets can be stimulated with various agents. Strong 
activators such as thrombin capable of stimulating intact platelets, as shown in Fig.3.20B, 
induce granule secretion only within few minutes following permeabilization. However, due to 
leakage of cytosol, molecules critical for signal transduction diffused from the platelets 
interior, resulting in platelet irresponsiveness (data not shown). Therefore, to induce granule 
secretion of permeabilized platelets, calcium ions and the non-hydrolysable GTP analogue 
guanosine 5`-O-[γ-thio] triphosphate (GTPγS) were used. In order to optimize the time of 
Ca
2+ and GTPγS stimulation, kinetics of Ca
2+- and GTPγS-induced granule secretion of 
streptolysin-O permeabilized platelets was analyzed. As shown in Fig.3.21B, Ca
2+-induced  
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Figure 3.21: Validation of serotonin secretion assay (2). 
A: Assessment of platelet permeabilization. Washed human platelets were permeabilized using 0.6 µg/ml 
streptolysin-O as indicated, and centrifuged. Aliquots of supernatants (sup) and total platelet suspensions (tot) of 
permeabilized and non-permeabilized platelets were mixed with 3x SDS electrophoresis loading buffer and 
boiled for 5 min. Proteins were separated by SDS-PAGE and blotted onto a nitrocellulose membrane. The 
presence of lactate dehydrogenase (LDH) was determined by immunoblot using anti-LDH antibody.  
B  and C: Time-dependent Ca
2+- and GTPγS-induced serotonin secretion of permeabilized platelets. 
Permeabilized platelets were stimulated with Ca
2+ (B) or GTPγS (C) for the indicated periods of time. Released 
serotonin (5HT) was measured as described in Materials and Methods (2.5.4).  
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Figure 3.22: Slp1 inhibits platelet dense 
granule secretion in a dose-dependent 
manner. 
A: Ca
2+-induced dense granule secretion after 
incubation of permeabilized platelets with Slp1. 
Permeabilized platelets were incubated with 
the indicated concentrations of purified 
recombinant His6-tagged Slp1 and then 
stimulated with Ca
2+ for 1 min. For baseline 
serotonin secretion platelets were left 
unstimulated in absence or presence of Slp1. 
Baseline and Ca
2+-induced secretion of dense 
granules were analyzed by measuring released 
serotonin (5HT) as described in Materials and 
Methods (2.5.4). The results shown are 
expressed as means + S D  o f  t h r e e  
independent experiments performed in 
triplicate. P values are expressed as follows * p 
< 0.05 and *** p < 0.001 and considered as 
statistically significant.  
B: GTPγS-induced dense granule secretion 
after incubation of permeabilized platelets with 
Slp1. Permeabilized platelets were incubated 
with the indicated concentrations of purified 
recombinant His6-tagged Slp1 and then 
stimulated with GTPγS for 5 min. Baseline and 
GTPγS-induced secretion of dense granules 
were analyzed by measuring released 
serotonin (5HT) as described in Materials and 
Methods (2.5.4). The results shown are 
expressed as means + S D  o f  t h r e e  
independent experiments performed in 
triplicate. P values are expressed as follows * p 
< 0.05 and *** p < 0.001 and considered as 
statistically significant. 
 
dense granule secretion was very quick, and granules were efficiently secreted within 1 min 
after stimulation. In contrast, GTPγS-induced dense granule secretion was much slower 
(Fig.3.21C). While almost 70 % of stored serotonin was released after 1 min stimulation with 
Ca
2+, the same amount of serotonin was released after 10 min stimulation with GTPγS. Thus, 
we decided to stimulate permeabilized platelets with Ca
2+ for 1 min and GTPγS for 5 min.  
To test whether Slp1 and Rap1GAP2 are involved in platelet dense granule secretion, 
permeabilized platelets were incubated with purified recombinant Slp1 and Rap1GAP2 
proteins. Upon incubation of permeabilized platelets with purified recombinant Slp1, Ca
2+- 
and GTPγS-induced dense granule secretion was significantly inhibited (Fig.3.22). The 
inhibitory effect of Slp1 was dose-dependent, while baseline serotonin secretion was not 
affected by Slp1 (Fig.3.22). In contrast, incubation of permeabilized platelets with purified 
recombinant wild-type Rap1GAP2 significantly enhanced Ca
2+- and GTPγS-induced dense 
granule release (Fig.3.23A). Baseline levels of serotonin secretion were not changed by 
Rap1GAP2 (Fig.3.23A). To investigate the relevance of the Rap1GAP2/Slp1 interaction in  
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Figure 3.23: Rap1GAP2 augments platelet 
dense granule secretion by binding to 
Slp1. 
A: Ca
2+- and GTPγS-induced dense granule 
secretion after incubation of permeabilized 
platelet with wild-type Rap1GAP2. 
Permeabilized platelets were incubated with 
or without 1 µM of purified recombinant His6-
tagged wild-type Rap1GAP2 and then 
stimulated with Ca
2+ for 1 min or with GTPγS 
for 5 min. For baseline serotonin secretion, 
platelets were left unstimulated (-stim) in 
absence or presence of Rap1GAP2. 
Baseline and induced secretion of dense 
granules were analyzed by measuring 
released serotonin (5HT) as described in 
Materials and Methods (2.5.4). The results 
shown are expressed as means + SD of 
three independent experiments performed in 
triplicate. P values are expressed as follows 
** p < 0.01 and *** p < 0.001 and considered 
as statistically significant.  
B: Ca
2+- and GTPγS-induced dense granule 
secretion after incubation of permeabilized 
platelet with Rap1GAP2ΔEVTKTT mutant 
that is deficient in Slp1 binding. 
Permeabilized platelets were incubated with 
or without 1 µM of purified recombinant His6-
tagged Rap1GAP2ΔEVTKTT mutant which 
does not bind Slp1. Then, platelets were 
stimulated with Ca
2+ for 1 min or with GTPγS 
for 5 min. For baseline serotonin secretion, 
platelets were left unstimulated (-stim) in 
absence or presence of Rap1GAP2 
ΔEVTKTT. Baseline and induced secretion 
of dense granules were analyzed by 
measuring released serotonin (5HT) as 
described in Materials and Methods (2.5.4). 
The results shown are expressed as means 
+ SD of seven independent experiments 
performed in triplicate.  
C: Permeabilized platelets were incubated 
with 100 µM of Rap1GAP2 wild-type peptide 
(RG2wt peptide) or Rap1GAP2 peptide 
lacking the Slp1 binding motif EVTKTT 
(RG2ΔEVTKTT peptide). The solvent DMSO 
was used as negative control. Baseline and 
Ca
2+-induced secretion of dense granules 
were analyzed by measuring released 
serotonin (5HT) as described in Materials 
and Methods (2.5.4). The results shown are 
expressed as means + S D  o f  f i v e  
independent experiments performed in 
triplicate. P values are expressed as follows 
*** p < 0.001 and considered as statistically 
significant. 
 
 
73 
 Results 
_________________________________________________________________________________ 
 
74 
 
 
 
 
 
Figure 3.24: Rap1GAP2 effect on platelet dense 
granule secretion is not mediated by Rap1. 
Ca
2+-induced dense granule secretion after incubation 
of permeabilized platelets with Rap1. Permeabilized 
platelets were incubated with 1 µM of either BSA as 
control or purified recombinant His6-tagged native 
Rap1b or Rap1b loaded with GTP. Then, platelets 
were stimulated with Ca
2+ for 1 min. Baseline and 
Ca
2+-induced secretion of dense granules were 
analyzed by measuring released serotonin (5HT) as 
described in Materials and Methods (2.5.4). The 
results shown are expressed as means + SD of five 
independent experiments performed in triplicate. 
 
secretion, Rap1GAP2ΔEVTKTT mutant deficient in Slp1 binding was purified and tested in 
the serotonin secretion assay. Incubation of permeabilized platelets with this mutant had no 
effect on Ca
2+- and GTPγS-induced dense granule secretion (Fig.3.23B). In order to 
corroborate the Rap1GAP2 effect on secretion, Rap1GAP2 peptides, described in 3.2.3, 
were tested in secretion assays of permeabilized platelets. The wild-type Rap1GAP2 peptide 
containing the Slp1 binding -TKXT- motif, but not the mutant Rap1GAP2 peptide lacking this 
motif, augmented Ca
2+-induced platelet dense granule secretion (Fig.3.23C). To assure the 
Rap1GAP2 function in platelet secretion to be independent of the GAP activity of 
Rap1GAP2, permeabilized platelets were incubated with purified recombinant Rap1 either 
native or GTP-loaded. As expected, no effect on Ca
2+-induced serotonin secretion of platelet 
dense granules was observed (Fig.3.24). The same results were obtained if permeabilized 
platelets were incubated with Rap1 and stimulated with GTPγS (data not shown). 
In summary, to study the functional relevance of the interaction between Rap1GAP2 and 
Slp1 in platelet secretion, a serotonin secretion assay using streptolysin-O permeabilized 
human platelets was set up and validated. Incubation of permeabilized platelets with purified 
recombinant Slp1 markedly decreased dense granule secretion, whereas addition of purified 
Rap1GAP2 increased secretion. The stimulation of dense granule secretion by Rap1GAP2 
was independent of its GTPase activity but dependent on its ability to bind to Slp1, and 
deletion of the Slp1-binding -TKXT- motif abolished the Rap1GAP2 effect on secretion. Thus, 
from these data we conclude that Slp1 and Rap1GAP2 play a role in platelet dense granule 
secretion, and that the effect of Rap1GAP2 depends on the binding of Rap1GAP2 to Slp1. Results 
_________________________________________________________________________________ 
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4. DISCUSSION 
4.1 Interaction of Rap1GAP2 and Slp1 
4.1.1 The Slp1 binding -TKXT- motif of Rap1GAP2 
Rap1GAP2 is a unique protein in platelets because it is the only GTPase activating protein of 
Rap1 expressed in these cells (Schultess et al. 2005). In order to understand the regulation 
of Rap1GAP2 and to identify possible new functions for this protein, a genetic two-hybrid 
screening for interacting proteins was performed in yeast using Rap1GAP2 as bait. In 
addition to the previously described 14-3-3 protein (Hoffmeister et al. 2008), the tandem C2 
domain containing protein synaptotagmin-like protein 1 (Slp1) was found to interact with 
Rap1GAP2. The direct interaction of Rap1GAP2 and Slp1 was verified in yeast as well as in 
transfected mammalian cells (Fig.3.1 and Fig.3.2). It was shown that Slp1 is expressed in 
platelets, and the interaction of endogenous Slp1 and Rap1GAP2 was demonstrated by 
engagement of 14-3-3 (Fig.3.4). 14-3-3 proteins bind to phosphorylated serine 9 within the N-
terminus of Rap1GAP2 (Hoffmeister et al. 2008). The serine- and threonine-rich C-terminus 
of Rap1GAP2, however, has so far been of unknown function. In the present work it was 
demonstrated that at least part of this C-terminal region of Rap1GAP2 is involved in protein-
protein interactions. Mapping studies revealed that Rap1GAP2 binds through amino acids 
T524-K525-X-T527 within its C-terminus to the C2A domain of Slp1. The Slp1 binding -
TKXT- motif was verified by three complementary approaches, i.e. pull-down assays using 
alanine point mutants of Rap1GAP2 protein (Fig.3.9C) and peptide binding assays using 
either immobilized (Fig.3.9D) or solubized (Fig.3.10) Rap1GAP2 peptides, respectively. 
Interestingly, this -TKXT- motif is not conserved in Rap1GAP1, the closest relative of 
Rap1GAP2 (Schultess et al. 2005). Consequently, no binding between Rap1GAP1 and Slp1 
was observed (Fig.3.3). In Rap1GAP1, both threonine residues are changed to alanines, 
whereas the lysine residue K525 which corresponds to K503 in Rap1GAP1 is present 
(Schultess et al. 2005). However, K503 does not suffice to mediate binding of Rap1GAP1 to 
Slp1. Database search (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi) revealed the -TKXT- 
motif in numerous proteins (e.g. lipoxygenase homology domain containing protein 1, 
accession number Q8IVV2.2; NEDD4, accession number P46934; phospholipase D2, 
accession number 014939.2; PTEN-induced putative kinase protein 1, accession number 
Q9BXM7). However, it remains to be investigated whether any of these proteins are capable 
of Slp1 binding. The outcome of such binding studies would help define the biochemical 
value of the -TKXT- motif in terms of having a general role in mediating binding to C2 
domains. At present, the -TKXT- motif of Rap1GAP2 represents a unique new binding motif 
for the C2A domain of Slp1. The Slp1 binding -TKXT- motif could be involved in subcellular 
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targeting of Rap1GAP2 to the plasma membrane via Slp1 and we indeed observed a co-
localization of Rap1GAP2 and Slp1 at the plasma membrane in transfected HeLa cells 
(Fig.3.13). 
4.1.2 The role of the C2 domains of Slp1 
C2 domains are generally considered as phospholipid binding domains (Lemmon 2008), and 
in particular, the C2A domain of Slp1 has been described to bind to phosphoinositides in-
vitro and in transfected mammalian cells (Catz et al. 2002). Overexpressed DsRed-tagged 
C2A domain of Slp1 exclusively localized to the plasma membrane in LNCaP cells 
(Fig.3.6A), and the same was previously observed and reported for the EGFP-C2A chimera 
in transfected NIH3T3 cells (Catz et al. 2002). Thus, the C2A domain of Slp1 is sufficient and 
required for Slp1 binding to the plasma membrane. On the other hand, mapping studies in 
this work revealed that the C2A domain of Slp1 serves as a protein-protein interaction 
domain and mediates binding of Slp1 to Rap1GAP2. Certain C2 domains have been 
observed to be involved in protein-protein interactions before. Protein-protein interactions 
mediated by C2 domains include e.g. the interaction of the C1 and C2 domain of protein 
kinase C (Kheifets and Mochly-Rosen 2007) and the binding of the C2 domain to the 
catalytic GAP domain in SynGAP (Pena et al. 2008). In contrast to the C2A domain, the role 
of the C2B domain of Slp1 remains to be determined. In pull-down assays using the isolated 
C2B domain of Slp1, no binding to Rap1GAP2 was observed (Fig.3.5). Nonetheless, an 
engagement of the C2B domain of Slp1 in protein-protein and/or protein-membrane 
interactions cannot be ruled out. In particular, a cooperative function of both C2 domains of 
Slp1 appears to be conceivable. For example, the C2 domains of the Ca
2+-sensor protein 
synaptotagmin-I have recently been shown to function synergistically in promoting Ca
2+-
dependent membrane fusion (Martens et al. 2007, Stein et al. 2007, Fuson et al. 2007, 
reviewed by Martens and McMahon 2008). Because of similarities observed between the 
C2A domain of Slp1 and the C2 domains of synaptotagmin-I one could speculate that 
binding of Slp1 to Rap1GAP2 might be modulated by
 calcium. However, the two C2 domains 
of Slp1 are not very likely to bind calcium ions
 because some aspartic residues known to be 
involved in calcium binding by synaptotagmins are not conserved in Slp1. To address this 
point experimentally, we performed pull-down assays in absence or presence of calcium. No 
difference in binding of Slp1 to Rap1GAP2 was observed (data not shown). This observation 
renders a possible role for calcium in Slp1/Rap1GAP2 interaction rather unlikely. Moreover, 
previous studies suggested that increased intracellular calcium concentration decreases 
binding of the C2A domain of Slp1 to membranes (Catz et al. 2002).  
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In order to further assess whether the C2A domain of Slp1 is capable of binding to 
phospholipids and thus plasma membrane and to Rap1GAP2 simultaneously, phospholipid 
binding (or protein lipid overlay) assays were performed. As expected, the C2A domain and 
the full-length Slp1 protein bound to phospholipids (Fig.3.6). Interestingly, the lipid specificity 
of both was different compared to that observed previously (Catz et al. 2002). Both, the C2A 
domain and Slp1 bound preferentially to phosphatidic acid followed by phosphatidyl-
inositolmono- and -bisphosphates. Binding to PtdIns(3,4,5)P3 was apparent, but rather weak. 
However, one has to argue that protein lipid overlay assays, albeit fast and convenient, often 
yield inconsistent results which are mostly due to experimental deviations associated with 
lipid deposition and preservation on the nitrocellulose membrane. For example, 
monophosphorylated phosphoinositides such as PtdIns(3)P, PtdIns(4)P, PtdIns(5)P most 
stably associate with the nitrocellulose membrane and thus tend to give the strongest results 
(Narayan and Lemmon 2006). Therefore, to define the exact lipid specificity of Slp1 and its 
C2A domain, additional experiments (e.g. studies in solution using specific lipid vesicles) are 
required. Nonetheless, protein lipid overlay assays as they have been carried out in this work 
are sufficient to state that Slp1 binds via its C2A domain to phospholipids and thus the 
plasma membrane, and that the phospholipid binding ability of Slp1 is not affected by binding 
of Rap1GAP2. 
4.1.3 Phosphorylation at the -TKXT- motif of Rap1GAP2 
The Slp1 binding -TKXT- motif of Rap1GAP2 contains two threonines that could be subject 
to phosphorylation, and recently the C2 domain of PKCδ was reported to be a 
phosphotyrosine binding domain (Benes et al. 2005). However, data of the present study 
suggest that phosphorylation is not required for binding of the C2A domain of Slp1 to the -
TKXT- motif of Rap1GAP2 (Fig.3.9). On the other hand, platelet inhibition by activation of 
protein kinase A resulted in enhanced binding of Slp1 to endogenous Rap1GAP2 (Fig.3.11). 
These data suggest that either Rap1GAP2 or other protein(s) that is/are possibly involved in 
binding of Rap1GAP2 to Slp1 are phosphorylated by PKA, and that this phosphorylation 
impacts complex formation of Rap1GAP2 and Slp1 in platelets. From previous studies of our 
group we know that Rap1GAP2 is a substrate of both, PKA and PKG (Schultess et al. 2005). 
For example, phosphorylation of serine 7 by PKA and PKG inhibits binding of 14-3-3 to 
Rap1GAP2, and conversely, phoshorylation of serine 9 by a so far unidentified kinase 
increases 14-3-3 binding to Rap1GAP2 (Hoffmeister et al. 2008). Supposed that direct 
phosphorylation of Rap1GAP2 is responsible for the increase in binding of Slp1 to 
Rap1GAP2, phosphorylation does not occur at the -TKXT-  motif.  In-vitro kinase assays 
revealed that neither T524 nor T527 are phosphorylated by the purified catalytic subunit of 
PKA (data not shown). Therefore, it is reasonable to assume that the PKA phosphorylation 
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site is elsewhere within Rap1GAP2 and that this site once phosphorylated is able to 
positively modulate the interaction of Rap1GAP2 and Slp1. For instance, serine 549 
corresponds to the consensus sequence -(R/K)2-X-S/T- for phosphorylation by PKA 
(http://scansite.mit.edu/motifscan_seq.phtml). However, mutation of serine 549 to alanine did 
not affect phosphorylation by PKA in in-vitro kinase assays (Schultess et al. 2005), and it did 
not alter binding of Slp1 to Rap1GAP2 in transfected forskolin-treated HeLa cells (data not 
shown). Recently, a phosphopeptide of Rap1GAP2, comprising the sequence 
TTFS*PPVVAATVK (amino acids 526-538 of Rap1GAP2), in which serine 529 was 
phosphorylated, was identified in HeLa cells (Beausoleil et al. 2006). However, mutation of 
serine 529 to alanine did not affect binding of Slp1 to Rap1GAP2 in transfected cells (data 
not shown). Thus, the questions whether direct PKA phosphorylation of Rap1GAP2 is 
responsible for the enhanced binding of Slp1 to Rap1GAP2 and which serine or threonine 
residue(s) is/are phosphorylated remain to be answered. Also the issue of other protein(s) 
that could be phosphorylated by PKA and upon phosphorylation could modulate complex 
formation of Slp1 and Rap1GAP2 is subject for future studies.  
Taken together, in the present work Slp1 was identified and verified as a new direct binding 
partner of Rap1GAP2 in platelets, and has been shown to bind through its C2A domain to 
the -TKXT- motif of Rap1GAP2. Evidence suggests that Slp1 binding to Rap1GAP2 is not 
affected by calcium or phosphorylation at the -TKXT- motif. However, activation of protein 
kinase A in platelets resulted in enhanced binding of Slp1 to Rap1GAP2. Supposed that PKA 
directly phosphorylates Rap1GAP2, the exact phosphorylation site remains to be defined. On 
the other hand, it is also possible that some other protein(s) is/are involved in complex 
formation between Slp1 and Rap1GAP2 and upon kinase activation modulate binding of Slp1 
to Rap1GAP2 in platelets.  
4.2 Complex formation of Slp1, Rab27, Rap1GAP2 and other proteins 
4.2.1 The Slp1/Rab27 complex  
Slp1 is a Rab27 binding protein and is known to interact with Rab27a and Rab27b via its N-
terminal Slp homology domain (SHD). Moreover, binding of Slp1 to Rab27 has been reported 
to be nucleotide-dependent, i.e. Slp1 binds to the GTP-bound form of Rab27 (Kuroda et al. 
2002, Strom et al. 2002). In the present work binding of Slp1 to Rab27 was verified in 
transfected cells and in platelets, and Rap1GAP2 was shown to join the Slp1/Rab27 complex 
(Fig.3.12 and Fig.3.14).  
Binding of Slp1 to Rab27 was first confirmed by co-immunoprecipitation experiments in 
transfected cells. Therein, binding of Slp1 to Rab27a was stronger than to Rab27b (Fig.3.12). 
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In pull-down assays, however, binding of Slp1 to both Rab27 isoforms was similar (Fig.3.14). 
This discrepancy was probably due to different protein amounts of Rab27 used in these 
different approaches, i.e. co-immunoprecipitation and pull-down experiments, and especially, 
slight variations in binding of Slp1 to Rab27a or Rab27b, as they might exist, could have 
been blurred by much higher amounts of Rab27 used in pull-down assays. Therefore, in 
order to precisely and definitely assess the affinity of Slp1 binding to Rab27a and Rab27b, 
further studies (e.g. real time and quantitative analysis of the Slp1/Rab27 interaction using 
BIAcore technology) will be necessary. Notably, also binding of Munc13-4 to Rab27a has 
been shown to be stronger than its binding to Rab27b (Shirakawa et al. 2004). The question 
whether the nucleotide state of Rab27 has an effect on Slp1 binding was addressed in pull-
down assays using GDP- versus GTP-loaded Rab27. No difference in binding was observed 
(Fig.3.10). These data confirm recent findings by Johnson et al. 2005 and Hattula et al. 2006, 
arguing against a role for the nucleotide state of Rab27 in Slp1/Rab27 complex formation. 
For example, also Slp4/granuphilin-a has been reported to bind Rab27 independently of the 
nucleotide state of the Rab protein (Fukuda 2005). Additionally, there is evidence suggesting 
that binding of Slp1 to Rab27 is regulated by phosphorylation. Recently, it was demonstrated 
that Slp1 is a substrate of protein kinase B (PKB, also termed Akt) and is phosphorylated by 
this kinase mainly at serine 241 which is located in proximity to the phospholipid binding C2A 
domain of Slp1 (Johnson et al. 2005). Accordingly, phosphorylation of Slp1 by PKB did not 
alter binding of Slp1 to Rab27. Instead, phosphorylation of Slp1 by PKB led to the 
dissociation of Slp1 from the plasma membrane and consequently, redistribution of Slp1 into 
the cytosol in LNCaP cells (Johnson et al. 2005). In the present work, in-vitro kinase assays 
revealed that Slp1 is a substrate of protein kinase A, and serine 111, which is localized within 
the Rab27 binding Slp homology domain, was identified as phosphorylation site (Fig.3.15). In 
platelets activation of PKA resulted in enhanced binding of Slp1 to Rab27 (Fig.3.14), 
indicating that phosphorylation of Slp1 by PKA could affect binding of Slp1 to Rab27, and 
indeed, mutation of serine 111 to alanine diminished binding of Slp1 to Rab27 in transfected 
cells (Fig.3.15). However, it is also possible that Rab27 itself is subject to phosphorylation 
and likewise, phosphorylation of Rab27 could impinge on binding of Rab27 to Slp1.  
Altogether, the results of the present study suggest a constitutive binding of Slp1 to Rab27 in 
platelets and indicate that Slp1/Rab27 complex formation is affected by phosphorylation. 
Since Slp1 binding to Rab27 occurred independently of the nucleotide state of the Rab 
protein and since Rab27 associates with granules only in its GTP-bound state (Behnia and 
Munro 2005, Barral et al. 2002), it is likely that different pools of Slp1 are present in platelets 
(Fig.4.1). Slp1 that is bound to GDP-Rab27 may be soluble (reserve cytosolic pool), whereas 
Slp1 associated with GTP-Rab27 may mainly localize to platelet dense granules (active 
granule-associated pool). Moreover, the ability of the C2A domain of Slp1 to bind to 
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phospholipids and thus the plasma membrane suggests that Slp1 may also localize to the 
plasma membrane in platelets. Thus, it is reasonable to assume that Slp1 might be able to 
shift between these three distinct subcellular compartments, and accordingly, this might 
determine the functionality of the Slp1 protein. In particular, association of Slp1 with GTP-
Rab27 on platelet dense granules might turn Slp1 into a Rab27 effector, and subsequent 
interaction of Slp1 with other proteins and/or lipids might help to position the granules to 
cellular targets (e.g. actin cytoskeleton or plasma membrane). Of course, further studies will 
be required in order to foremost precisely define the subcellular distribution of Slp1 in 
platelets and to answer the question of whether and how this distribution might be regulated. 
 
 
 
 
 
Figure 4.1: Possible subcellular distribution of Slp1 in platelets. 
Slp1 is a Rab27 and membrane binding protein and might therefore distribute between three different subcellular 
compartments in platelets: (1) due to its binding to the inactive GDP-bound form of Rab27 Slp1 is cytosolic; (2) 
binding of Slp1 to the active GTP-bound form of Rab27, however, shifts Slp1 to platelet dense granules and turns 
it into a Rab27 effector; (3) finally, membrane binding of Slp1 positions the Slp1 protein at the plasma membrane 
and/or promotes tethering/docking of Rab27-coated dense granules to the plasma membrane during platelet 
secretion. 
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4.2.2 The platelet Slp1 interactome 
Rab27 has been shown to regulate platelet dense granule secretion (Shirakawa et al. 2004, 
Tolmachova et al. 2007). It probably acts by promoting granule motility or by enhancing 
docking and fusion of granules with the plasma membrane (Seabra and Coudrier 2004, 
Behnia and Munro 2005, Fukuda 2006). For these functions Rab27 needs to interact with 
effector proteins, and Slp1 is the second Rab27 effector protein identified in platelets, in 
addition to Munc13-4 (this work, Shirakawa et al. 2004). In some cases the Rab27/effector 
protein complex in turn associates with other proteins (e.g. myosin, SNARE or SNARE 
regulatory proteins) to mediate membrane transport, docking and fusion. For example, 
Slac2-a/melanophilin simultaneously interacts with Rab27 and the cytoskeletal motor protein 
myosin Va, thereby enabling melanosome transport in melanocytes (Strom et al. 2002). The 
Rab27 binding protein Slp4/granuphilin-a directly binds to syntaxin-1a (Torii et al. 2002) and 
Munc18-1 (Coppola et al. 2002), both important for membrane docking and fusion. In 
addition, Slp4 is also known to bind to Rab8 and Rab3 at least in-vitro (Fukuda 2005). 
Recently, Slp1 has also been reported to bind to Rab8 in transfected HeLa cells (Hattula et 
al. 2006). However, the existence of the endogenous Slp1/Rab8 complex e.g. in platelets 
has not yet been demonstrated. The results of the present work clearly show that Slp1, 
Rab27 and Rap1GAP2 form a trimeric complex in transfected cells and in platelets, and 
demonstrate that this complex is affected by phosphorylation (Fig.3.14). In order to identify 
further proteins that could be involved in the complex formation around Slp1 in platelets, Slp1 
affinity chromatography was performed. On the whole, fourteen new putative Slp1 interacting 
proteins were identified in platelets (Tab.3.1). The presence of Rab27 and Rab8 argues for 
the success of this biochemical method, and binding of Rab8 to Slp1 was confirmed in pull-
down assays (Fig.3.16). The fact that Slp1 interacts with both Rab27 and Rab8 in platelets is 
of particular interest. Both Rab proteins might functionally overlap. For example, Rab27 and 
Rab8 colocalize on zymogen granules in pancreatic acinar cells and on melanosomes in 
melanocytes, and they are both involved in actin-based movement and secretion of these 
organelles (Chen et al. 2004, Chen et al. 2005, Faust et al. 2008, Fukuda et al. 2002, 
Chabrillat et al. 2005). In platelets, however, Rab8 has been reported to be present on alpha 
granules, whereas Rab27 mainly localizes to dense granules (Karniguian et al. 1993, Barral 
et al. 2002). Therefore, one could speculate that in contrast to Rab27 and in addition to 
Rab4, Rab8 could play a role in secretion of alpha granules in platelets. However, 
experimental proof is still missing. In addition, Rab8 has been implicated to regulate the 
formation of cell shape (Hattula et al. 2006) and cell polarity (Sato et al. 2007). In contrast to 
Rab8, binding of Rap1 to Slp1 could not be verified in pull-down assays, suggesting that 
Rap1 is a false-positive because of its very high expression level in platelets (data not 
shown). On the other hand, absence of Rap1GAP2 on the Slp1 affinity column might be 
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caused by low expression of Rap1GAP2 in platelets, and could potentially be tackled by 
forskolin treatment of platelets to enhance Rap1GAP2 binding to Slp1. The presence of 
Rab32 among the six Rab proteins that were purified with Slp1 is remarkable. Rab32 
functions as an A-kinase anchoring protein, as it associates with protein kinase A in intact 
cells (Alto et al. 2002). In addition, Rab32 has been implicated in protein trafficking in 
melanosomes (Wasmeier et al. 2006), and has recently been shown to regulate melanosome 
transport in Xenopus melanophores by PKA recruitment (Park et al. 2007). As Slp1 is a 
substrate of protein kinase A (Fig.3.15), binding of Slp1 to Rab32 might provide an 
opportunity to spatially and temporally control phosphorylation of Slp1 by PKA in platelets. 
The presence of myosin-9 (non-muscle myosin heavy chain IIA, NMHC-IIA) together with 
myosin regulatory light chain 2 and myosin light polypeptide 3 and 6 might be important as 
well. Myosin-9 is encoded by MYH9, and is the only myosin heavy chain isoform expressed 
in platelets (Sellers 2000). Mutations in MYH9 are responsible for the so-called MYH9-
related disorders, i.e. May-Hegglin anomaly, Fechtner syndrome, Sebastian syndrome and 
Epstein syndrome, which are characterized by the triad of thrombocytopenia, large platelets 
and leukocyte inclusions (Seri et al. 2003). Myosin-9 is a heterohexameric protein, and 
becomes activated by phosphorylation of its regulatory light chain subunit. Myosin-9 plays a 
central role in the cytoskeletal rearrangements underlying platelet shape change during 
activation, and in platelet secretion (Blockmans et al. 1995, Nishikawa et al 1980, Watanabe 
et al. 2001).  
Altogether, the identified new putative Slp1 interacting proteins are interesting and promising. 
However, it remains unclear if all these proteins bind to the same macromolecular complex 
around Slp1 or whether there may be different subcomplexes. In the present study Slp1 was 
found to interact with Rap1GAP2 in platelets and the trimeric complex of Rap1GAP2, Slp1 
and Rab27 was proven. However, it appears unlikely that for example Rab8 can be found 
within this complex. Slp1 might rather bind to either Rab27 or Rab8 and act as effector 
protein in separate secretory processes. According to its subcellular localization in platelets 
(Karniguian et al. 1993), one could speculate that Rab8 regulates platelet alpha granule 
secretion by e.g. involving the formation of the trimeric complex of Slp1, Rab8 and 
Rap1GAP2. In addition, myosin-9 might be engaged into these complexes and might help to 
promote granule motility by connecting platelet alpha and dense granules with the actin 
cytoskeleton. Certainly, the identified Slp1 interacting proteins complement the Slp1 
interactome in platelets (Fig.4.2). The platelet Slp1 interactome can be drawn based on the 
data of the present study, previously published data and predicted platelet protein-protein 
interactions by PlateletWeb-Knowledgebase (http://plateletweb.bioapps.biozentrum.uni-
wuerzburg.de). PlateletWeb-Knowledgebase allows creating a “virtual” platelet by combining 
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Figure 4.2: The Slp1 interactome in platelets. 
Protein-protein interactions that were verified in platelets in the present work are colored in violet and indicated by 
violet solid line. Protein-protein interactions that were published and demonstrated in platelets by others are 
colored in grey and indicated by grey solid line. Protein-protein interactions that were published by others but 
need to be verified in platelets are colored in grey and indicated by grey dashed line. Protein-protein interactions 
that were identified by affinity chromatography and mass spectrometric analysis but need to be verified by 
alternative approaches are uncolored and indicated by dashed line. Protein-protein interactions that are predicted 
by PlateletWeb-Knowledgebase (http://plateletweb.bioapps.biozentrum.uni-wuerzburg.de) are colored in green 
and indicated by green dashed line. ST denotes serine and threonine phosphorylation. ARPC5: actin-related 
protein 2/3 complex subunit 5; ATPO: ATP synthase subunit O; CDC42: cell division cycle 42; DUSP3: dual 
specificity protein phosphatase 3; NMHC-IIA: non-muscle myosin heavy chain IIA, also myosin-9; NCF1; 
neutrophil cytosolic factor 1 (also termed p47
phox subunit of NADPH oxidase); NCF2: neutrophil cytosolic factor 2 
(also termed p67
phox subunit of NADPH oxidase); NSF: N-ethylmaleimide-sensitive factor; PDCD10: programmed 
cell death protein 10; PKB: protein kinase B; RabGDI: Rab GDP dissociation inhibitor; RG2: Rap1GAP2; Slp: 
synaptotagmin-like protein; STX: syntaxin; VAMP; vesicle-associated membrane protein. 
 
large scale proteome and transcriptome data with literature-curated data of the Human 
Protein Reference Database (http://www.hprd.org) (Dittrich et al. 2008). For example, 
previous publications demonstrated that Slp1 stably associates with PKB (Johnson et al. 
2005), and directly interacts with p67
phox subunit of NADPH oxidase (NCF2, McAdadra 
Berkowitz et al. 2001). Although these interactions were not demonstrated in platelets, they 
are predicted by PlateletWeb-Knowledgebase. Additionally, Slp4 is known to bind to Rab27 
(Fukuda 2005). However, the Slp4/Rab27 complex has not yet been verified in platelets. On 
the other hand, Slp4 expression and its binding to Rab27 in platelets are predicted by 
PlateletWeb-Knowledgebase. Interestingly, within the platelet Slp1 interactome, Slp1 
interacting proteins can be grouped into secretion-related proteins such as Rab and SNARE 
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proteins and into signaling- or cytoskeleton-related proteins such as Rap1GAP2, PKB, 
NMHC-IIA and NCFs linking Slp1 to Rac, CDC42 and actin (Fig.4.2). Moreover, the fact that 
several proteins of the platelet Slp1 interactome are subject to phosphorylation suggests a 
dynamic regulation of the protein-protein interactions by kinases and phosphates. So far, the 
results of the present study demonstrate that phosphorylation by protein kinase A modulates 
the formation of the trimeric complex of Slp1, Rab27 and Rap1GAP2. However, since Slp1 is 
a substrate of both, PKA and PKB (this work, Johnson et al. 2005), and Rap1GAP2 is known 
to be phosphorylated by both, PKA and PKG (Schultess et al. 2005), other kinases could be 
involved as well. In consequence, protein-protein interaction patterns might be significantly 
rearranged, leading to the so-called dynamic Slp1 interactome in platelets.  
Finally, the question whether the new putative Slp1 interacting proteins constitute the 
complete list of Slp1 protein-protein interactions in platelets will need to be addressed in 
future studies. Further experiments will also help to validate the identified protein-protein 
interactions and clarify their relevance for platelet functions (e.g. platelet secretion of alpha 
and dense granules). 
4.3 Involvement of Slp1 and Rap1GAP2 in platelet dense granule secretion 
4.3.1 Serotonin secretion assay of permeabilized platelets 
To determine the significance of the Slp1/Rap1GAP2 interaction for platelet function and in 
particular to dissect the roles of Slp1 and Rap1GAP2 in platelet secretion, a previously 
described technology was adopted and modified, in which platelets were permeabilized by 
the pore forming bacterial toxin streptolysin-O and secretion of serotonin was measured by a 
non-radioactive flourimetric method (Flaumenhaft 2004, Shirakawa et al. 2005, Holmsen and 
Dangelmaier 1989). Since platelets are anucleate cells, they cannot be transfected. 
Therefore, in order to be able to introduce peptides or proteins into platelets, they need to be 
permeabilized. In the present work, permeabilization at 30°C with 0.6 µg/ml streptolysin-O 
proved to allow access to the platelet cytosol without damaging the granule membranes, and 
was monitored by the appearance of lactate dehydrogenase in the supernatants of 
permeabilized platelets (Fig.3.21). Then, permeabilized platelets were incubated on ice with 
peptides and proteins of interest to equilibrate them into the platelet interior. Since 
streptolysin-O is inactive at 4°C, this cold step decreased the activity of the toxin, thereby 
lessening the extent of permeabilization of granule membranes (Ahnert-Hilger et al. 1989). 
When this step was performed at room temperature or extended over the time indicated in 
Materials and Methods (2.4.5.), an increase in the baseline secretion of serotonin from 
platelet dense granules was observed (data not shown). After rewarming to 30°C for 5 
minutes, permeabilzed platelets were treated with 20 µM Ca
2+ or 100 µM GTPγS to induce 
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secretion. Several groups have previously demonstrated that Ca
2+ and GTPγS at the 
indicated concentrations can stimulate secretion of permeabilized platelets (Padfield et al. 
1996, Sloan and Haslam 1997). Interestingly, granule secretion was induced rapidly after 
addition of Ca
2+ and reached a plateau after 3 minutes (Fig.3.21). In contrast, GTPγS 
stimulated granule secretion only after a certain time lag, but once initiated, secretion 
occurred at comparable rates (Fig.3.21). The delay in GTPγS-induced secretion was perhaps 
due to the dilution of an important cytosolic factor. Such a dilution apparently has only a 
limited effect on the Ca
2+-induced secretion, although it also requires cytosol (Shirakawa et 
al. 2005). Alternatively, the delay might be caused by the need for a GDP-GTPγS exchange 
to activate a G protein which is not needed on Ca
2+ stimulation. Thus, the difference in 
kinetics suggests that the two types of stimuli induce secretion through different but 
potentially parallel pathways. Ca
2+ probably induces granule secretion by stimulating the final 
fusion step of the granule with the plasma membrane, whereas GTPγS stimulation might be 
mediated by small GTPases such as Rab27 or Ral (Padfield et al. 1996, Shirakawa et al. 
2004, Kawato et al. 2008). In all cases, dense granule secretion was dependent on ATP, and 
the creatine phosphate/creatine phosphokinase system was used as an ADP scavenger.  
The major difference between the properties of permeabilized and intact platelets was the 
extent of granule release. The extent of release from permeabilzed platelets was 
approximately 50 % of that seen for thrombin-induced secretion from intact platelets 
(Fig.3.20, Flaumenhaft 2004). This difference in release efficiency was again probably due to 
the dilution of important cytosolic components as they diffused from the platelets, and was 
further supported by the observation that permeabilized platelets became irresponsive to 
thrombin within few minutes following permeabilzation (data not shown). Additionally, it 
should be noted that platelet dense granule secretion was induced at 30°C rather than at 
37°C, which also might account for some decrease in release efficiency.   
4.3.2 The role of Slp1 in platelet dense granule secretion 
Using the above assay a role for Slp1 in platelet dense granule secretion was assigned. 
Addition of purified recombinant Slp1 to permeabilized platelets strongly inhibited Ca
2+- and 
GTPγS-induced secretion of serotonin in a dose-dependent manner (Fig.3.22). This finding 
suggests that Slp1 is a negative regulator of platelet dense granule secretion. The inhibitory 
effect of Slp1 on platelet dense granule secretion was further supported by the observation 
that the isolated C2A domain of Slp1 augmented serotonin secretion of permeabilized 
platelets (data not shown). In line with the argument that the C2A domain might compete 
against a function of endogenous Slp1 protein, this result substantiates the inhibitory role of 
Slp1 in platelet secretion. However, the literature about effects of Slp1 on secretion in other 
cells is controversial. Slp1 has previously been demonstrated to positively regulate secretion 
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of prostate-specific antigen by prostate cells (Johnson et al. 2005) and secretion of 
azurophilic granules by granulocytes (Munafo et al. 2007). Studies in mice lacking Slp1, 
however, suggest an inhibitory role for Slp1 in amylase secretion by pancreatic acinar cells 
(Saegusa et al. 2008). Additionally, data obtained from studies of other Slp family members 
indicate that Slp proteins have cell type specific functions and may play both, stimulatory and 
inhibitory roles in secretion through diverse interactions with other proteins or the membrane 
(Rizo and Rosenmund 2008). For example, Slp2 has been shown to positively affect basal 
mucus secretion in gastric cells (Saegusa et al. 2006). Moreover, Slp2 has further been 
implicated in targeting Rab27-coated melanosomes to the plasma membrane in melanocytes 
(Kuroda and Fukuda 2004), and this effect was attributed to its N-terminal Rab27 binding 
domain and its C2A domain that mediates binding to phospholipids and thus the plasma 
membrane. Similarly, Slp2 has been proposed to dock glucagon containing granules to the 
plasma membrane in pancreatic α-cells (Yu et al. 2007). On the other hand, Slp4 has been 
reported to negatively regulate dense granule secretion by neuroendocrine PC12 cells 
(Fukuda et al. 2002) and insulin secretion by pancreatic β-cells (Gomi et al. 2005). The 
inhibitory effect of Slp4 on secretion is supposed to be mediated by its binding to Munc18-1 
and syntaxin-1a (Torii et al. 2002, Coppola et al. 2002, Fukuda 2006). In contrast to Slp1, 
addition of Munc13-4 enhanced Ca
2+-induced secretion of platelet dense granules 
(Shirakawa et al. 2004). Since Munc13 proteins appear to play prominent roles in vesicle 
priming (Rizo and Rosenmund 2008), Munc13-4 could presumably be involved in priming of 
platelet dense granules with the plasma membrane (Fukuda 2005).  
Altogether, the results of the present study clearly suggest that Slp1 negatively regulates 
platelet dense granule secretion. However, the exact molecular mechanism of Slp1 action in 
platelets remains yet to be determined. A further more detailed study will be required, 
including experiments on the role of other Slp1 domains and other Slp1 binding partners 
such as Rab27, Rab8, Rab32 and myosin-9 in platelet secretion. 
4.3.3 The role of Rap1GAP2 in platelet dense granule secretion 
Next, the role of Rap1GAP2 in secretion was analyzed. Studies in LNCaP cells pointed to a 
putative stimulatory role of Rap1GAP2 in secretion of prostate-specific antigen (Fig.3.19). 
Addition of purified recombinant Rap1GAP2 protein to permeabilized platelets led to a small 
but highly significant stimulation of platelet dense granule secretion. Rap1GAP2 augmented 
both, Ca
2+- and GTPγS-induced secretion of platelet dense granules (Fig.3.23A). Importantly, 
this effect was strictly dependent on the binding of Rap1GAP2 to Slp1. Deleting the Slp1 
binding -TKXT- motif in Rap1GAP2 abolished the stimulatory effect of Rap1GAP2 on platelet 
secretion (Fig.3.23B). The Rap1GAP2 effect on platelet secretion was further confirmed by a 
complementary approach using Rap1GAP2 peptides. Rap1GAP2 wild-type peptide 
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containing the Slp1 binding -TKXT- motif augmented serotonin secretion comparable to the 
full-length Rap1GAP2 protein. In contrast, a mutant peptide lacking the -TKXT- motif had no 
effect on secretion (Fig.3.23C). Moreover, it was demonstrated that the stimulatory effect of 
Rap1GAP2 on secretion was not dependent on the GTPase activating function of 
Rap1GAP2 and thus Rap1. Given the fact that Rap1 was found to be associated with 
secretory granules in e.g. neutrophils and pancreatic acinar cells (Maridonneau-Parini and de 
Gunzburg 1992, Chen X et al. 2005), it has been speculated that Rap1 might be involved in 
secretion (Bos et al. 2001). However, we and others did not observe any effect of Rap1 on 
secretion of platelet dense granules (Fig.3.24, Shirakawa et al. 2004). In addition, Slp1 
binding to Rap1GAP2 also had no effect on the catalytic GTPase activity of Rap1GAP2 in in-
vitro GAP assays using purified proteins (Fig.3.17).  
 
 
 
Figure 4.3: Rap1GAP2 is involved in both platelet secretion and aggregation. 
The -TKXT-mediated interaction of Rap1GAP2 (RG2) with the Rab27 and membrane binding protein Slp1 is 
important for platelet dense granule secretion (A). Slp1 is recruited to Rab27 on platelet dense granules. By 
simultaneously interacting with Rab27 and phospholipids (denoted by PL) Slp1 presumably links dense granules 
with the plasma membrane. Rap1GAP2 interacts with Slp1 via the Slp1 binding -TKXT- motif and augments 
platelet dense granule secretion. On the other hand, Rap1GAP2 is a GTPase activating protein specific for Rap1 
and is required for the GTPase function of Rap1 (B). Rap1GAP2 enables the formation of Rap1-GDP, thereby 
terminating the activatory effect of Rap1-GTP on platelet integrin αIIbβ3 ( denoted by dashed line), leading to 
reduced platelet aggregation. 
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Thus, the results of the present study for the first time demonstrate that Rap1GAP2 is 
involved in secretion, and the stimulatory effect of Rap1GAP2 is mediated by a completely 
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one could speculate that binding of the -TKXT- motif of Rap1GAP2 to the C2A domain of 
Slp1 positively affects the cooperation between the Slp1 tandem C2A and C2B domains 
(Fuson et al. 2007), which might be required for full activation of membrane fusion by both 
domains (Martens et al. 2007, Stein et al. 2007).  
From these data we conclude that Rap1GAP2 and Slp1 are important new components of 
the protein machinery mediating platelet dense granule secretion. Since Rap1GAP2 is a 
regulator of Rap1 and thus of platelet aggregation, the findings of the present study suggest 
that Rap1GAP2 is involved in both, aggregation and secretion (Fig.4.3), and might serve to 
coordinate these crucial platelet functions.  
 
 Future perspectives 
_________________________________________________________________________________ 
 
5. FUTURE PERSPECTIVES 
In the present work it was demonstrated that the tandem C2 domain containing and Rab27 
binding protein Slp1 is expressed in platelets and interacts with the GTPase activating 
protein of Rap1, Rap1GAP2. Binding of Rap1GAP2 to Slp1 is mediated by the new -TKXT- 
protein motif in Rap1GAP2 that binds to the C2A domain of Slp1. Furthermore, both Slp1 
and Rap1GAP2 were shown to be involved in platelet dense granule secretion. Of course, 
further experimentation will be required to clarify the exact molecular mechanism of Slp1 and 
Rap1GAP2 action in platelet secretion. For example, it will be necessary to analyze the 
subcellular distribution of Slp1 and Rap1GAP2 e.g. in resting and activated platelets. To this 
end, platelet fractionation assays and electron microscopy approaches could be used. 
Besides dense granules, platelets contain alpha granules and lysosomes. Thus, it is 
interesting to know whether Slp1 and Rap1GAP2 are involved in platelet dense granule 
secretion alone or whether they also play a role in platelet alpha and lysosomal granule 
release. This could be addressed in secretion assays of permeabilized platelets by 
monitoring the release of von Willebrand factor and β-hexosaminidase, respectively. 
Moreover, on the way to further unravel the molecular details of Slp1 and Rap1GAP2 action 
in platelet secretion, one could perform lipid binding assays using liposomes as described by 
Martens et al. 2007. For example, it has been reported that Slp2, a member of the 
synaptotagmin-like protein family, binds to Folch liposomes in a Ca
2+-independent manner 
and induces membrane curvature in-vitro (Martens et al. 2007), and this phenomenon was 
attributed to the presence of the two tandem C2 domains in Slp2. Thus, one could ask the 
question whether Slp1 or its tandem C2A and C2B domains are also capable of membrane 
deformation and how it might be affected by Rap1GAP2 protein or peptide containing the 
Slp1 binding -TKXT- motif.  In addition to Slp1, database search using PlateletWeb-
Knowledgebase (http://plateletweb.bioapps.biozentrum.uni-wuerzburg.de) revealed Slp4 to 
be present in platelets. It will be interesting to verify whether Slp4 is expressed in platelets 
and whether it also might be involved in platelet secretion. Initial studies were performed to 
analyze binding of Rap1GAP2 to Slp2, Slp3, Slp4, and Slp5, however, further experiments 
e.g. using purified Slp proteins will be required to conclusively exclude binding of Rap1GAP2 
to Slp family members apart from Slp1. Moreover, a number of putative new Slp1 interacting 
proteins were identified in platelets. Binding of Slp1 to Rab8 was confirmed in pull-down 
assays, however, it remains to be investigated whether Slp1 and Rab8 interact at the 
complete endogenous level in platelets and whether a trimeric complex of Slp1, Rab8 and 
Rap1GAP2 can be formed. In addition, the question whether Rab8 is involved in platelet 
secretion has to be addressed in secretion assays of permeabilized platelets. Given the fact 
that multiple Rab27 binding proteins (e.g. Slp1 and Munc13-4) are present in platelets one 
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could also ask the question how these proteins discriminately bind to Rab27 or other Rab 
proteins (e.g. Rab8), and how they differentially, sequentially or synergistically function in the 
same cell. Moreover, the question how all these protein-protein interactions are regulated 
during platelet activation or platelet inhibition will be a future challenge. Finally, the obtained 
knowledge on the molecular mechanisms governing platelet granule secretion needs to be 
consolidated in order to develop new strategies for antiplatelet drugs. First evidence 
suggests that targeting the platelet secretory machinery might be an effective way to manage 
thrombosis in-vivo, i.e. limiting clot formation without inducing excessive bleeding (reviewed 
by Ren et al. 2008). In particular, the identification of the Slp1 binding -TKXT- motif raises the 
question of its pharmacological value in terms of being a potential target to modify platelet 
granule release. One could imagine developing specific and cell permeable -TKXT- 
peptidomimetics that bind Slp1 but do not augment but rather block platelet granule release. 
Structural analysis of the Rap1GAP2/Slp1 complex by means of crystallography approaches 
will help to proceed in that direction. 
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7. APPENDIX 
7.1 List of constructs 
Table 7.1.1: Slp1 constructs 
Name Vector  Primer  Template  Source 
GST-Slp1 pGEX-4T-3  235,236  Slp1_RZPD  this  work 
His6-Slp1  pET28  563, 236  Slp1_RZPD  this work 
GST-C2A pGEX-4T-3  337,338  Slp1_RZPD  this  work 
GST-C2B pGEX-4T-3  339,236  Slp1_RZPD  this  work 
GST-C2AB pGEX-4T-3 337,236  Slp1_RZPD  this  work 
Slp1-myc  pcDNA3.1/myc-His  235, 336  Slp1_RZPD  this work 
C2A-myc  pcDNA3.1/myc-His  337, 365  Slp1_RZPD  this work 
Slp1ΔC2B-myc  pcDNA3.1/myc-His  235, 365  Slp1_RZPD  this work 
Slp1S117A-myc  pcDNA3.1/myc-His  469, 470  Slp1_RZPD  this work 
Slp1S311A-myc  pcDNA3.1/myc-His  471, 472  Slp1_RZPD  this work 
Slp1-3xFLAG  pCMV-3Tag-3  235, 405  Slp1_RZPD  this work 
 
Table 7.1.2: Rap1GAP2 constructs 
Name Vector  Primer  Template  Source 
RG2-FLAG pcDNA4/TO      A.  Smolenski 
RG2ΔCterm-FLAG  pcDNA4/TO     A.  Smolenski 
RG2Nterm-FLAG pcDNA4/TO      M.  Hoffmeister 
RG2ΔNterm-FLAG  pcDNA4/TO     M.  Hoffmeister 
VSV-RG2ΔNterm-
C1 
pSG8-VSV-EGFP     J.  Schultess 
VSV-RG2ΔNterm-
C2 
pSG8-VSV-EGFP     J.  Schultess 
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VSV-RG2ΔNterm-
C3 
pSG8-VSV-EGFP     J.  Schultess 
VSV-RG2ΔNterm-
C4 
pSG8-VSV-EGFP 367,  368  VSV-RG2ΔNterm  this work 
VSV-RG2ΔNterm-
C5 
pSG8-VSV-EGFP 346,  347  VSV-RG2ΔNterm  this work 
VSV-RG2ΔNterm-
C6 
pSG8-VSV-EGFP 369,  370  VSV-RG2ΔNterm  this work 
VSV-RG2ΔNterm-
C7 
pSG8-VSV-EGFP 343,  344  VSV-RG2ΔNterm  this work 
VSV-RG2ΔNterm-
C8 
pSG8-VSV-EGFP     J.  Schultess 
RG2Δ522-527 
-FLAG 
pcDNA4/TO 401,402  RG2-FLAG  this  work 
RG2Δ536-542 
-FLAG 
pcDNA4/TO 399,400  RG2-FLAG  this  work 
RG2E522A-FLAG pcDNA4/TO  481,482  RG2-FLAG  this  work 
RG2V523A-FLAG pcDNA4/TO  479,480  RG2-FLAG  this  work 
RG2T524A-FLAG pcDNA4/TO  496,497  RG2-FLAG  this  work 
RG2K525A-FLAG pcDNA4/TO  477,478  RG2-FLAG  this  work 
RG2T526A-FLAG  pcDNA4/TO  456, 457  RG2-FLAG  this work 
RG2T527A-FLAG pcDNA4/TO  452,453  RG2-FLAG  this  work 
RG2-VSV pcDNA4/TO      M.  Hoffmeister 
RG2-His6 pcDNA4/TO      M.  Hoffmeister 
RG2Δ522-527-His6  pcDNA4/TO 401,402  RG2-His6 this  work 
Table 7.1.3: Other Constructs 
Name Vector  Primer  Template  Source 
T7-Slp2a pEF-T7      M.  Fukuda 
T7-Slp3a pEF-T7      M.  Fukuda 
T7-Slp4a pEF-T7      M.  Fukuda 
T7-Slp5 pEF-T7      M.  Fukuda 
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RG1-HA pMT2-HA      J.  Bos 
His6-Rap1B pET28      M.  Hoffmeister 
GST-14-3-3 pGEX-4T-3      P.  Riha 
EGFP-rRab27a pEGFP-C3      M.  Seabra 
EGFP-hRab27b pEGFP-C3      M.  Seabra 
rRab27a-VSV pcDNA4/TO  448,468  EGFP-rRab27a  this  work 
hRab27b-VSV  pcDNA4/TO  446, 447  EGFP-hRab27b  this work 
GST-rRab27a  pGEX-4T-3  559, 560  EGFP-rRab27a  this work 
GST-hRab27b  pGEX-4T-3  561, 562  EGFP-hRab27b  this work 
PKI pcDNA3      R.  Maurer 
Rap1GAP2-
Gal4BD  pGBKT7     O.  Danielewski 
Slp1-Gal4AD pACT2      A.Smolenski 
 
7.2 List of primers 
Table 7.2.1: Primers for cloning 
Primer 
No.  Name  Sequence 5´→ 3` 
235 Slp1-EcoRI-for  ATTGAATTCCATGCCCCAGAGGGGCCACCCATCG 
236 Slp1-XhoI-rev  AATCTCGAGCTACGTCCTGGGGGCCAGG 
336 Slp1-XhoI-rev  AATCTCGAGAACGTCCTGGGGGCCAGG 
337 C2A-EcoRI-for  ATTGAATTCCATGGAGCTGCGCGTGCACGTGATC 
338 C2A-XhoI-rev  AATCTCGAGCTAAGCCAGGTGGGCTCAGAGC 
339 C2B-EcoRI-for  ATTGAATTCCATGGAGCTGCACTTCTGGGTG 
365 C2A-XhoI-rev  AATCTCGAGAACCCGCTCGGGGGCAGTCCTG 
405 Slp1-XhoI-rev  AATCTCGAGCGTCCTGGGGGCCAGGTTG 
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446 Rab27b-EcoRI-for  ATTGAATTCATGACCGATGGAGACTATG 
447 Rab27b-VSV-XhoI-rev 
AATCTCGAGCTACTTACCCAGGCGGTTCATTTCGATATCAGTGTA
GCAGATACATTTCTTC 
448 Rab27a-HindIII-for  ATTAAGCTTATGTCGGATGGAGATTATGAC 
468 Rab27a-VSV-XhoI-rev 
AATCTCGAGCTACTTACCCAGGCGGTTCATTTCGATATCAGTGTA
ACAGCCGCATAACCCCTTC 
559 Rab27a-SmaI-for  ATTCCCGGGTCATGTCGGATGGAGATTATGAC 
560 Rab27a-XhoI-rev  AATCTCGAGTCAACAGCCGCATAACCCCTTC 
561 Rab27b-EcoRI-for  ATTGAATTCCATGACCGATGGAGACTATG 
562 Rab27b-XhoI-rev  AATCTCGAGCTAGCAGATACATTTCTTCTC 
563 Slp1-NheI-for  ATTGGCTAGCATGCCCCAGAGGGGCCACCCATCG 
 
Table 7.2.2: Primers for mutagenesis 
Primer 
No.  Name  Sequence 5´→ 3` 
344  RG2ΔNC7-for  CAGTGGGGGCATCCCTGGCTGACTCAGCGGGGGCATCTCCCAC 
345  RG2ΔNC7-rev  GTGGGAGATGCCCCCGCTGAGTCAGCCAGGGATGCCCCCACTG 
346  RG2ΔNC5-for  CTCGCCTCCAGTGGTGGCGTGAACGGTGAAGAACCAGTCACGG 
347  RG2ΔNC5-rev  CCGTGACTGGTTCTTCACCGTTCACGCCACCACTGGAGGCGAG 
367  RG2ΔNC4-for  GAACCAGTCACGGAGTCCCTGAAAGCGACGCTCGGGGCTCTTC 
368  RG2ΔNC4-rev  GAAGAGCCCCGAGCGTCGCTTTCAGGGACTCCGTGACTGGTTC 
369  RG2ΔNC6-for  CAGCATGGAGGTCACCAAGTGAACCTTCTCGCCTCCAGTGGTG 
370  RG2ΔNC6-rev  CACCACTGGAGGCGAGAAGGTTCACTTGGTGACCTCCATGCTG 
399  RG2Δ536-542-for  CTCGCCTCCAGTGGTGGCGGCACGGAGTCCCATCAAGCGAC 
400  RG2Δ536-542-rev  GTCGCTTGATGGGACTCCGTGCCGCCACCACTGGAGGCGAG 
401  RG2Δ522-527-for  CATCTCCCACAACAGCATGTTCTCGCCTCCAGTGGTG 
402  RG2Δ522-527-rev  CACCACTGGAGGCGAGAACATGCTGTTGTGGGAGATG 
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452 RG2T527A-for  GAGGTCACCAAGACCGCCTTCTCGCCTCCAGTG 
453 RG2T527A-rev  CACTGGAGGCGAGAAGGCGGTCTTGGTGACCTC 
469 Slp1S111A-for  CTATGCGCAGGAAGAAGGCCACCAGGGGAGACCAGGCTC 
470 Slp1S111A-rev  GAGCCTGGTCTCCCCTGGTGGCCTTCTTCCTGCGCATAG 
471 Slp1S301A-for  GCCGCCCGGCGCCGCCGCGCGGACCCCTACGTCAAAAG 
472 Slp1S301A-rev  CTTTTGACGTAGGGGTCCGCGCGGCGGCGCCGGGCGGC 
477 RG2K525A-for  CAGCATGGAGGTCACCGCGACCACCTTCTCGCCTCCAGTG 
478 RG2K525A-rev  CACTGGAGGCGAGAAGGTGGTCGCGGTGACCTCCATGCTG 
479 RG2V523A-for  CTCCCACAACAGCATGGAGGCCACCAAGACCACCTTCTCGCCTC 
480 RG2V523A-rev  GAGGCGAGAAGGTGGTCTTGGTGGCCTCCATGCTGTTGTGGGAG 
481 RG2E522A-for  CATCTCCCACAACAGCATGGCGGTCACCAAGACCACCTTCTC 
482 RG2E522A-rev  GAGAAGGTGGTCTTGGTGACCGCCATGCTGTTGTGGGAGARG 
496 RG2T524A-for  CACAACAGCATGGAGGTCGCCAAGACCACCTTCTCGCCTCCAG 
497 RG2T524-rev  CTGGAGGCGAGAAGGTGGTCTTGGCGACCTCCATGCTGTTGTG 
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ZUSAMMENFASSUNG 
1. Einleitung 
Blutplättchen, auch Thrombozyten genannt, sind kernlose Zellen, die unter physiologischen 
Umständen eine wichtige Rolle in der primären Hämostase spielen. Nach einer 
Gefäßverletzung adhärieren Thrombozyten an Strukturen der freigelegten subendothelialen 
Matrix. Bei dieser primären Adhäsion werden Thrombozyten aktiviert und bilden durch 
Wechselwirkung untereinander ein zunächst fragiles Thrombozytenaggregat. Dieser initial 
gebildete Thrombus wird in der sekundären Hämostase  durch Fibrin verfestigt und 
ermöglicht dann die stabile Abdichtung der Gefäßwandläsion gegenüber dem Blutstrom 
(Kehrel 2003). Die Aktivierung von Thrombozyten durch Adhäsion oder durch lösliche 
Plättchenaktivatoren bewirkt eine Formveränderung der Thrombozyten. Gleichzeitig werden 
intrazelluläre Speichergranula von Thrombozyten ausgeschüttet. Thrombozyten enthalten 
drei verschiedene Arten von Granula: alpha-Granula, dichte Granula und Lysosomen. Die 
Granula in Thrombozyten dienen als Speicherorte für Proteine und Substanzen, welche 
sowohl autokrin die Thrombozytenaktivierung verstärken als auch parakrin noch ruhende 
Thrombozyten aus der Blutzirkulation rekrutieren. Die dichten Granula in Thrombozyten 
enthalten niedermolekulare Substanzen wie zum Beispiel ADP, ATP, Ca
2+ und Serotonin. In 
den alpha-Granula dagegen befinden sich vor allem Proteine, die für die Adhäsion, 
Aggregation und die Blutgerinnung wichtig sind. Zusätzlich enthalten alpha-Granula Zytokine 
und Wachtumsfaktoren. Die lysosomalen Granula in Thrombozyten enthalten hydrolytische 
Enzyme wie beispielsweise β-Hexosaminidase und Heparitinase (Gawaz 1999).  
Im Gegensatz zur Sekretion der alpha-Granula, die durch Rab4 reguliert wird (Shirakawa et 
al. 2000), steuert das kleine G-Protein Rab27 die Sekretion der dichten Granula in 
Thrombozyten (Shirakawa et al. 2004). Rab27 befindet sich auf der Oberfläche der dichten 
Granula (Barral et al. 2002) und es wird angenommen, dass Rab27 vor allem die Motilität 
und das Andocken der Granula an die Plasmamembran fördert (Seabra und Coudrier 2004, 
Fukuda 2006). Für diese Funktion interagiert Rab27 mit unterschiedlichen Effektorproteinen 
und Munc13-4 wurde als das erste Rab27-bindende Protein in Thrombozyten beschrieben 
(Shirakawa et al. 2004). Weitere Proteine, die für die Sekretion der dichten Granula von 
Bedeutung sind, sind SNARE (soluble  N-ethylmaleimide-sensitive-factor  attachment 
receptor)-Proteine. SNARE-Proteine spielen eine wichtige Rolle bei der Fusion von 
Membranen. So wird die Fusion der dichten Granula mit der Plasmamembran durch das sich 
auf der Granulaoberfläche befindende (v)-SNARE-Protein VAMP-8 und den an der 
Plasmamembran angesiedelten (t)-SNARE-Proteinen syntaxin-2 und SNAP-23 vermittelt 
(Ren et al. 2007, Chen et al. 2000a).  
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Die Sekretion der Speichergranula geht eng mit der Aggregation von Thrombozyten einher. 
Durch outside in und inside out signaling werden Integrinrezeptoren auf der Oberfläche von 
Thrombozyten aktiviert. Eines der bedeutendsten Plättchenintegrine ist αIIbβ3, auch GPIIb-IIIa 
genannt. Im aktivierten Zustand bindet Integrin αIIbβ3 an Fibrinogen. Durch die Ausbildung 
von Fibrinogenbrücken erfolgt dann die Quervernetzung mehrerer Thrombozyten. Das kleine 
G-Protein Rap1 reguliert den Aktivitätszustand von Integrin αIIbβ3 und besitzt damit eine 
zentrale Rolle bei der Thrombozytenaggregation. Rap1 selbst durchläuft einen 
Aktivitätszyklus: GDP-gebundenes Rap1 ist inaktiv und GTP-gebundenes Rap1 ist aktiv. Die 
Aktivierung von Rap1 erfolgt mit Hilfe verschiedener GEF (guanine nucleotide exchange 
factor)-Proteine, welche den Austausch von GDP zu GTP fördern. In Thrombozyten sind 
CalDAG-GEFI und III sowie PDZ-GEF1 exprimiert (Schultess et al. 2005). Die Inaktivierung 
von Rap1 erfolgt durch Hydrolyse von GTP zu GDP und Phosphat. Da Rap1 eine nur sehr 
schwache eigene intrinsische GTPase Aktivität besitzt, beschleunigen Rap1-spezifische 
GAP (GTPase activating protein)-Proteine die Hydrolyse von GTP. Bisher sind zwei Familien 
von Rap1GAP-Proteinen bekannt (Stork und Dillon 2005). Zur ersten Familie gehören die 
Proteine SPA-1 und E6TP1α. Die zweite Familie umfasst die Proteine Rap1GAP1 und das 
von unserer Arbeitsgruppe kürzlich entdeckte Rap1GAP2. In Thrombozyten ist Rap1GAP2 
das einzige GAP-Protein für Rap1 (Schultess et al. 2005). Rap1GAP2 enthält eine 
konservierte zentrale GAP-Domäne, eine N-terminale Bindungsstelle für 14-3-3-Proteine 
sowie einen großen C-terminalen Bereich mit bisher noch unbekannter Funktion. Die 
Aktivierung von Thrombozyten führt zur Phosphorylierung von Rap1GAP2 an Serin 9, 
woraufhin 14-3-3-Proteine an Rap1GAP2 binden und wahrscheinlich die GAP-Funktion 
hemmen (Hoffmeister et al. 2008).  
2. Zielsetzung dieser Arbeit 
Um weitere Einblicke in die Funktion und Regulation von Rap1GAP2 in Thrombozyten zu 
gewinnen, wurde ein Hefe-zwei-Hybrid-Screening durchgeführt (O. Danielewski und A. 
Smolenski, IBCII, Frankfurt). Neben 14-3-3-Proteinen (Hoffmeister et al. 2008), wurde das 
Rab27-bindende Protein synaptotagmin-like protein 1 (Slp1, auch JFC1 genannt) als neuer 
putativer Interaktionspartner von Rap1GAP2 gefunden. Ausgehend von den Ergebnissen 
dieses Hefe-zwei-Hybrid-Screenings waren die konkreten Ziele der vorliegenden Arbeit (1) 
die Bindung von Slp1 an Rap1GAP2 zu verifizieren, (2) die für die Bindung verantwortlichen 
Bindebereiche zu identifizieren, (3) die mögliche Komplexbildung von Rap1GAP2, Slp1, 
Rab27 und anderen Proteinen zu untersuchen sowie (4) die funktionale Bedeutung der 
Interaktion zwischen Rap1GAP2 und Slp1 zu bestimmen.  
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3. Ergebnisse und Diskussion 
Slp1 ist ein neuer Interaktionspartner von Rap1GAP2 in Thrombozyten 
Die direkte Interaktion zwischen Rap1GAP2 und Slp1 wurde zunächst durch 
Retransformation in Hefe bestätigt. Durch Transfektion von HeLa und COS-1 Zellen mit 
anschließenden Pulldown- und Koimmunpräzipitationsexperimenten wurde die Interaktion 
zwischen Rap1GAP2 und Slp1 in Säugerzellen verifiziert. Mit Hilfe des eigens hergestellten 
polyklonalen Slp1-Antikörpers konnte ferner gezeigt werden, dass Slp1 in Thrombozyten 
exprimiert wird. Weder der Slp1- noch unser Rap1GAP2-Antikörper eigneten sich zur 
Immunpräzipitation ihrer endogenen Antigene aus Thrombozyten. Um dennoch den Beweis 
für die Interaktion zwischen Rap1GAP2 und Slp1 auf endogener Ebene in Thrombozyten zu 
erbringen, wurde ein alternativer Lösungsansatz entwickelt und angewandt (Hoffmeister et 
al. 2008). Unter Ausnutzung der Fähigkeit von Rap1GAP2 an 14-3-3-Proteine zu binden, 
wurde aus Escherichia coli gereinigtes GST-14-3-3-Protein verwendet, um endogenes 
Rap1GAP2 und das daran gebundene Slp1 aus humanen Thrombozyten zu präzipitieren. In 
Kontrollversuchen wurde zuvor eine direkte Interaktion zwischen 14-3-3-Proteinen und Slp1 
ausgeschlossen. Auf diese Art und Weise gelang es die Interaktion zwischen Rap1GAP2 
und Slp1 auf endogener Ebene in Thrombozyten nachzuweisen. 
Um die für die Bindung von Rap1GAP2 und Slp1 verantwortlichen Binderegionen zu 
identifizieren, wurden Mutations- und Peptidbindungsstudien durchgeführt. Es konnte gezeigt 
werden, dass die Bindung von Rap1GAP2 an Slp1 durch das -TKXT- Proteinmotiv im C-
terminalen Bereich von Rap1GAP2 vermittelt wird. Das -TKXT- Motiv bindet Ca
2+-
unabhängig an die C2A Domäne von Slp1. C2 Domänen sind im Allgemeinen als 
Phospholipidbindedomänen bekannt und speziell die C2A Domäne von Slp1 vermittelt die 
Bindung von Slp1 an die Plasmamembran (Lemmon 2008, Catz et al. 2002). Andererseits 
sind einige C2 Domänen auch an Protein-Protein-Interaktionen beteiligt (Kheifets und 
Mochly-Rosen 2007, Pena et al. 2008). In Lipidbindungsversuchen wurde nachgewiesen, 
dass Slp1 gleichzeitig sowohl an Phospholipide als auch an Rap1GAP2 binden kann. Die 
Aktivierung der Proteinkinase A in Thrombozyten verstärkte die Bindung von GST-Slp1 an 
endogenes Rap1GAP2. Zusammen mit der Tatsache, dass im -TKXT- Motiv von Rap1GAP2 
zwei Threonine (T524 und T527) enthalten sind, ließ dieser Befund über eine 
Phosphorylierung am -TKXT- Motiv spekulieren. Nachfolgende Experimente sprachen 
jedoch gegen eine Phosphorylierung am -TKXT- Motiv von Rap1GAP2. Vielmehr konnte 
eine Phosphorylierung eines oder beider Threonine am -TKXT- Motiv von Rap1GAP2 die 
Bindung an Slp1 aufheben. Es bleibt demzufolge offen, ob eine Phosphoyrlierung durch 
Proteinkinase A am Rap1GAP2 an anderer Stelle als dem Slp1 bindenden -TKXT- Motiv 
erfolgt und folglich die Bindung von Slp1 an Rap1GAP2 positiv beeinflusst. Alternativ 
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könnten aber auch weitere an der Bindung von Rap1GAP2 und Slp1 beteiligte Proteine 
durch Proteinkinase A phosphoryliert werden und in Folge, die Komplexbildung zwischen 
Rap1GAP2 und Slp1 in Thrombozyten verstärken. Die detaillierte Rolle der Phosphorylierung 
bei der Regulation der Rap1GAP2/Slp1 Interaktion bleibt jedoch in zukünftigen Studien zu 
klären. 
 
Komplexbildung von Slp1, Rab27 und Rap1GAP2 
 
Slp1 bindet über die N-terminale Slp Homologiedomäne (SHD) an das kleine G-Protein 
Rab27, welches, wie bereits erwähnt, die Sekretion der dichten Granula in Thrombozyten 
reguliert (Fukuda 2005, Shirakawa et al. 2004). Rab27 besitzt zwei Isoformen Rab27a und 
Rab27b, die 71 % in ihrer Aminosäuresequenz übereinstimmen (Pereira-Leal und Seabra 
2001). Beide Isoformen kommen in Thrombozyten vor (Barral et al. 2002). In der 
vorliegenden Arbeit wurde die direkte Interaktion zwischen Slp1 und Rab27 in Pulldown- und 
Koimmunpräzipitationsexperimenten bestätigt. Dabei konnte festgestellt werden, dass Slp1 
unabhängig vom gebundenen Nukleotid an Rab27 bindet. Desweiteren konnte gezeigt 
werden, dass ein trimärer Komplex aus Slp1, Rab27 und Rap1GAP2 sowohl bei 
Überexpression in Säugerzellen als auch endogen in Thrombozyten gebildet wird. Um 
weitere Slp1-assoziierte Proteine, die an der Komplexbildung um Slp1, Rab27 und 
Rap1GAP2 in Thrombozyten beteiligt sein könnten, zu identifizieren, wurde ein 
affinitätschromatographisches Screening durchgeführt. Durch die anschließende massen-
spektrometrische Analyse (Conway Institut, Dublin, Irland) konnten insgesamt 14 neue 
putative Slp1 Interaktionspartner in Thrombozyten ermittelt werden. Unter den identifizierten 
Proteinen befand sich beispielsweise das kleine G-Protein Rab8, dessen Bindung an Slp1 
bereits in transfizierten HeLa Zellen beschrieben war (Hattula et al. 2006). In der 
vorliegenden Arbeit wurde jedoch die Bindung von Rab8 an Slp1 erstmalig in Thrombozyten 
nachgewiesen.  
 
Slp1 und Rap1GAP2 sind an der Sekretion der dichten Granula in Thrombozyten beteiligt 
 
Um die funktionale Bedeutung der Interaktion zwischen Rap1GAP2 und Slp1 zu analysieren, 
sollte die Interaktion (i) im Hinblick auf die Rap1GAP2-Funktion in Rap1-vermittelter 
Zelladhäsion und (ii) im Hinblick auf die Slp1-Funktion in Rab27-vermittelter Sekretion 
untersucht werden (Bos et al. 2001, Johnson et al. 2005, Shirakawa et al. 2004). Es konnte 
kein Einfluss der Interaktion zwischen Rap1GAP2 und Slp1 auf die Adhäsion von 
transfizierten HeLa Zellen festgestellt werden. Zudem zeigten in-vitro GAP Assays, dass die 
Bindung von Slp1 an Rap1GAP2 die katalytische GAP-Aktivität von Rap1GAP2 nicht 
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beeinflusst. Demgegenüber deuteten Sekretionsversuche in transfizierten LNCaP Zellen 
darauf hin, dass Rap1GAP2 einen positiven Effekt auf die Sekretion von 
prostataspezifischem Antigen hat. Um dieses Ergebnis im endogenen System der 
Thrombozyten zu bestätigen, wurde ein Assay entwickelt, bei dem die Sekretion von 
Serotonin (5-Hydroxytryptamin, 5HT) aus dichten Granula der Thrombozyten fluorometrisch 
gemessen wurde. Da Thrombozyten kernlose Zellen sind, eignen sie sich nicht zur 
Transfektion. Um dennoch Proteine oder Peptide in das Innere von Thrombozyten zu 
bringen, wurden Thrombozyten mit dem bakteriellen Toxin Streptolysin-O permeabilisiert. 
Die nachfolgende Zugabe von rekombinantem Slp1-Protein hemmte konzentrationsabhängig 
sowohl die Ca
2+- als auch die GTPγS-induzierte Sekretion der dichten Granula. Die Zugabe 
von rekombinantem Rap1GAP2-Protein dagegen verstärkte die Sekretion. Der Rap1GAP2 
Effekt konnte zusätzlich durch Experimente mit kurzen synthetischen Rap1GAP2-Peptiden 
bestätigt werden. Durch Deletion des Slp1-bindenden -TKXT- Motivs sowohl im Rap1GAP2-
Protein als auch im Rap1GAP2-Peptid wurde die sekretionsfördernde Wirkung von 
Rap1GAP2 in Thrombozyten vollständig aufgehoben. Die Zugabe von rekombinantem Rap1 
zu permeabilisierten Thrombozyten hatte keinen Einfluss auf die Sekretion. 
Zusammenfassend weisen diese Ergebnisse darauf hin, dass sowohl Slp1 als auch 
Rap1GAP2 an der Sekretion der dichten Granula in Thrombozyten beteiligt sind. Der 
Einfluss von Rap1GAP2 auf die Sekretion war dabei nicht auf die GTPase-aktivierende 
Wirkung von Rap1GAP2 gegenüber Rap1, sondern vielmehr auf die -TKXT-  vermittelte 
Bindung von Rap1GAP2 an Slp1 zurückzuführen. Der genaue molekulare Mechanismus 
sowohl des Rap1GAP2 als auch des Slp1 Effekts auf die Sekretion der dichten Granula in 
Thrombozyten bleibt jedoch in zukünftigen Studien zu klären. 
 
4. Fazit 
 
Die Ergebnisse der vorliegenden Arbeit zeigen, dass das Rab27-bindende Protein Slp1 ein 
neuer direkter Interaktionspartner des GTPase-aktivierenden Proteins Rap1GAP2 in 
Thrombozyten ist. Die Expression von Slp1 wurde in Thrombozyten nachgewiesen. Damit ist 
Slp1 neben Munc13-4 das zweite bisher bekannte Rab27-bindende Protein in diesen Zellen. 
Der Nachweis der Interaktion von  Slp1 mit GTP-gebundenen Rab27 legte eine Funktion von 
Slp1 als Rab27-Effektorprotein nahe und es konnte in dieser Arbeit gezeigt werden, dass 
Slp1 die Sekretion der dichten Granula in Thrombozyten beeinflusst.  
Darüber hinaus zeigen die Ergebnisse der vorliegenden Arbeit, dass Rap1GAP2, zusätzlich 
zu seiner bereits bekannten Funktion bei der Thrombozytenaggregation durch die Regulation 
des kleinen G-Proteins Rap1, auch an der Sekretion der dichten Granula in Thrombozyten 
beteiligt ist.  Der Rap1GAP2 Effekt auf die Sekretion in Thrombozyten beruht auf der -TKXT- 
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vermittelten Wechselwirkung mit Slp1, welche Teil eines komplexen Netzwerks von Protein-
Protein-Interaktionen in Thrombozyten ist. Rap1GAP2 könnte somit eine zentrale Rolle bei 
der Koordination der wichtigen Funktionen Aggregation und Sekretion in Thrombozyten 
spielen. 
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